<SEC-DOCUMENT>0001019687-15-001438.txt : 20150415
<SEC-HEADER>0001019687-15-001438.hdr.sgml : 20150415
<ACCEPTANCE-DATETIME>20150415060110
ACCESSION NUMBER:		0001019687-15-001438
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20150409
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150415
DATE AS OF CHANGE:		20150415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		15770459

	BUSINESS ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		9635 GRANITE RIDGE DRIVE, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report (Date of earliest event reported):
April 15, 2015 (April 9, 2015)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</td>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">of incorporation)</P></td>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</P></td>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Identification Number)</P></td></tr>
</table>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 55%; font-size: 10pt">&nbsp;</td>
    <td style="width: 3%; font-size: 10pt">&nbsp;</td>
    <td style="width: 42%; font-size: 10pt">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">9635 Granite Ridge Drive, Suite 100</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P></td>
    <td style="vertical-align: bottom; font-size: 10pt">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">92123</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Zip Code)</P></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 97%">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top"><font style="font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#111;</FONT>&nbsp;</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>
</table>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.8pt">This Form 8-K and other reports filed by
Registrant from time to time with the Securities and Exchange Commission (collectively, the &quot;Filings&quot;) contain or may
contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant's
management as well as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate,&rdquo;
&quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;future,&quot; &quot;intend,&quot; &quot;plan&quot; or the
negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward-looking
statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties,
assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses
that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions
prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.8pt">Although Registrant believes that the expectations
reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance
or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not
intend to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">ITEM 1.01</FONT> <FONT STYLE="font-size: 10pt">ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On April 9, 2015, Aethlon Medical, Inc.
(&ldquo;we&rdquo;) entered into an investigator-initiated clinical trial agreement (the &ldquo;Agreement&rdquo;) with the University
of California, Irvine (&ldquo;UCI&rdquo;). Under the Agreement, UCI will conduct a five-year clinical study protocol entitled &ldquo;Plasma
Exosome Concentration in Cancer Patients Undergoing Treatment&rdquo; (the &ldquo;Protocol&rdquo;). The Protocol will seek to enroll
five (5) individuals in each of nine defined tumor types for a total study population of up to forty-five (45) subjects (the &ldquo;Clinical
Trial&rdquo;). The tumor types include the following forms of cancer; Breast adenocarcinoma, Colorectal, Gastric &amp; Gastroesophageal,
Pancreatic, Cholangiocarcinoma, Lung (NSCLC), Head &amp; Neck (SCC), Melanoma and Ovarian adenocarcinoma. The principal investigator
of the study is Edward Nelson, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The budget for the Protocol provides for
(i) $19,032 in startup charges; (ii) $8,039 in Protocol related variable pass-through charges; and (iii) per subject visit charges
of $3,359 per subject, for a total subject visit charge of $151,155 for forty-five (45) subjects. These costs will be borne by
us. UCI may disseminate the results of the Clinical Trial through presentation and/or publication, but may not disclose any of
our confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Agreement,
the Protocol, the Clinical Trial and the budget does not purport to be complete and is qualified in its entirety by the Clinical
Trial Agreement attached hereto as Exhibit 10.1, the Protocol attached hereto as Exhibit 10.2, and the Budget attached hereto as
Exhibit 10.3, each of which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ITEM 8.01 OTHER EVENTS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 15, 2015,
the Registrant issued a press release announcing the Clinical Trial Agreement with UCI. A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">EXHIBIT NO.</font></td>
    <td><font style="font-size: 10pt">DESCRIPTION</font></td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.1</font></td>
    <td><font style="font-size: 10pt">UCI Clinical Trial Agreement</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.2</font></td>
    <td><font style="font-size: 10pt">Protocol for UCI Clinical Trial </font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">10.3</font></td>
    <td><font style="font-size: 10pt">Budget for UCI Clinical Trial</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">99.1</font></td>
    <td><font style="font-size: 10pt">&ldquo;Aethlon Medical Announces Cancer Clinical Trial Agreement&rdquo;</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: bottom">
    <td style="width: 2%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 46%">&nbsp;</td>
    <td style="width: 3%">&nbsp;</td>
    <td style="width: 48%"><font style="font-size: 10pt">&nbsp;AETHLON MEDICAL, INC.</font></td></tr>
<tr>
    <td style="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</td>
    <td style="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:&nbsp;<u>/s/ James B. Frakes</u></P></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">James B. Frakes</font></td></tr>
<tr>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Dated: April 15, 2015</font></td>
    <td style="vertical-align: bottom">&nbsp;</td>
    <td style="vertical-align: top"><font style="font-size: 10pt">Chief Financial Officer</font></td></tr>
</table>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>aethlon_ex1001.htm
<DESCRIPTION>UCI CLINICAL TRIAL AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CLINICAL TRIAL AGREEMENT NO. AMI-201951</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">This clinical
trial agreement (&ldquo;Agreement&rdquo;) is entered into this 24<SUP>th</SUP> day of March 2015, by and between <B>The Regents
of the University of California, on behalf of its Irvine campus</B>, a California corporation with a place of business at 5171
California Avenue, Suite 150, Irvine, CA 92697-7600</FONT> <FONT STYLE="font-size: 10pt">(hereinafter referred to as the &ldquo;Institution&rdquo;)
and <B>Aethlon Medical, Inc. and its subsidiaries</B><FONT STYLE="color: blue"><I>,</I></FONT> a Nevada corporation with a place
of business at 9635 Granite Ridge Drive, Suite 100, San Diego, CA. 92123, (hereinafter referred to as the &ldquo;Sponsor&quot;),
the Institution and Sponsor each being a &ldquo;party&ldquo; and hereinafter collectively referred to as the &ldquo;Parties&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WITNESSETH</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS,</B> Sponsor is interested in
supporting a clinical trial by providing financial support;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS,</B> the Institution acknowledges
and affirms that it is familiar with and understands the regulations of the United States Food and Drug Administration governing
clinical trials and that it is capable of complying with such regulations as applicable to this trial; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS, </B>the Institution and Sponsor
have entered into this Agreement in order to set forth the terms pursuant to which a clinical trial shall be performed by the Institution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>NOW THEREFORE,</B> the Parties agree
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B>SCOPE OF WORK</B></TD></TR>                                                                                                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Institution shall exercise reasonable efforts to conduct the investigator-initiated clinical
trial (&ldquo;Clinical Trial&rdquo;) set forth in the protocol entitled &quot;Plasma Exosome Concentration in Cancer Patients Undergoing
Treatment&quot; (&quot;Protocol&quot;), in accordance with this Agreement. The Protocol, which is approved by the Sponsor and the
Institution&rsquo;s Institutional Review Board (&ldquo;IRB&rdquo;), is attached hereto as Exhibit A and incorporated by reference
(along with any approved subsequent modifications). In the event of any conflict between the terms of this Agreement and the Protocol,
the terms of this Agreement shall govern.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><B>PRINCIPAL INVESTIGATOR</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Institution's principal
investigator shall be Edward Nelson, M.D. (&quot;Principal Investigator&quot;) who shall be responsible for the direction of the
Clinical Trial in accordance with applicable Institution policies. If, for any reason, (s)he is unwilling or unable to continue
to serve as the Principal Investigator and a successor, acceptable to both the Institution and Sponsor, is not available, this
Agreement may be terminated by either party in accordance with the provisions of Paragraph A of Section 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><B>PERIOD OF PERFORMANCE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">This Agreement shall commence
on March 24, 2015<FONT STYLE="color: blue"><I> </I></FONT>and shall continue through March 23, 2020, unless extended by mutual
written agreement of the Parties or unless sooner terminated pursuant to Paragraph A of Section 13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><B>RECORDKEEPING, REPORTING AND ACCESS</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                          <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>A.</TD><TD STYLE="text-align: justify">The
Institution shall notify Sponsor of each serious adverse event encountered in the Clinical Trial within twenty-four (24) hours
of becoming aware of it. <FONT STYLE="color: blue"><I> </I></FONT> </TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The Institution shall, in a timely manner, prepare and maintain complete and accurate written records
related to the Clinical Trial (&ldquo;Records&rdquo;).</TD></TR>                                                                <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">D.</TD><TD STYLE="text-align: justify">The Institution will provide the Sponsor with quarterly updates concerning the progress of the
Clinical Trial. Upon completion of Clinical Trial, or earlier termination of this Agreement, the Institution will provide a final
written report (&ldquo;Final Report&rdquo;) to Sponsor describing the outcomes of the work performed.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">5. <B>COSTS,
PAYMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">As consideration for Institution&rsquo;s performance of the Clinical Trial under the terms of this
Agreement, Sponsor agrees to pay Institution in accordance with the terms of Exhibit B, which is attached hereto and incorporated
by reference.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">All costs set forth in Exhibit B shall remain firm for the duration of the Clinical Trial, unless
otherwise agreed to in writing by the Parties.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">Checks shall be made payable to &ldquo;The Regents of the University of California.&rdquo; Checks
shall reference this Agreement number and shall be mailed to the address shown in Exhibit B.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><B>CONFIDENTIAL INFORMATION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Institution shall not disclose or use for any purpose other than the performance of the Clinical
Trial any privileged records and other confidential or proprietary information disclosed to the Institution by or on behalf of
Sponsor (&ldquo;Confidential Information&ldquo;). Confidential Information shall be marked as confidential or, if not so marked,
shall be treated as confidential if a reasonable person involved in the conduct of clinical trials would reasonably believe such
information was a trade secret, confidential or proprietary information of Sponsor. This obligation of non-disclosure and non-use
shall not apply to any Confidential Information:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">that is or becomes publicly available through no fault of the Institution;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">already known to the Institution prior to receipt from Sponsor, as shown by Institution&rsquo;s
prior written records;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">disclosed to the Institution by a third-party without an obligation of confidentiality;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">developed and/or discovered independently by Institution without reference to and/or use of Confidential
Information, as evidenced by written contemporaneous documentation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">required to be released by any governmental entity with jurisdiction, provided that the Institution
gives notice to Sponsor at least ten (10) days (if reasonably possible, and, if not, as many days as is reasonably possible) prior
to making such release of Confidential Information.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The obligations of the Institution under this Section shall survive the termination of this Agreement
for a period of five (5) years.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">7.<B>
PRESENTATIONS AND PUBLICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Institution may, consistent with scientific standards, disseminate the results of the Clinical
Trial through either presentation or publication including, but not limited to, full papers, manuscripts, abstracts, poster presentations,
and oral presentations (&ldquo;Publications&rdquo;), but will not disclose any Confidential Information without Sponsor' prior
written consent.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">Institution shall submit Publications to Sponsor for review thirty (30) days prior to any publication.
Sponsor may comment upon, but may not make any editorial changes to, the results and conclusions set forth in the Publications;
however, if identified by Sponsor, the Institution will delete any of Sponsor's Confidential Information that may be contained
therein. In the event that Sponsor determines patentable subject matter is disclosed in a Publication, it shall immediately notify
Institution and, if Institution concurs, such Publication will be delayed: (a) for up to ninety (90) days to permit preparation
and filing of appropriate patent application(s); (b) until a patent application thereon has been prepared and filed; or (c) until
Institution and Sponsor mutually agree in writing that no patent application(s) shall be prepared or filed, whichever of (a), (b),
or (c) is earlier in time.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">8.<B>
INTELLECTUAL PROPERTY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">Title to any inventions and discoveries conceived and reduced to practice in the performance of
the Clinical Trial (&quot;Invention&quot;) shall be determined in accordance with the rules of inventorship under United States
Patent law in effect at the time of the invention. Sponsor shall own each Invention made solely by one or more inventors under
an obligation to assign inventions to Sponsor (&ldquo;Sponsor Inventions&rdquo;). Institution shall own each Invention made solely
by one or more inventors under an obligation to assign inventions to Institution (&ldquo;Institution Inventions&rdquo;). The Parties
shall jointly own each Invention jointly made by one or more inventors under an obligation to assign inventions to the Institution
and one or more inventors under an obligation to assign inventions to Sponsor (&ldquo;Joint Inventions&rdquo;). Each party shall
make all decisions concerning, and shall bear all expenses of, the patenting of, and the maintenance of patents on, each Invention
that it owns and shall own the resulting applications and patents. In the case of Joint Inventions, the Parties shall enter into
good faith negotiations concerning the patenting thereof and the maintenance of patents thereon.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">                                                                                                                                                                                                                                                                                                                                                                                                                              <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>B.</TD><TD STYLE="text-align: justify">To the
extent that Institution has the legal right to do so, Sponsor shall be given a time-limited first right to negotiate an
exclusive, worldwide, royalty-bearing commercial license to all rights, title and interest which Institution may have or obtain
in Joint Inventions and in Institution Inventions, with such license to include the right to make, use and sell such Inventions.</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">Institution shall promptly disclose to Sponsor in writing any Joint Inventions and Institution
Inventions. Sponsor shall hold such disclosure on a confidential basis and will not disclose the information to any third party
without consent of the Institution. Sponsor shall advise Institution in writing within sixty (60) days of disclosure to Sponsor
whether it wishes to secure a commercial license for any such Inventions. If Sponsor elects to secure such a license, Sponsor shall
assume all costs associated with securing and maintaining patent protection for such Invention(s), whether Letters Patent issue
or not. Sponsor shall have ninety (90) days from the date of election to conclude a license agreement with Institution. Said license
shall contain reasonable terms, and shall require diligent performance by Sponsor for the timely commercial development and early
marketing of such Inventions, and include Sponsor's continuing obligation to pay patent cost. If such license agreement is not
concluded in said period, Institution has no further obligations to Sponsor. If Sponsor does not elect to secure such license,
rights to the Inventions disclosed hereunder shall be disposed of in accordance with Institution policies with no further obligation
to Sponsor.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">D.</TD><TD STYLE="text-align: justify">Nothing contained in this Agreement shall be deemed to grant, either directly or by implication,
estoppel or otherwise, any license under any patents, patent applications or other proprietary interests of any other invention,
discovery or improvement of either party.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><B>PUBLICITY</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Neither party shall use the
other party's name in advertising nor publicity, without the prior written permission of the other party, except as required by
law (and, in such case, only with ten (10) days prior notice to the other party (if reasonably possible, and, if not, as many days
as is reasonably possible). If the relationship is deemed material under U.S. securities law, the parties recognize any required
public disclosure shall be on a timely basis. Such prior permission shall not be unreasonably withheld. Institution, as an instrumentality
of the State of California, is subject to a State requirement that the Institution make available the terms and conditions of its
contracts. Sponsor acknowledges that Institution maintains a publicly accessible listing of all proposals and awards; the listing
includes the name of the campus, sponsor, award amount, begin and end dates, principal investigator and co-investigator&rsquo;s
name, project type, award instrument, descriptive project title, indirect cost rate, account and fund number, department and academic
discipline. The actual contract agreement must be released upon request, although portions of the document may be withheld when
redaction meets one of the legal exemptions under the California Public Records Act. As such, the general terms and conditions
of this Agreement will be released to the public upon request, although portions of the scope of work may be withheld to the extent
that patentable inventions are so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><B>APPLICABLE LAW</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">This Agreement shall be governed
by the laws of the State of California without regard to any conflict of laws provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">11. <B>NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Any notice required or permitted
by this Agreement shall be in writing and delivered by hand or sent by registered or certified mail, postage prepaid, return receipt
requested, or by nationally recognized overnight delivery service, delivery charges prepaid, in each case addressed to the party
to receive such notice at the address set forth below or such other address as is subsequently specified in writing in accordance
with this Section. Such notice shall be deemed given or provided as of the date of such hand delivery or date of sending.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><B>IF
TO SPONSOR:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">9635 Granite Ridge Drive, Suite
100</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">San Diego, CA. 92123</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attention: Jim Joyce, CEO 858-459-7800
x301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><B>IF TO INSTITUTION:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">University of California, Irvine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Office of Research, Sponsored
Projects Administration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">5171 California Avenue, Suite
150</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Irvine, CA 92697-7600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -4.5pt">Attention: Chris Abernethy,
Principal C&amp;G Officer, 949-824-1749</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -4.5pt"><I><U>If sent via overnight
delivery service to Institution, then to</U></I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">University of California, Irvine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Office of Research, Sponsored
Projects Administration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">5171 California Avenue, Suite
150</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Irvine, CA 92617-3067</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -4.5pt">Attention:<I> </I>Chris Abernethy,
Principal C&amp;G Officer, 949-824-1749</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 40.5pt; text-indent: -4.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><B>INDEMNIFICATION AND INSURANCE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">A. The
Institution shall indemnify, defend, and hold harmless Sponsor and its officers, directors, employees and agents (collectively
&quot;Sponsor Indemnitees&quot;) against and from any and all claims, actions, suits, proceedings and investigations (&ldquo;Claims&rdquo;)
arising out of, or in connection with, the Clinical Trial, but only in proportion to and to the extent that such Claims are due
or claimed to be due to the negligent acts or omissions of Institution, its officers, employees or agents. Sponsor Indemnitees
shall: (i) promptly notify the Institution of any Claims for which such Sponsor Indemnitees may seek indemnification hereunder,
(ii) permit the Institution to conduct and exercise sole control of the defense (including all decisions relative to litigation,
appeal or settlement) thereof, and (iii) fully cooperate and assist the Institution in such defense, at the Institution&rsquo;s
expense; provided, however, that the Institution shall not settle such Claims which admits fault or wrongdoing on the part of any
of the Sponsor Indemnitees without obtaining the Sponsor Indemnitees&rsquo; prior written consent, which will not be unreasonably
withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The Sponsor shall indemnify, defend, and hold harmless the Institution, its officers, agents and
employees (collectively &ldquo;Institution Indemnitees&rdquo;) against and from any and all claims, actions, suits, proceedings
and investigations (&ldquo;Claims&rdquo;) arising our of, or in connection with, the Clinical Trial, but only in proportion to
and to the extent that such Claims are due or claimed to be due to the negligent acts or omissions of Sponsor, its officers, directors,
employees or agents. The Institution Indemnitees shall: (i) promptly notify the Sponsor of any Claim for which such Institution
Indemnitee may seek indemnification hereunder, (ii) permit the Sponsor to conduct and exercise sole control of the defense (including
all decisions relative to litigation, appeal or settlement) thereof, and (iii) fully cooperate and assist the Sponsor in such defense,
at the Sponsor&rsquo;s expense; provided, however, that the Sponsor shall not settle such Claim which admits fault or wrongdoing
on the part of any of the Institution Indemnitees without obtaining the Institution Indemnitees&rsquo; prior written consent, which
will not be unreasonably withheld.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">Each party certifies that it maintains a policy or program of insurance or self-insurance at levels
sufficient to support the indemnification obligations assumed herein. Upon request, evidence of a party&rsquo;s insurance or self-insurance
shall be provided to the other party. Unless a party is self-insured, it shall name the other party as an additional insured party
under its insurance policies and shall provide notice to the other party within thirty (30) days of any change in or cancellation
of its coverage.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><B>TERMINATION</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">This Agreement may be terminated by either party for any reason upon not less than thirty (30)
days prior written notice to the other.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">Within sixty (60) days of the effective date of the termination, the Institution shall return to
Sponsor any funds paid by Sponsor that were not expended or irrevocably committed by the Institution prior to said date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">C.</TD><TD STYLE="text-align: justify">Termination of this Agreement shall not affect the rights and obligations of the Parties accrued
prior to the effective date of the termination. The rights and obligations under Sections 4, 6, 7, 8, 9, 11, 12, 17 and 18 shall
survive the termination or expiration of this Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">14. <B>ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Neither this Agreement nor any
rights and obligations hereunder may be assigned by the Institution without the written consent of Sponsor, which will not be unreasonably
withheld.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">15. <B>INDEPENDENT
CONTRACTOR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The relationship of the Parties
is that of independent contractors. Neither party is the partner, joint venturer, nor agent of the other and neither party has
authority to make any statement, representation, commitment, or action of any kind which purports to bind the other without the
other party&rsquo;s prior written authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">16.<B>
CHANGES TO AND DEVIATIONS FROM THE PROTOCOL</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">If, at any time, changes in the Protocol appear desirable, such changes may be made by the Institution
with the prior written consent of Sponsor.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">If, during the performance of the Clinical Trial, generally accepted standards of clinical trial
studies and medical practice relating to the safety of the Subjects requires a deviation from the Protocol, such standards shall
be followed. In such case, the party aware of the need for a deviation from the Protocol shall promptly inform the other party
in writing of the facts necessitating such deviation.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify"><B>CONFORMANCE WITH APPLICABLE LAW</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">A.</TD><TD STYLE="text-align: justify">The Institution shall perform the Clinical Trial in conformance with generally accepted standards
of good clinical practice, the Protocol and all applicable Federal, state and local government laws and regulations and applicable
ICH guidelines governing the performance of clinical investigations, including, but not limited to, the Federal Food, Drug and
Cosmetic Act and regulations of the FDA. All shipments of diagnostic specimens obtained as the result of the performance of a Clinical
Trial shall comply with all applicable Federal regulations including, but not limited to, 49 CFR Part 173, such as 49 CFR 173.199
(if applicable), and the Institution shall execute any declarations required in connection therewith on forms provided, or approved,
by Sponsor.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">B.</TD><TD STYLE="text-align: justify">The Institution hereby certifies that, as of the date of enrollment of each individual participating
in the Clinical Trial (a &ldquo;Subject&rdquo;), it will obtain from each such Subject an authorization that meets the requirements
of the privacy rule issued under the Health Insurance Portability and Accountability Act of 1996 (&quot;HIPAA Privacy Rule&quot;)
set forth at 45 CFR 164.508(b) and (c). Such authorization shall permit (i) all necessary uses of the individual's &quot;protected
health information&quot;, as that term is defined in the HIPAA Privacy Rule, 45 CFR 164.501, by the Institution as part of the
Clinical Trial and (ii) delivery of reports that may contain some protected health information by the Institution to Sponsor and
its authorized agents and the Clinical Trial team and other professionals involved in the Clinical Trial for purposes relating
to the Clinical Trial or other purposes permitted by law under the randomization number assigned to the Subject. Such reports shall
not contain the Subject&rsquo;s name, address, telephone number, social security number or number assigned by the Institution or
healthcare insurer to the Subject for the purposes of billing and locating medical records.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">18.</TD><TD STYLE="text-align: justify"><B>SEVERABILITY</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The invalidity or unenforceability
of any term or provision of this Agreement shall not affect the validity or enforceability of any other term or provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">19.</TD><TD STYLE="text-align: justify"><B>WAIVER; MODIFICATION OF AGREEMENT</B></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">No waiver, amendment, or modification
of any of the terms of this Agreement shall be valid unless in writing and signed by authorized representatives of each party.
Failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of such rights nor shall
a waiver by either party in one or more instances be construed as constituting a continuing waiver or as a waiver in other instances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">[THIS REMAINDER OF THIS PAGE
IS INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">20.</TD><TD STYLE="text-align: justify"><B>ENTIRE AGREEMENT</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">This Agreement represents the
entire understanding of the Parties and supersedes all prior negotiations, representations or agreements, either written or oral,
with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>IN WITNESS WHEREOF</B>, the Parties
have executed this Agreement in duplicate by proper persons thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -3.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 45%"><B>Aethlon Medical, Inc.</B></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%"><B>THE REGENTS OF THE UNIVERSITY OF CALIFORNIA</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">By: </TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">By:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-left: 11pt">(signature)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 11pt">(signature)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding-left: 11pt">(print or type name)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 11pt">(print or type name)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">Title:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Title:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid">Date:</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Date:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><B>PRINCIPAL INVESTIGATOR</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>I have read this Agreement and understand my obligations hereunder.</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">By: </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 11pt">(signature)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-left: 11pt">(print or type name)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Title: </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Date:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">PROTOCOL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>PART I: PAYEE INFORMATION</I></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 1.5in"><B>Project:</B></TD><TD><B>Plasma Exosome Concentration in Cancer Patients Undergoing Treatment </B></TD></TR>                                                                                                                                                                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><B>Effective Period:</B></TD><TD>From <B>3/24/15</B> To <B>3/23/20</B></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><B>Investigator:</B></TD><TD><B>Edward Nelson, M.D. </B></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><B>Institution:</B></TD><TD>University of California, Irvine<B> </B></TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><B>Payee:</B></TD><TD>The Regents of the University of California<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax
ID:</B> 95-2226406</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD><B>Mailing Address:</B></TD><TD>UCI Contracts &amp; Grants Accounting</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>BioSci III, Suite 1400</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>Irvine, CA 92697-1050</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>Attention: Rebecca Tangen, Manager/Principal
Accountant</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">PART II: PAYMENT INSTRUCTIONS AND DETAILED BUDGET</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify"><B>As consideration for performance
under the terms of this Agreement, Sponsor agrees to pay the Institution a total sum of $178,226. Actual charges shall be based
upon a rate of $3,359 per Subject. The maximum sum assumes completion of <U>45</U> Subjects in accordance to the work set forth
in the Protocol. A one time, non-refundable start-up fee of $19,032.30 (which includes institutional overhead) will be made within
30 days of full execution of the Agreement. Subsequent payments will be made quarterly, within forty-five (45) days of the end
of each calendar quarter, on a completed visit per subject. Invoices for the annual renewal fee shall be sent to Aethlon within
two (2) months from the date of incurrence of the invoice item. Payment includes all applicable overhead. Checks will be made payable
to Payee as listed above and will be sent to the address as listed under Payee.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>aethlon_ex1002.htm
<DESCRIPTION>PROTOCOL FOR UCI CLINICAL TRIAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.2</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>Plasma Exosome Concentration in Cancer Patients
Undergoing Treatment</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Objectives of the
Study:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 22pt"><B>This
is a pilot study of a putative biomarker, circulating exosomes, which are increased in patients with cancer and hypothesized to
play a role in tumor-associated immune suppression. We will address the following <U>Specific Aims</U>:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 22pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left">1)</TD><TD STYLE="text-align: justify">Characterize the baseline concentration of circulation
exosomes in patients with various tumor types (in and around the time of diagnosis) and the kinetics of longitudinal changes in
the circulating exosome concentration associated with primary therapy (surgery, radiation therapy, chemotherapy, and/or neoadjuvant
chemotherapy).</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left">2)</TD><TD STYLE="text-align: justify">In patients with metastatic tumor burden, examine baseline
and longitudinal changes associated with chemotherapy treatment.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left">3)</TD><TD STYLE="text-align: justify">In patients with metastatic tumor burden evaluate associations
between changes in circulating exosome concentrations and response to chemotherapy.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><U>RESEARCH DESIGN
AND METHODS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Overview of Study
Design</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 22pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
proposed clinical study will provide critical initial data to direct future clinical investigations of a novel treatment approach
using extracorporeal hemofiltration for the removal of tumor-derived exosomes. Exosomes are small, 30-120 nm, membrane bound vesicles
shed from all cells, but at higher levels from tumor cells [1], providing a logical candidate for the association between tumor
burden and tumor-associated immune suppression. First described &gt; 30 years ago, exosomes were originally thought to be cellular
&ldquo;garbage bags,&rdquo; found in the peripheral blood, containing proteins (including various receptors and signaling molecules)
and nucleic acids, (genomic, mRNA, and microRNAs) [1, 2]. Exosomes are now recognized to have many biological functions including
expressing tumor associated antigens [3-7], to tumor-associated immune suppression [8-19], and have been hypothesized to directly
contribute to the metastatic process and treatment resistance, but with mechanisms less well characterized [8, 12, 20-23]. It
has been observed that circulating exosome concentration is increased in patients with metastatic melanoma, ovarian epithelial,
prostate and colorectal neoplasms [24-29] and as such is hypothesized to vary with tumor burden.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Exosome ELLSA:</B></P>

<P STYLE="margin: 0pt 0; text-indent: 22pt">P<FONT STYLE="font: 10pt Times New Roman, Times, Serif">revious studies have established that tumor-
secreted exosomes display high mannose glycoprotein signatures on their surfaces [30], thus sharing this feature in common with
enveloped viruses. To this end, Aethlon has examined exosomes from various tumor sources and tested their binding to GNA affinity
matrices, <I>in vitro, </I>in studies with Dr. Douglas Taylor. In a variation of a traditional ELISA, GNA was used as a substrate
for coating plates to measure exosome binding, enzyme linked lectin sorbent assay (ELLSA). Ovarian cancer exosomes that were purified
by a conventional ultracentrifugation method bound to GNA and were detectable against a mannan standard curve, <B>Figure 1</B>.</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<IMG SRC="ex1002_01.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>FIGURE 1. </B>Exosome ELLSA. Binding of purified
exosomes from an ovarian cancer patient (obtained by ultracentrifugation) to GNA coated plates (1 &mu;g/mL) in a modified
ELISA assay using serial dilutions of mannan and HRP labeled GNA as a detection agent to generate a standard curve.</P>


<P STYLE="margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aethlon&rsquo;s initial studies were
conducted by Dr. Douglas Taylor using exosomes from ovarian cancer patients. Exosomes were purified from ascites fluid of two
ovarian cancer patients using an established ultracentrifugation method [31, 32] or using the </FONT>Hemopurifier&reg;. The
Hemopurifier&reg; provides the capacity to elute adsorbed exosomes for subsequent evaluation. Analysis of the
tumor-associated exosome marker, EpCAM, revealed that the presence of EpCAM in the material eluted from the
Hemopurifier&reg; as well as in the control exosome preparation, <B>Figure 2 Panel A</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 92pt; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: Red; text-align: left"><IMG SRC="ex1002_02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; color: Red; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FIGURE
2</B>. Panel A: Western blot for EpCam in conventionally purified exosomes and exosomes eluted from the Hemopurifier from ascites
of 2 cancer patients. Panel B: Effect of co-culture of eluted exosomes at increasing concentrations with Jurkat T cells followed
by western blotting of cell lysates for CD3 zeta chain and phospho JAK3. C=control (no exosomes).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Subjects and Recruitment:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Subject Recruitment/Informed
Consent: </I></B>Recruitment of participants in the study will be through the use of internal and outside referrals to the University
of California, Irvine (UCI) Medical Center (UCIMC). Review and approval of this human protocol will be conducted by the UCI Institutional
Review Board (IRB) Human Subjects Review Committee. Subjects must be able to understand and sign an informed consent form, which
must comply with U.S. regulations (U.S. 21 CFR 50) and ICH guidelines to be eligible for this trial. All study materials, including
consent forms will be provided in the patient&rsquo;s primary language. In addition, each subject will be given a copy of the
consent form, the Experimental Subjects&rsquo; Bill of Rights, and HIPAA Release form, all of which will be explained to the subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Accrual Capacity:
</I></B>The NCI designated Chao Family Comprehensive Cancer Center (CFCCC) at UCI has an active clinical cancer care and research
program. UCI Medical Center has a large referral base and sufficient numbers of patients will be available for enrollment onto
the protocol described herein. Data from the cancer registry documents that over the past three years, we have seen a steady rise
from our baseline of approximately 1700 individual new &ldquo;analytic&rdquo; patients: 2010 = 1697, 2011 = 2000, 2012 = 2164,
2013 = 2189 (with 257 of these being new cases with metastatic disease) and are on track for a further increase in 2014. We have
an outstanding record of accrual to clinical trials with over 24% of patients being accrued to clinical studies in each of these
three years; the national average at NCI designated comprehensive cancer centers is 15% and nation wide is only 5%. Even given
a conservative 30% accrual rate of screened and eligible patients and not accounting from recruitment from the larger surrounding
non-UCI affiliated oncology care community, we have adequate capacity to successfully complete accrual to this study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Study Population
Demographics: </I></B>Those who satisfy the inclusion/exclusion criteria and will be enrolled in the study. Patient enrollment
will include all ethnic groups and both genders as available. The current demographics of the patient population seen at CFCCC
and the University of California at Irvine Medical Center are as follows: 42% male; 59% female; 45%Caucasian; 5% Black; 20% Asian;
30% Hispanic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Study Endpoints</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">A. Baseline circulating exosome concentration</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">B. Longitudinal changes in circulating exosome concentrations
associated with tumor treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.85pt 0pt 42pt; text-align: justify; text-indent: -0.25in">C.
Association of longitudinal changes in circulating exosome concentrations with response to treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.9pt 0pt 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Evaluation of clinical outcome per se,
(i.e., progression free or overall survival) is beyond the scope of this pilot study, we will explore potential associations with
clinical outcomes and the putative biomarker, circulating exosome concentration which will provide additional pilot data to direct
future studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B><I>Study Population - Patient Inclusion
and Exclusion Criteria</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Patients with a diagnosis of cancer are
potential subjects for this study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">In order to be eligible for this study, patients must meet <B>all </B>of the following criteria:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">1. Patients must have a histologically proven diagnosis
of cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">2. Have measurable tumor burden.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">3. Expected survival must be greater than six (6) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.85pt 0pt 42pt; text-align: justify; text-indent: -0.25in">4.
A Karnofsky Performance Status (KPS) must be 70 or greater, equivalent to ECOG 0 to &asymp;2 (Appendix A).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">5. Patients must be <U>&gt;</U>21 years of age.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.7pt 0pt 42pt; text-align: justify; text-indent: -0.25in">6. Patients
must be able to understand and sign an informed consent form, which must comply with U.S. regulations (U.S. 21 CFR 50) and ICH
guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.55in 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Patients with any <B>one </B>of
the following conditions <B>must </B>be excluded from this trial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">1. History of repeated central line associated thrombosis
or bleeding diathesis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">2. Chronic anti-coagulation therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">3. More than one malignant diagnosis, except for the
basal cell epithelioma of the skin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">4. Persistent fever greater than 38 C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt">5. Calculated CrCl less than 60 ml/min.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.95pt 0pt 42pt; text-align: justify; text-indent: -0.25in">6.
Required use of chronic corticosteroids or immune suppression for any reason including an organ allograft or HIV infection</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.85pt 0pt 42pt; text-align: justify; text-indent: -0.25in">7.
Patients with any acute or chronic illness including cardiovascular disease or history of myocardial infarction, autoimmune state,
or any psychiatric illness that in the opinion of the Investigators would compromise treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 388.95pt 0pt 6pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Study Design/Sample
Size:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">As this is a pilot,
hypothesis generating early phase non-randomized, clinical study, designed to provide initial characterization of a tumor biomarker,
and is not a hypothesis testing Phase II or III study, standard calculations of &ldquo;power&rdquo; or &ldquo;sample size&rdquo;
are not appropriate or applicable for this study. It is not known if there are significant differences in circulating exosome
concentrations by tumor type, treatment type, or kinetics of treatment response. Thus, the final target study cohort size will
be dependent upon early observations in a range of subjects from various tumor types. We will employ cohort expansion modifications
as indicated. We initially plan on enrolling 5 patients with defined tumor types, see table next page, for a total initial study
population of 45 subjects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">If analysis of
the initial 5 subjects with a given tumor type suggests impact of histologic subtype (e.g. for breast cancer &ndash; hormone
receptor positive, HER2/neu positive, triple negative, lobular vs. ductal), treatment type or kinetics of treatment response;
expansion cohorts consisting of 5 subjects will be added, via modification of the IRB approved protocol, as needed to
characterize the impact of these factors on circulating exosome concentrations.</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 29%; border-top: black 1pt solid; border-right: black 1pt solid; border-left: black 1pt solid; border-bottom: black 3pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Tumor Type</font></td>
    <td style="width: 21%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 3pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Study Cohort</font></td>
    <td style="width: 50%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 3pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.1pt">Approximate number of cases at UCIMC on</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.1pt">treatment with tumor present - 2013</P></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Breast adenocarcinoma</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">30</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Colorectal</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">21</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Gastric &amp; Gastroesophageal</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">30</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Pancreatic</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">60</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Cholangiocarcinoma</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">9</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Lung (NSCLC)</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">44</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Head &amp; Neck (SCC)</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">42</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Melanoma</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">22</font></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">Ovarian adenocarcinoma</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid"><font style="font: 10pt Times New Roman, Times, Serif">23</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Research Methodology/Study
Procedures</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Enrolled subjects will
have standard phlebotomy performed with collection of blood into 4 ml vacutainer tubes containing K2EDTA anticoagulant. These
tubes will be transported to Dr. Nelson&rsquo;s laboratory at 4 C (in the presence of a cool pack) for centrifugation at 300 g
(&asymp; 1200 RPM for tabletopcentrifuge - Beckman GH-3.8). Plasma will be removed from the vacutainer tube and distributed as
1 ml aliquots into 1.5 ml eppendorf snap top tubes labeled with the subjects 4 digit study ID number (e.g. 1001, cohort 1, subject
#1). These tubes will be placed at -80 C until shipment on dry ice to Princeton NJ, for assay of exosome concentration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Subjects will have phlebotomy
performed immediately before the administration of treatment, primary treatment or treatment for advanced disease. This blood
sample will be collected prior to the administration of any pre-medications for subsequent treatment, (surgery, chemotherapy,
chemoradiation, or radiation alone, the latter will be rare). Each sample will be labeled to identify the patient as with any
other biospecimen collected for clinical evaluation. Ideally, the first sample will be collected before any treatment has been
initiated, however there is no absolute requirement that the patients have not received prior treatment if they have advanced
disease. For those patients continuing treatment but with measurable, advanced disease, progression free survival and time to
treatment failure will have less meaning and we hypothesize, will be less likely to demonstrate associations with circulating
exosome concentrations. Never the less, the first collection will be considered the patient&rsquo;s baseline value. For multiple
day regimens, patients will have 4 ml of blood collected on the first and last day of the chemotherapy regimen. Additional 4 ml
samples will be collected no more frequent than weekly during the first four weeks of enrollment on this protocol. Thus, regardless
of whether treatment is primary (for a new diagnosis and therefore potentially primary surgical treatment), is neoadjuvant, or
is secondary for advanced disease the subjects will get a minimum of 4 x 4 ml phlebotomy samples collected in the first month.
Thereafter, phlebotomy will be performed with each cycle of chemotherapy (neoadjuvant or secondary) or with each post primary
treatment follow-up visit for no more than 6 months from the baseline collection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>Endpoint Data and Evaluations:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><U>Circulating Exosome
Concentrations:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 22pt">Samples of plasma shipped
frozen to Princeton NJ, will be analyzed in replicate via the ELLSA assay described above, quantifying the concentration of circulating
exocomes in each sample. Raw and mean data will be provided for data analyses. Grubbs test will be used to identify outliers from
triplicate or larger replicate determinations of exosome concentration from each sample.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Other Data to be
Collected:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><I><U>Treatment and
Response</U>: </I>Patients may be receiving so called &ldquo;targeted therapies&rdquo;, standard cytotoxic chemotherapy, combined
chemoradiation, and/or symptomatic/palliative support without cytotoxic therapies. Select agents can induce different types of
tumor cell death and may have different effects on the release of tumor-associated exosomes. It is conceivable that an immediate
and profound cytotoxic effect may lead to a transient &ldquo;bolus&rdquo; release of tumor-associated exosomes. Thus, treatment
administered will be collected to investigate the impact of particular agents or combinations thereof, on the longitudinal changes
in circulating exosome concentration. Additionally, we will collect tumor response data from the clinician&rsquo;s notes to assess
the association between changes in tumor burden and the longitudinal changes in circulating exosome concentrations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><I><U>Progression Free
Survival and Time to Relapse: </U> </I>All patients will be followed from the time of enrollment for PFS and TTR for a maximum
of five years. These clinical parameters will be used to investigate potential associations with longitudinal changes in the circulating
exosome concentration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><I><U>Sociodemographic
Characteristics:</U> </I>Race and ethnicity will be recorded for all participants in order to ascertain whether these impact circulating
exosome concentration. This will inform the design of future studies. In addition, the use of prescription and nonprescription
medications will be recorded as these may also confound the circulating exosome concentration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><I><U>Cancer &amp; Medical
History<B>: </B></U></I>Diagnosis, prior treatment, comorbidities, as well as histology classification will be recorded. Social
history including education level, activity level, will also be recorded to investigate potential confounding co-variables.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Statistical Considerations
&amp; Data Analysis</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-indent: 22pt">Descriptive statistics
will be computed to summarize demographic and background variables, efficacy variables and toxicity variables. Comparisons of
baseline characteristics will be performed using univariate analysis of variance for continuous variables and Chi-square analyses
for categoric variables. Changes over time in circulating exosome concentrations and associations with other categoric variables
will be evaluated by multivariate analysis of variance methods for repeated measures. Because this is an early phase study, the
sample size is not based on the power necessary to test a hypotheses for a given or expected effect size.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The risk to the subjects
is limited to the risk of phlebotomy and the risk of breach of HIPAA security <U>Phlebotomy Risk:</U> Collection of blood during
the phlebotomy visit may cause pain, brief dizziness, possible fainting, slight bleeding, swelling or bruising at the collection
site, and a very remote chance of infection.&#9;To minimize this risk certified and experienced phlebotomists or RNs will collect
the specimens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><U>HIPAA Risk:</U> We
recognize that there is a risk for confidential information to be exposed. Biomarkers are stored in Dr. Nelson&rsquo;s laboratory.
Clinical data is maintained within the EMR and if transferred to any desktop computer, that computer will be maintained in a locked
office, encrypted and password protected in accordance with University of California policies. Access to the computers and files
is restricted by a high security system through password. Within our secure network, data will only be accessible to the study
personnel who have signed confidentiality agreements, taken online IRB tutorials for the protection of human subjects and taken
the Health Insurance Portability and Accountability Act online tutorial. Computers are located in offices where office doors are
closed and locked after working hours and during weekends. All office doors are locked after working hours and during weekends.
To additionally protect the confidentiality of participants, our central informatics system includes the following features: 1)
use of encryption software to secure data transport; 2) a firewall system that protects the informatics network from intrusion
or unauthorized access; 3) access to the central informatics system requires a valid password; 4) confidential data are stored
in a separate secure database table and linked to data in other tables by a number only with no personal identifiers; 5) extract
files and reports will not contain any confidential information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Potential Benefits
of the Proposed Research to Subjects and Others:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B></B>There will be no benefits for participants in the study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B><I>References:</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>1.</B></TD><TD STYLE="text-align: justify"><B>Thery, C., <I>Exosomes: secreted vesicles and intercellular
communications. </I>F1000 Biol Rep, 2011. 3: p. 15.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>2.</B></TD><TD STYLE="text-align: justify"><B>Valenti, R., et al., <I>Human tumor-released microvesicles
promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
</I>Cancer Res,2 006. 66(18): p. 9290-8.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>3.</B></TD><TD STYLE="text-align: justify"><B>Schartz, N.E., et al., <I>From the antigen-presenting
cell to the antigen-presenting vesicle: the exosomes. </I>Curr Opin Mol Ther, 2002. 4(4): p. 372-81.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>4.</B></TD><TD STYLE="text-align: justify"><B>Wolfers, J., et al., <I>Tumor-derived exosomes are a
source of shared tumor rejection antigens for CTL cross-priming. </I>Nat Med, 2001. 7(3): p. 297-303.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>5.</B></TD><TD STYLE="text-align: justify"><B>Mignot, G., et al., <I>Prospects for exosomes in immunotherapy
of cancer. </I>J Cell Mol Med, 2006. 10(2): p. 376-88.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>6.</B></TD><TD STYLE="text-align: justify"><B>Delcayre, A. and J.B. Le Pecq, <I>Exosomes as novel
therapeutic nanodevices. </I>Curr Opin Mol Ther, 2006. 8(1): p. 31-8.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>7.</B></TD><TD STYLE="text-align: justify"><B>Hao, S., T. Moyana, and J. Xiang, <I>Review: cancer
immunotherapy by exosome-based vaccines. </I>Cancer Biother Radiopharm, 2007. 22(5): p. 692-703.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>8.</B></TD><TD STYLE="text-align: justify"><B>Filipazzi, P., et al., <I>Recent advances on the role
of tumor exosomes in immunosuppression and disease progression. </I>Semin Cancer Biol, 2012. 22(4): p. 342-9.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>9.</B></TD><TD STYLE="text-align: justify"><B>Whiteside, T.L., <I>Immune modulation of T-cell and
NK (natural killer) cell activities by TEXs (tumour-derived exosomes). </I>Biochem Soc Trans, 2013. 41(1): p. 245-51.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>10.</B></TD><TD STYLE="text-align: justify"><B>Marton, A., et al., <I>Melanoma cell-derived exosomes
alter macrophage and dendritic cell functions in vitro. </I>Immunol Lett, 2012. 148(1): p. 34-8.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>11.</B></TD><TD STYLE="text-align: justify"><B>Peng, P., Y. Yan, and S. Keng, <I>Exosomes in the ascites
of ovarian cancer patients: origin and effects on anti-tumor immunity. </I>Oncol Rep, 2011. 25(3): p. 749-62.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>12.</B></TD><TD STYLE="text-align: justify"><B>Azmi, A.S., B. Bao, and F.H. Sarkar, <I>Exosomes in
cancer development, metastasis, and drug resistance: a comprehensive review. </I>Cancer Metastasis Rev, 2013.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>13.</B></TD><TD STYLE="text-align: justify"><B>Chalmin, F., et al., <I>Membrane-associated Hsp72 from
tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.
</I>J Clin Invest, 2010. 120(2): p. 457-71.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>14.</B></TD><TD STYLE="text-align: justify"><B>Xiang, X., et al., <I>TLR2-mediated expansion of MDSCs
is dependent on the source of tumor exosomes. </I>Am J Pathol, 2010. 177(4): p. 1606-10.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>15.</B></TD><TD STYLE="text-align: justify"><B>Liu, Y., et al., <I>Contribution of MyD88 to the tumor
exosome-mediated induction of myeloid derived suppressor cells. </I>Am J Pathol, 2010. 176(5): p. 2490-9.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>16.</B></TD><TD STYLE="text-align: justify"><B>Xiang, X., et al., <I>Induction of myeloid-derived suppressor
cells by tumor exosomes. </I>Int J Cancer, 2009. 124(11): p. 2621-33.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>17.</B></TD><TD STYLE="text-align: justify"><B>Yu, S., et al., <I>Tumor exosomes inhibit differentiation
of bone marrow dendritic cells. </I>J Immunol, 2007. 178(11): p. 6867-75.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>18.</B></TD><TD STYLE="text-align: justify"><B>Clayton, A., et al., <I>Human tumor-derived exosomes
selectively impair lymphocyte responses to interleukin-2. </I>Cancer Res, 2007. 67(15): p. 7458-66.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>19.</B></TD><TD STYLE="text-align: justify"><B>Peche, H., et al., <I>Induction of tolerance by exosomes
and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. </I>Am J Transplant, 2006. 6(7): p. 1541-50.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>20.</B></TD><TD STYLE="text-align: justify"><B>Rana, S., K. Malinowska, and M. Zoller, <I>Exosomal
tumor microRNA modulates premetastatic organ cells. </I>Neoplasia, 2013. 15(3): p. 281-95.</B></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>21.</B></TD><TD STYLE="text-align: justify"><B>Hood, J.L., R.S. San, and S.A. Wickline, <I>Exosomes
released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. </I>Cancer Res, 2011. 71(11): p. 3792-801.</B></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>22.</B></TD><TD STYLE="text-align: justify"><B>Aung, T., et al., <I>Exosomal evasion of humoral immunotherapy
in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. </I>Proc Natl Acad Sci U S A, 2011. 108(37): p.15336-41.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>23.</B></TD><TD STYLE="text-align: justify"><B>Pilzer, D., et al., <I>Emission of membrane vesicles:
roles in complement resistance, immunity and cancer. </I>Springer Semin Immunopathol, 2005. 27(3): p. 375-87.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>24.</B></TD><TD STYLE="text-align: justify"><B>Jimenez, C.R., et al., <I>Proteomics of colorectal cancer:
overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers.
</I>J Proteomics, 2010. 73(10): p. 1873-95.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>25.</B></TD><TD STYLE="text-align: justify"><B>Khan, S., et al., <I>Plasma-derived exosomal survivin,
a plausible biomarker for early detection of prostate cancer. </I>PLoS One, 2012. 7(10): p. e46737.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>26.</B></TD><TD STYLE="text-align: justify"><B>Kucharzewska, P., et al., <I>Exosomes reflect the hypoxic
status of glioma cells and mediate hypoxia- dependent activation of vascular cells during tumor development. </I>Proc Natl Acad
Sci U S A, 2013. 110(18): p. 7312-7.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>27.</B></TD><TD STYLE="text-align: justify"><B>Liang, B., et al., <I>Characterization and proteomic
analysis of ovarian cancer-derived exosomes. </I>J Proteomics, 2013. 80C: p. 171-182.</B></TD>
</TR></TABLE>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>28.</B></TD><TD STYLE="text-align: justify"><B>Logozzi, M., et al., <I>High levels of exosomes expressing
CD63 and caveolin-1 in plasma of melanoma patients. </I>PLoS One, 2009. 4(4): p. e5219.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>29.</B></TD><TD STYLE="text-align: justify"><B>Silva, J., et al., <I>Analysis of exosome release and
its prognostic value in human colorectal cancer. </I>Genes Chromosomes Cancer, 2012. 51(4): p. 409-18.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>30.</B></TD><TD STYLE="text-align: justify"><B>Batista, B.S., et al., <I>Identification of a conserved
glycan signature for microvesicles. </I>J Proteome Res, 2011. 10(10): p. 4624-33.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>31.</B></TD><TD STYLE="text-align: justify"><B>Momen-Heravi, F., et al., <I>Current methods for the
isolation of extracellular vesicles. </I>Biol Chem, 2013. 394(10): p. 1253-62.</B></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 22pt; text-align: left"><B>32.</B></TD><TD STYLE="text-align: justify"><B>Thery, C., et al., <I>Isolation and characterization
of exosomes from cell culture supernatants and biological fluids. </I>Curr Protoc Cell Biol, 2006. Chapter 3: p. Unit 3 22.</B></TD>
</TR></TABLE>





<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>aethlon_ex1003.htm
<DESCRIPTION>BUDGET FOR UCI CLINICAL TRIAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 10.3</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protocol No.: UCI 14-25 Plasma Exosome Concentration in Cancer
Patients Undergoing Treatment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Protocol Target Accrual: 45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PI: Edward Nelson, MD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short Title:
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Startup Charges</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 67%; font-size: 10pt; text-align: center">Event</TD>
    <TD STYLE="width: 33%; font-size: 10pt; text-align: center"><B>Negotiated Charge</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Protocol Set-Up &amp; Administration Fees (Feasibility, Budget, Medicare Cost Coverage, IRB
    Application/Doc Prep, IRB Institutional Review Fee, Annual CRC Administrative Fees, and Study Supplies)</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: right; margin-bottom: 0pt"><I>15,105.00&nbsp;&nbsp;&nbsp;&nbsp;</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; text-align: right"><B>Subtotal:</B></TD><TD STYLE="width: 2%"><B>&nbsp;</B></TD>
    <TD STYLE="width: 1%; text-align: left"><B>&nbsp;</B></TD><TD STYLE="width: 13%; text-align: right"><B>15,105.00</B></TD><TD STYLE="width: 1%; text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right"><B>Overhead Charges @ 0.0%:</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>0.00</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: right"><B>Indirect Costs @ 26.0%:</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>3,927.30</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right"><B>Total Startup Charges:</B></TD><TD><B>&nbsp;</B></TD>
    <TD STYLE="text-align: left"><B>&nbsp;</B></TD><TD STYLE="text-align: right"><B>19,032.30</B></TD><TD STYLE="text-align: left"><B>&nbsp;</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Per Subject Visit Charges (Items include 26.0% indirect charges)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 14%; text-align: center; border-bottom: Black 1pt solid"><B># occurances</B></TD>
    <TD STYLE="width: 47%; border-bottom: Black 1pt solid"><B>Event</B></TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid"><B># of Subjects</B></TD>
    <TD STYLE="width: 19%; text-align: right; border-bottom: Black 1pt solid"><B>Visit Reimbursement</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>1</TD>
    <TD>Phlebotomy</TD>
    <TD>45</TD>
    <TD STYLE="text-align: right">84.00</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>1</TD>
    <TD>Cancer Center Data Management</TD>
    <TD>45</TD>
    <TD STYLE="text-align: right">1,497.00</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">1</TD>
    <TD STYLE="border-bottom: Black 1pt solid">Study Oversight, Coordination, and Biostatistics</TD>
    <TD STYLE="border-bottom: Black 1pt solid">45</TD>
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid">1,778.00</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><B>Total Subject Charges (Maximum)</B></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><B>3,359.00</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 83%; text-align: right">Direct Cost Subtotal for (1) Subjects:</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 13%; text-align: right">2,665.87</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">Indirect Costs @ 26.0%:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">693.13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: right; border-bottom: Black 1pt solid"><B>Total Per Subject Charges for (1) Subjects</B></TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><B>3,359.00</B></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: right">Total Per Subject Charges for (45) Subjects</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151,155.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Protocol Related Variable Passthrough Charges (Items include
26.0% indirect charges)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Event</B></TD><TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid"><B>Negotiated Charge</B></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="width: 76%; text-align: left">Protocol Annual Renewal Prep Fee (Payment triggered at IRB renewal. Includes study project management outside visit activities for sponsor site visits, IRB renewal prep, bill reconciliation, OnCore managment, SAE reporting, IRB modifications, close out and storage, etc.)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right"><B>7,000.00</B></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">IRB Committee Renewal Review Fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>1,039.50</B></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(238,238,238)">
    <TD STYLE="text-align: left">Consent Translation (Pass through cost, based on language and length of document)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><B>TBD</B></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other Tests/Procedures not included above</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: left"><B>TBD</B></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 54pt; width: 144.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Aethlon Medical Announces Cancer Clinical
Trial Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SAN DIEGO, April 15, 2015 /PRNewswire/ --Aethlon Medical, Inc.
(OTCQB:AEMD), a pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, announced today that
it has entered into an investigator-initiated clinical trial agreement with the University of California, Irvine (UCI). Under the
agreement, a clinical study protocol entitled, &ldquo;Plasma Exosome Concentration in Cancer Patients Undergoing Treatment,&quot;
will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The
tumor types include the following forms of cancer; Breast adenocarcinoma, Colorectal, Gastric &amp; Gastroesophageal, Pancreatic,
Cholangiocarcinoma, Lung (NSCLC), Head &amp; Neck (SCC), Melanoma and Ovarian adenocarcinoma. The principal investigator of the
study is Edward Nelson, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The study endpoints include establishing baseline exosome levels
and monitoring changes in circulating exosome concentration associated with tumor treatment and the association of longitudinal
changes in circulating exosome concentrations with response to treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The clinical study will also provide data to help direct future
clinical investigations of the Aethlon Hemopurifier&reg; as a therapeutic candidate to reduce the presence of circulating tumor-derived
exosomes, which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis. Aethlon
Medical believes that the Hemopurifier is a first-in-class bio-filtration device that targets the single-use removal of viruses
and tumor-derived exosomes from the circulatory system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recruitment of participants in the study will be through the
use of internal and outside referrals to the University of California, Irvine Medical Center (UCIMC). Review and approval of this
human protocol will be conducted by the UCI Institutional Review Board (IRB) Human Subjects Review Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aethlon
Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company's
lead product is the Aethlon Hemopurifier&reg;,&nbsp;a first-in-class device that selectively targets the rapid elimination of circulating
viruses and tumor-secreted exosomes that promote cancer progression. &nbsp;Exosome Sciences, Inc. is a majority owned subsidiary
that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.&nbsp;Additional
information can be found online at&nbsp;</FONT><FONT STYLE="font-size: 10pt">www.AethlonMedical.com<FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">and connect with the Company on Twitter</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,
LinkedIn</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">, Facebook</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
and Google+</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that Exosome Sciences, Inc. will not be able to commercialize its future products,
including any that can be described as a liquid biopsy, that the FDA will not approve the initiation of the Company's future clinical
programs or provide market clearance of the Company's products, future human studies, whether revenue or non-revenue generating,
of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg; as an adjunct therapy to improve patient responsiveness to
established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development
of its planned products, the Company's ability to manufacture its products, either internally or through outside companies, and
provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability
of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance,
competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result
of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors
detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or
revise any forward-looking statements, whether as a result of new information, future events, or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James A. Joyce<BR>
Chairman and CEO<BR>
(Office) 858.459.7800 x301</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Cell) 619-368-2000<BR>
jj@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jim Frakes<BR>
Chief Financial Officer<BR>
858.459.7800 x300<BR>
jfrakes@aethlonmedical.com&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex1002_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1002_01.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`#S`6D#`2(``A$!`Q$!_\0`
M'``!`0$!`0$!`0$```````````8%!P0#`@$(_\0`2Q```0,#`@(%"04%!08&
M`P$``0(#!``%$082(3$'$Q94TQ05(C9!4766M3)689/40E5TDK(C)#=2LR8S
M0V)Q@0@T<G.1H41CHO#_Q``9`0$!`0$!`0```````````````0(#!`7_Q``N
M$0`"`0(#!P0"`@,!`````````1$A\`(Q00,246&AL=$B<<'A!)$R@1-"\<+_
MV@`,`P$``A$#$0`_`/\`3-^O$*PVQ=PN:W41D+;;_LF5O+4MQ:6T)2A`*E$J
M4D``'G6+V\M'<]2?+EQ\"G27ZN0_C5I^HQZJJ`E>WEH[GJ3Y<N/@4[>6CN>I
M/ERX^!552@)7MY:.YZD^7+CX%.WEH[GJ3Y<N/@554H"5[>6CN>I/ERX^!3MY
M:.YZD^7+CX%?75FKF=.W&SV_S9<;E.NJW&XS,/J024)W*R77$)'#\:]</445
M3)\[(\RRDM+D+B3Y#`=0RDX+IZMQ:=GXYX>W%`9_;RT=SU)\N7'P*=O+1W/4
MGRY<?`K8E7ZSQ'83<NZV]AR=_P"50[)0DR/_`&P3Z7,<LU^E7NU)O";2JYP4
MW52.L$(R$!XI_P`VS.['XXH#%[>6CN>I/ERX^!3MY:.YZD^7+CX%:K6I+&ZB
M>MJ\VQ:+?GRQ2939$;'/K./H8_'%?%.K=-J6E"=06@K4\(P2)K>2Z1D-CTOM
M$?L\Z9@\';RT=SU)\N7'P*=O+1W/4GRY<?`K<7>+8W=F[6Y<8:;FXCK$1%/I
M#RD?Y@C.XC\<5EZRU7'TLW;"]!G3W[C+3"CL0PWO4XI*E#)<6A('HGCF@//V
M\M'<]2?+EQ\"G;RT=SU)\N7'P*_3>L`W<;1`NEDNMLE71]QB.B28Z^*&RX5*
M+3JP!@$#VY]F.->RX:G@6_4D>RR0\E]Z$]/ZW`ZI+;12%;CG.?3'L]AIE?\`
M8OX/#V\M'<]2?+EQ\"G;RT=SU)\N7'P*_ND=:1M4%I<.V79B)(9\HBS'V4EB
M0WG&4K0I02?^5>U7X<#7ZL.M;7>]5WK3\-$E,RU;>M<<0`V[GGU:LY5M/!7`
M8-6',":2?CMY:.YZD^7+CX%.WEH[GJ3Y<N/@5I7;4=OM5S8@S'"AQR.]+6O@
M$LLM`;W%DG@,J`X9XG_J:\5IU7YQDQDBQ7N/#EC,::\P@M.C;N!(0M2VP0.;
MB4>P<SBH,CY=O+1W/4GRY<?`IV\M'<]2?+EQ\"LFV]+&GKEIUN\1$35LFZ(M
M"V=B.M:>4O8DJ&[&WB#D$\#RSPK9&M;6=?'2.R3YR$;RGK=@ZGW]7NSG?M]+
M&.7'-6)OE/8.F=UCN?CMY:.YZD^7+CX%.WEH[GJ3Y<N/@5IW?4$6U7FRVR0V
M^I^[.N-,*0D%*2ALK.XD@@8!Y`\:]-TO%LM/D_G6XPX/E#@:9\I?2UUJSR2G
M<1D_@*@,/MY:.YZD^7+CX%.WEH[GJ3Y<N/@5MW&]6NV/Q6;E<H4-Z4K8PW(?
M2VIY7N0"1N/X"L-K7^GY-SEV^#-8E2XDYN`^VB0R@H<7R^VM.X`Y&$Y.00`2
M#@JY#)2?WMY:.YZD^7+CX%.WEH[GJ3Y<N/@5JQ=26.7/3!B7FVOS5%:1';E(
M4X2@X6-H.?1/`^[VU^-0:@8LSD2/Y/)FW"85"-"BA)==VC*B"M24I`&,E2@.
M(&<D4!F]O+1W/4GRY<?`IV\M'<]2?+EQ\"O6G5EK8M2)U\>\P(+I8*+NI$8A
MP?L@E6U7X%*E`^PFO5<M26.V/):N5ZMD-U2$N)1(E-MJ*5':E0!(X$\`?:>%
M`97;RT=SU)\N7'P*=O+1W/4GRY<?`K[.ZXTTSJ";9I%Y@LSH;")#Z77TH"$*
M.!DD\^1/NW)SS%:,O4-EANO-3+O;H[C!;2ZAV2A!;*_L!0)X%6#C//'"G,&1
MV\M'<]2?+EQ\"G;RT=SU)\N7'P*UFM161Z3"CLWBW.2)K?716DRD%4A'/<V,
MY4G\1D5DZHUM#T^\65P+A.?,B/$2W%#65NO;MB05K2!]G)R1]H<_8`[>6CN>
MI/ERX^!3MY:.YZD^7+CX%>BV:NM\ENX^<D.V5^W)2N8Q<EM(+"%9VK*TK4C:
M<'B%'D0<&EWUMIVTQ;3)F7>$(UU>2S#>2\DH=)]H5G&W\<XXCVD4@'G[>6CN
M>I/ERX^!3MY:.YZD^7+CX%;D2\6R;<)4"'<84B=%QY1':?2MQG/+>D'*?^]9
M%YUUIBT6ZYS9=[MZF[:0F4AJ0A:VE$X"5)!R%$\`#0'R[>6CN>I/ERX^!3MY
M:.YZD^7+CX%:-AU);K[*G,6]PK5$ZLE64E+B'$!:'$$$A2""0#[TFMFJU`3D
ME>WEH[GJ3Y<N/@4[>6CN>I/ERX^!552H"5[>6CN>I/ERX^!3MY:.YZD^7+CX
M%55*`S[#>(5^MB+A;%NKC+6XW_:LK96E;:U-K2I"P%)(4E0(('*M"I7HT]7)
MGQJ[?49%55`2O27ZN0_C5I^HQZJJE>DOU<A_&K3]1CU54`I2L+4&K;-I^0AB
MZR76W%(ZU75QG7DM-YQO<4A)#:,_M+('`\>!IR!NTKQW.YQ+9`5-F.E,<8`*
M$*<4HDX2E*4@J4HD@``$DGA7YLMVAWJ")=O<6MK<I"@XTMI:%`X*5(6`I)'N
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M>XTXHN)XJX8&WB<`^S-=KI6M]MS>K^212+T\(XZ]H>^JUW.>><NKMMEW:-=&
MW&),5MAH-H0,.;VU/E0*"`E&$E)XJ3DUO=,M@N-]C:9-MM\R>B#=VY<EJ%*3
M&>#00L$H67&\'*AR4#71*5G1+A'2/"+JWQ4=_)R2;;;LBZZ4N%LTIJ93%JG/
MO/L3[HQ)D*2XPI`4A;DI8QDC@5C''`K9>@7B[:^M=^587HL5JT3(CC$Y]D'K
M%N-E"5=6MP84$GB-V!SX\*Z%2K/SU4"^LG"^C_0=XTEJN;==.6>Z6:U+AO*D
M6:1/9?8?E8'5B.4KX)R#Z3FTX(&`,@>S3&A]7:>EZ/NCSMON$F.ZZFXLL1RR
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M68[K*'$I6PI`QUKB$GB1[:F==:>U%J2]L7B/;[Y%C2+6_:WK>V_`2\@K6#N6
MISK4!M0'$MDK&$X!Y5V"E2_W0LW[.3F,G3ETM5\=?%C[2PYEGC6SJ9$AG:TI
MI2RKKBX!EM6X$J0A1RG['*LRZ:4U`YJ29U5J*HKNI8-W3(0^UU890TA"Q@J"
MMR2@G&WB",9Y5V&E:WG.]>:?=&8]+P\HZ1V.*V?0]_B+L*U6X-KCZMEW-]0>
M;R(S@="5G"N.0I/`9/O%7.K+5.;U;9-36V&Y<50&)$5Z$TXA#BT.[#N05J2D
MD%`X*4.!/'(P;&E93A)+3Q'8NK?'RWW9RK7=OU9J1#"D61R/%>@S(JH[$QE,
MAM;B4=677<C:C@K<EI2N(3]KV2<"!<[;JZV6IZR*N-T1H=J&['#S66U]9L5E
M2E!)3GF02<#@#RK_`$#2G*\L2_\`19=^Z?P<+N71[J1JS7"U,Q_+ER=.P8*9
M?7H"?*(RU*4A6Y05Z6X!)`(]^*_MWT=J2^ZIN=S>L+D>++GV9]+3TEA2NK84
MHO;MJR,ISR!.?9FNYTK>^WBWGG,]9,Q3=Y1T2^#C]_T/?96O+H_ONK]KN4V%
M+0J-)BM,L!C;P<+C:WL@IRD-\#G!*<DUI:PL%ZD6^--BVMZ9-3J1JY.QFGFD
MK+#1V)*2M83DH0@XW#G_`-:Z=2L)Q$:?7A%=9G7PU\G&-7Z-U%J:Y3-21X\V
MU2`[`ZJW];'5)<:CN+6HY)6SO)6"D*44^@-V,\/8WI2]0[!9Y#,&XRI;.H#=
MGXLF7&5(V*"TJ(*$MLA7I;B@$CGA1KK=**G?MX0=<_;HU\G&M`Z$OULN\5NZ
MO78BWB:&Y:I$01U]>HD%"4-]<LG(4KK%)PI/#<*_BM*WUWHU<TT-+QT7.#:C
M"1<G)#(,E84E6UK&5!*]NXES9@XX'F.S4JS?[\@Y_HYM^;TE:DNZHSD5H0(4
M)QIQ2%*2\D+<4E10HIRD.('`D<>==`I2C<D2@4I2H44I2@)7HT]7)GQJ[?49
M%552O1IZN3/C5V^HR*JJ`E>DOU<A_&K3]1CU55*])?JY#^-6GZC'JJH!7,=<
M>40-0:D6;;<9R;S9&X4018;KZ2\E3P*%J0"EL'K4G<O`Y\>%=.I3.C-8<6[E
M=9.?ZQ@.R[!9XV+FH6B7&<G>1MNI=6V&R%%I0&Y>-P)ZO*N!`]+A6UH`2Q:I
M7E'EWD?E2S`\O+AD>3X3MZSK/[3.[=C?Z6,9JFI5FK?'Z\=68BB7#[\]CFL+
M3;DW7]Y@7K46I+DU&MD%]D^<EPMBG'9:5^C$ZE*L]4CBI)/#GC`J@[!VCOFI
M/F.X^/2W?XIZB^"VS_7GURS1?2!KZY=.=RLERLJD6I`V.Q>`3#;!.UX+_:W?
M_P!9X8QPZ[+88MJL3PQZ5(;@ZGV#M'?-2?,=Q\>G8.T=\U)\QW'QZY_J^>WI
MOIGFZI?6I,.!:HD:7C)'4O+D#./>'$-?]B:S]#JG6E=_ANW2;`NURNZ)#PB1
MD2'UK7#0\XALN`H0$DXRI)&!C@3D<DJ3P\^*]#34.+R.H=@[1WS4GS'<?'IV
M#M'?-2?,=Q\>N76+6.K+Y:;K,3?7(OFRS+FI2F-'47W6Y$E`ZPA*DX4EE.X(
M(&>*2/;OP=27_"[S*O9$)%\,`PS&:ZI+!2.)(3O*DDY!"APX$'G1J'#NL=R8
MO2I=TGL678.T=\U)\QW'QZ=@[1WS4GS'<?'KF5SUKJ*&N4S!O<R3Y39TW!B3
M,@QVDH67VD`M-I&\-E+AX.[CP&%$@UT[2<BXMWV_VNY7%RXHAJ9<9>=:;0L!
MQ!)2=B4@@%)QPS@\2>=&HJ[K!G>4Q>4G\[!VCOFI/F.X^/3L':.^:D^8[CX]
M0$.+%@3K?>PW"N+,F[!I-]AK+-RWK?*>H>;6@E;8R$*3N&`G(2,#'VT_*F0=
M/KA-ZDNR9<F[W-:>HBQG9"TMOK!"5+0&T#."2M)^U@%(QB?Z[UZ>3<7^_!<]
M@[1WS4GS'<?'IV#M'?-2?,=Q\>N7VC6FJKOI^[WA-[4P+79H]P2PW&8*7W-[
MX4%G:KT5!I.=A''BD@<]&[WR9)>LE[N=[3&9;OLIKR%;""W&2PU)2%C`#BCM
M2%*!400H8`YU<6'=S)A]2I=)+_L':.^:D^8[CX].P=H[YJ3YCN/CUSU_5NH(
MTNX0(]ZG/*7$A2FI,V)&;4V792&U=6V@9#92HX#@*O<H\Z^]_?N<@`3M1/O-
MP-1P+>F(\RPDO`/,K#BRE"5=8<D^CA.T?9]M7#AWFEQ?REW9&Z-WE/8J-&6R
M0W==70H][O*(D*ZH98;>D^5E"3"BN$;WPXO&YQ1QNP,\!51YKE_OVY?R1_"K
M*T;ZQZ[^--_3H=559*97FN7^_;E_)'\*GFN7^_;E_)'\*M6E`97FN7^_;E_)
M'\*GFN7^_;E_)'\*M6E`97FN7^_;E_)'\*GFN7^_;E_)'\*M6E`97FN7^_;E
M_)'\*GFN7^_;E_)'\*M6E`97FN7^_;E_)'\*GFN7^_;E_)'\*M6E`97FN7^_
M;E_)'\*GFN7^_;E_)'\*M6E`97FN7^_;E_)'\*GFN7^_;E_)'\*M6E`97FN7
M^_;E_)'\*GFN7^_;E_)'\*M6E`97FN7^_;E_)'\*GFN7^_;E_)'\*M6E`97F
MN7^_;E_)'\*GFN7^_;E_)'\*M6E`9%K,EF]3HC\U^6VB.PZ@O);!25*=!^PE
M/#T$\ZUZRHWK3<?X*-_6_6K0$KT:>KDSXU=OJ,BJJI7HT]7)GQJ[?49%55`2
MO27ZN0_C5I^HQZJJE>DOU<A_&K3]1CU54`I2N9:W5)GW_4K?G*X04V>R-SHA
MBRW&$AY1?)6L)(2X!U21M7D<^'&C<59K#AWJ*ZP=-I4;K!N]WG1$)%B:6J=*
M<BK=")JH9#6Y*G/[5'IH!2",I!5QX"O9H&0VJURH752&9,"2J-)0]/>G8<VI
M7Z+SOIK3A:<9`QRP*L5:X?7DQO*$^-_!\[;_`(IZA^"VS_7GU4A"0M2PE(6H
M`%6.)`S@?_9_^:@],W*7-Z0]42)%EGVYY%GMP3%E+8+CF'IQ!!:<6D`DXXJ!
MR#D8P3J-ZWMLB0(L-N2_.*6R(R4`+W+4XDI()]$HZI15G``QQ.:QBQX<-&ST
M;+\;:[9-[/#*6?+W-V3:K?*7(7)@1'ER$):>4XRE1<0DDI2K(X@$D@'D2:\]
MPT[9+BAY%PL]NEI>=2^X'XJ'`MQ("4K5D<5```$\0!6+JS4&H+/=+?'MUEM4
MR-.D)BLNOW1QA8<*%+.Y`CK`3A!XA1/+A1.O[+&5Y/=9/D\UM*P\&&'WHX<;
M25.-MO\`5!+BDA*O1'I<#Z-:53C#-R/8+/'1(1'M-O:3(06G@B,A(=02HE*L
M#B"5*.#[5'WFOJBTVY#?5H@1$M];Y1M#*0.L_P`^,?:_'G63J#5D*U*CM,XE
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MM3^]_P`J7UD1M6Y[&.L.1Q7CANYU^9FJ;/$C2'W92E-L/^2GJF7'%+=QG8VE
M*27%8]B`>1',&O`YK[3:([#_`)>XMIT%1+<5Y?4@*VDO`(/4@*!!+FW!!!Y&
MHN5ZE?%FNS8+,PQ)99M-O;9DHZM]M$9`2ZC*CM4`/2&5J.#_`)C[S7Y7IVRK
MN2KBNSVY5P5C,HQ4%TX!`]/&>1(Y\B:\LG5]DC7D6MZ:4RMZ6B0RX6DN*`*6
MU.A/5I601A)4%'(P.-9;?29I1UE3K=PD*0&NO3B!()<;!PI:!U>5I2?M%.0C
M]K%,ZB#9AZ4T[!;"(5AM,=`Y)9AMH`](+Y`?YDI5_P!0#S%?:5I^S2[FBY2[
M1;G[B@)"93L9"G4A*@I("R,C!`(X\",UXIFLK#$G,1'I^77DH6%-LN.-H2O[
M!<<2DH;"OV=Y&?9FOK:]56>Z75RW0I+BY*`LC='<0VX$$)66W%)"'-I(!V$X
M/.K42>#1OK'KOXTW].AU55*Z-]8]=_&F_IT.JJH!2E*`4I2@%*4H!2E*`4I2
M@%*4H!2A(`))``YDU*2=<VUR0Y$L#,G4$U"BE3=L2%MMJ!P0MXD-((/,%6[@
M>!H"KI7)[9TKL-])*=,ZBF6R&^\WU;<>*5/):?W<&W)!*1O(X;0C`/#<3@5U
MBMX]GCP1O*)$BE*5@"E*4!E1O6FX_P`%&_K?K5K*C>M-Q_@HW];]:M`2O1IZ
MN3/C5V^HR*JJE>C3U<F?&KM]1D554!*])?JY#^-6GZC'JJJ5Z2_5R'\:M/U&
M/550"L'4&D;-J"4B1=8[[CB6^I/52GF4NMYSL<2A20XG/[*P1Q/#B:WJ4Y@R
MKEI^WW)EYJ8B0M#JTN>C*=06E)&`IHI4"T<>U&WV^\UZ;3;8MIAIBPD+2V"5
M$N.J=6M1YJ4M9*E$^\DFO92@)*(I:.DW4JFD=8X+);2E!.-QZZ?@9]E9]OTQ
M>[?J65J),B)(G2VV42(_V$*`4O>E)VY&U/5[3D[BE60,C'YU-88=RZ4[1USU
MR8\JLLOK_(KE(B=;U#\?JMW5+3G;Y2_C_P!9]PQJ]@[1WS4GS'<?'K&/9K&T
MWH>K\?\`+Q_CX<6'`E&*CE9K./\`A[]1VE^YS+$ZPMI*8$\2G0LD$I#3B,)P
M#QRL<\>VHR?I/4DO4UON5WEQI,"V7%V6G$EY2G6%(<2$".EL("DA:0.*RK!P
M4Y(-)V#M'?-2?,=Q\>G8.T=\U)\QW'QZWE=\#S3/;OY)'2^D;E/TNMR1N9>=
MN<5R,);:F7$0(KR2TE22"H+*$J5@X.5\<>S]R-`7V58XMC>=MB(%IC26H#Z7
M5J=D*<8<91UJ2C#8`<.=I7N(SPY55]@[1WS4GS'<?'IV#M'?-2?,=Q\>JW*B
M\H";3E'VU98I%WT!/L<;R8R7X7DR0\HAHJVXPH@$[?\`L?\`I6#9=,S[<Q/;
MMFCM&6!Z3'+/E-O?*R<D#TTB*WN`!)QNXD`<,Y&QV#M'?-2?,=Q\>G8.T=\U
M)\QW'QZCJVWJ92B(T,=K1=QM5LL\:SKAO>89BG[>W(<4V'FE-K0I#JDH.U0Z
MQ6%@*S@$C)-9$[H_OSH7+8-K;O,IYV0N9'FR(CD):U9`0I"?[PA(QZ#@2%$$
MG&<"O[!VCOFI/F.X^/3L':.^:D^8[CX]67.\\RZ1=U,2;HZ]O.3+:E^WKLTV
MXLW-V6XM?E*5(4VM38;VE)!4V,*WC`.-IP#7[M6B;A$AV=IQZ&50[')MCA2I
M6"ZX6B%#T?L^@<G@>(X5L=@[1WS4GS'<?'IV#M'?-2?,=Q\>II%Y1V*G&5UG
MN1\OHSG.2"DJ9E1YD:,S*"[M-C(:4TTELX99*4OI(3GTB@CWD<!NZ7TG=+1J
MQZ8@0X-L)=4XS#F/K;E%9RE1C+&QE0YDH4=QR3C-:?8.T=\U)\QW'QZ=@[1W
MS4GS'<?'J[SF;J86%)1[=!HWUCUW\:;^G0ZJJRM/6"WZ?9E-VU,G^]/>4/N2
M9;LEQQS8E&2MU2E'T4(&,X`2*U:AH4I2@%*4H!2E*`4I0D`$D@`<R:`4J4EZ
MZM9D.Q+$W*O\]LE*F+8@.)0H8]%;Q(:0>(X*6#^%?+R/5]Z7_?YL73T$_P#!
MM^)$H^E[7EIV)R.82@D9X*]M`;U\OMJL3"'KQ/C0T+4$-]:L!3BCP"4IYJ)]
MP!-8/:&_7K`TU8UQXRL$3[R%1TX.>*&!_:J(X<%AOGSK3L>DK-9I*Y<6)UEP
M6,.3I2U/R%C)."ZLE6.)X9P/8!6[0$@C12;BG=J^YR;\I7VHRQU,,<.(#"3A
M0_\`<*S^-5<:.S%80Q%:;990-J&VTA*4CW`#@*^E*`YU+Z']*2ND-&KG8?\`
M>A_:*BX'4K?SD/%/^;\.1/'GSZ+2E=,>UQ[2-]S%$1*!2E*YE%*4H#*C>M-Q
M_@HW];]:M94;UIN/\%&_K?K5H"5Z-/5R9\:NWU&1554KT:>KDSXU=OJ,BJJ@
M)7I+]7(?QJT_48]552O27ZN0_C5I^HQZJJ`5"ZNU'?(UUNL:P"WA-HMR;C)3
M,86LR-Q<PTA25I#9PTKTB%<QPJZJ-U5I";=;G-E6J[,VX7&"+?.#D,O*6T"H
M@MJ#B=BP'%C)"AQ'#A3V-88UNM>ANS[Y'A:?3=74K4VMM"VVD\5N*7C8A(]J
MB2`/Q->'H]O<S46DH=SN<=F-,=4ZEQEDDI04.J1@$\_L\_;^%?NYZ6B7:.S$
MN:G50X;B'(0B/OQ'62E&SBXVX"H\5>X8/(\Z:$TRUI'3R+4S*?E)2ZZZ77G%
MK)WK*L#>I1&,@<^)R>9-6E>ASK3J8$34=CU!TIV3S#>;;<^HLMQZWR*4A[J]
MS\';NVDXS@XSSP:OZE;E_BGI[X+<_P#7@555#0I2E`*4I0"E*4`I2E`*4I0"
ME*4`I2E`*4I0"E?AYUMAI3KSB&VT#*EK.`![R34HK7,2<H-Z5A2]0K)']M#`
M3%3D\S(60@@>T(*E?A0%=63?=1VBPAOSK/9CN.G#3).YUT^Y#8RI9X<@#6%Y
MFU7>GD.7N^-VB%CTH%F3E:C[E27!N(_]"$'\:VK#I>S6%3CEK@--2'0.MDK)
M<?=P,96ZHE:S@#F30&1Y\U)>D@:>L@M\90X3KUELX*<A28R?3/'&0LMGG7].
MAV;DHKU9<9E^)S_=GCU409QPZA&$J'#_`(F\\3QJOI0'SC1V8K"&(K3;+*!M
M0VVD)2D>X`<!7TI2@%*4H!2E*`4I2@%*4H!2E*`RHWK3<?X*-_6_6K65&]:;
MC_!1OZWZU:`E>C3U<F?&KM]1D555*]&GJY,^-7;ZC(JJH"5Z2_5R'\:M/U&/
M7ZU)?+HS?H5DT_$@O3GV%RENSGU-MH;2I*>`2DJ6K*APX`#F>5?GI+]7(?QJ
MT_48]2?39>+7;UL-7^#:WHXAN/1'Y[1PW)ZQM"<+!&/14HD`@G;SJ:I7D[Z#
M1N\[[E?IF^W*3>[C9;[$A,W"(RU(#D)]3K3C;A4!D*2%)5E"N!SPP0?=3USS
MHQB-V*\7JPL>:Y"66V)2YD"+U!4MP*'5NC<K*@$I4#G.U0X>TTVH-6V;3\A#
M%UDNMN*1UJNKC.O):;SC>XI"2&T9_:60.!X\#6GHD.-W:-VE>"\7B#9X`F3W
M5)8*DH1U;:G5N*/)*$(!4HGV!()K]6:Z0[S;VYMN=+L=9*<J0I"DJ!P4J2H!
M25`@@@@$$<:@,*Y?XIZ>^"W/_7@555*W+_%/3WP6Y_Z\"JJ@%*4H!2E*`4I2
M@%*4H!2E*`4I7SD/M1F%O276VF4#*EN*"4I'O)/*@/I7%I'3K%:Z71I+S3+,
M%+GD:Y'5*Z[KR<`AO&>K]G+)SGESN5:W1<B6]'VV3?EXX26SU,(<#@F0H84.
M'_#"R,\JR7>CIV^ZD1J#5$UMF>EE3`:LX5'_`+,@>BM__>J//TD]7P.,8KML
M<>SPS_DPS2GN1SH55[U79K-)3$F34JGK3N1"CI+TA8]X:0"HCCSQBLSSAJV]
M'%LMD>PQ#_\`DW0AY\C(XI8;5M&1G!4YD<,IK=L=AM5ACK9LUOC0VUJ*U]4@
M`N*/-2CS43[R2:TJXE)-G0MN?>3)U$_*U#*20H&Y+"V4$$D%+"0&DD9X';NX
M#B:JT)2A`2A(2D#``&`!7]I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`9
M4;UIN/\`!1OZWZU:RHWK3<?X*-_6_6K0$KT:>KDSXU=OJ,BJJI7HT]7)GQJ[
M?49%55`2O27ZN0_C5I^HQZ\W24G5J(#$C2#T,H;)\KC/0_*''$>]L%:`5#_*
M2,^_/`^GI+]7(?QJT_48]>;I`3JHN1C8"X;4$*\L3!4VF<59&.J+HZO&,YS@
M\L&HRHS.A*9>+GI^7<KO=FI[<B6^&4BWF(X@(>6C*P5$\0D820"D#&3SKSZX
M\H@:@U(LVVXSDWFR-PH@BPW7TEY*G@4+4@%+8/6I.Y>!SX\*]/0TFVIM+J2W
M+1J8)'G0W!+GE1.Y>W>7.)3SQM)3SQ71:WCATT&'%#;5UDG7;CYJL`9<8NCK
ML5MN.^Y#AK=6@E`_M$`I/6@?\@6<\".8KP]%\23#L<Q#[<GJ5SGGH[\MHM2)
M*%D*+KR"$[5E15PVIX`>BGE5A2I-6WJ9B$L*T("):YEMZ4[)Y;?;E=^LLMQV
M^6MQT]5A^#G;U+3?/(SNSR&,<<W]2MR_Q3T]\%N?^O`JJJ%%*4H!2E*`4I7.
M.GK6=WT1H5VX6&`M^4XL,F3M"D1`?^(H>WCP&>&3Q]QZ;+9XMKC6SPYLC<5.
MCTJ)Z)]73=5]'\*^W^WFUO+2=ZG"$MNI'_&1DY"%>S/_`&R,$^@ZYASE=7I:
M',U"X<?VL)($8`G&3(60V0/:$E2OPJ;3`]GB>#%FBIR?N;J>1!*XDUAF/<A,
MCMH2HDMOQW)#;9<0>'$)7Q'[*L9!!&?DK7MJ9=<?ER&F+:KT(:N*WYRQDJ++
M205+0,<"`2KCCA@F`UI;=3:[AM&[R8%KLS$Z*TE-O;+SBW%OI:4$ON`92D+^
MTE"<D8XCC5[H&U6JR.2;>S:V8=Y:2GRA_"EKE(QA+G6KRM8X8PHDI(Q[B?)A
MQ/?ANEWS/L;?8[-?C;^'!ZY<UR_CIY_C+7"/WYUU/>U;;-:46:&21Y9=_2=(
MX8*(Z#GW_;6@C'V37[C:&@//HE:BD2M03$$*2JX*"F4$'(*&$@-I(/)6TJX#
MB:K*5Z#XX2`E("0`!P`'LI2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`
MI2E`*4I0&5&]:;C_``4;^M^M6LJ-ZTW'^"C?UOUJT!*]&GJY,^-7;ZC(JJJ5
MZ-/5R9\:NWU&1550$KTE^KD/XU:?J,>JJI7I+]7(?QJT_48]55`*4KF6MU29
M]_U*WYRN$%-GLC<Z(8LMQA(>47R5K"2$N`=4D;5Y'/AQHW%6:PX=[*ZP=-I4
M_<DLW+2D>1=+C)ML7J42)+L>08YV[<E)<&%)''FDI/#F*^/1ZB8FQ+5+<EKC
M.2'%P1,4I;Z8QQL#BE$J)YGTO2P1GCFK$-IZ7?LS"<I-:W?NCYW+_%/3WP6Y
M_P"O`JJJ`B/WQ[I3LGGZW6V%BRW'JO(IZY6_^W@[MVYEO;CAC&<Y/+'&_J%%
M*S+;?[3=+E<+?;[A&D3;>L(E,MK!4T2,@$?_`.X@CF#34MT9L]DF3'IL&$6V
ME%MZ<YU;(7CT=Q]V?=QJO"TX8-.E?YHZ$+OTKNZBOCDJWKN-ND.J6X[<G51V
M4O$C!:405;-OL0DC`2.&<UV5>D[I>'$.:IU%+<:2HGR"U$PHY'L"U`EU?\X!
M_P`OLKIM]DMECW5B3YHB<FE>M862TRC#>E^47+`(@PT*D2""<`]6@%0&?:0!
MPYUERG-4:EC.QF[3!LML?24.*NH$I]Q!)"AU"%;`"/:IP\^*:I;+9K98XGDU
MG@1H3&22AAL(!)XDG',GWGC7OKD4DH>@K65-.7QV3?GV\%'G%04RV0<IV,)`
M:1CV$(SP'$XJL0E*$!*$A*0,``8`%?VE`.7*GMI2@%*4H!2E*`4I2@%*4H!2
ME*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@,J-ZTW'^"C?UOUJUE1O6FX_P4;^
MM^M6@)7HT]7)GQJ[?49%552O1IZN3/C5V^HR*JJ`E>DOU<A_&K3]1CU55*])
M?JY#^-6GZC'JJH!6#J#2-FU!*1(NL=]QQ+?4GJI3S*76\YV.)0I(<3G]E8(X
MGAQ-;U*<P85_TG:;_&5'NC<MUE3S<@);G/M!"VQA!3L6-N.>$X&>//C7OLUJ
MCVB(8T1R8XWN*\RYCTI>3_SNJ4K'X9Q7NI3($K<O\4]/?!;G_KP*_MWUG9VW
M'[?!5*O%P`+:XEI07G$$ISA2P0AHXY%:D\Q7)/\`Q7WU^PN6%R*RVZ[*@3XH
M+CA2$`N0U%6W(#GV/L'(XY((!%=%Z"KI-N_1I:95PLS-H44;6VV&DM-O-@#:
MZE"?LA0]F!RR.!%>A_C8UL5M]&X)*F#F/1ET':@L.KIU\5>G;,TO>B.E"DR)
M75KYAP_[O<.'L6"1G'*NU6K1EF@3DSW67+A=!G$ZX.&0\G.,[2K@V.`X("1^
M%4=*QMMOCV^+>VCEA)+(4I2N112E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@
M%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H#*C>M-Q_@HW];]:M94;UIN/\%&_K?K
M5H"5Z-/5R9\:NWU&1554KT:>KDSXU=OJ,BJJ@)7I+]7(?QJT_48]552O27ZN
M0_C5I^HQZJJ`5"ZNU'?(UUNL:P"WA-HMR;C)3,86LR-Q<PTA25I#9PTKTB%<
MQPJZJ-U5I";=;G-E6J[,VX7&"+?.#D,O*6T"H@MJ#B=BP'%C)"AQ'#A3V-88
MUNM>AOS+F\BPIN%O@N377&T+;80M*"=V.:E$``9R3SP#@$\*\NA+R_J'1MFN
M\QMIJ1-C(?<;:SM25#.!GCBM&)$=89<CEQHQ4H2W'0ELA3:0D#"E%1W<>/`)
MX<./.O)H^R]G-+VNS^4>4^0QT,==LV;]HQG;DX_Z9-:I7^HZ_1E?Q4YG`^F'
M22NECI%T]'L<RZQ<0WG)*;I`DQ6V6FW&05LI=;3O6>NX@']E.2.&?]$6>"+9
M:8<!+[TA,9E#(=?5N<6$@#*C[2<5@7+_`!3T]\%N?^O`JJKIM/R,>TP8=GB=
M,.1$DG(I2E<2BE*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*\-TN;5M<@ID-
MNE$N0F,'$@;6U*!VE63P!("1C/%0KW5.=(<2;/TE.B6J(Y)N#P2(Q0M".I=!
M!0Z2L@80H)4<9/#@#RH5*:&A:[U&N4&5,CH?\GCO.LE75[BX6U%*B@)R5#*2
M!PR<<J\]EU-`O$M4>(Q=VW`@K)EVB7%1@8_;=;2DGCRSFOM8;,W:M-0[0''%
MH9CAE3@64K6<>DK<,$$G)R..37QLNF8%GEJD1'[NXX4%!$N[RY2,''[#KBD@
M\.>,U82<:&9E23FI-57B'/O;]N\WBU6+J?*VGV'%.O[TA:MBPL)1M2H'BE63
MPX5M:MNMQC2K/;;(J(U.N3ZT!^6RMYMI"&U+4HH2I!43@`>D.>?9BL_4&C)5
MRN=Q7%NC$:V77J?.,94,N..]7P]!P.)"-R0$G*5<!PQ7OU#8;C<WH4N)<H<6
MX6^4IZ(XN$IUL-J;*%-N(ZU)4<*)W!2?9PX',60<S0C6-=ZCN4>Y^;6K4W)L
M<5Q^>AYAQ:9*T//-[&E!P=7D,*.5;\;AP.#6E!UG=I;S%U0+>-.NW--L#)8<
M$@$D(ZWK-^W&\XV[.7'=[*^8Z-IL:/(1;+\S'=N,5<:ZO.0"XJ1O=<<4MK#H
MZI67G`,[P`1P../I<Z.RXXN`NY-=EUR_+56]$92'BYCEUZ7!A.[TN"-V?VJO
M^W+[KTRX>Y<<1Z;I3KGX/[:M?.3=0:D1Y`M=FMD1B5'=93N>DI4MU*W`,X*/
M[,[0.)`)&<@56V&]1;Y'>DV_>Y#0Z6VY'#JW\8RI!!XI!R,\.(.,CC4G`Z-H
M]INUTFV6ZW"+Y9`9@-H>DORNH0A2BHI+KI!)2K"<C"""1G<0:?3-D1I^$N!%
M=W6Y"\Q62GC'1@>ANR<C.2.6`<>RJXTN_/(/.ET\F;:M?Z8NNI)%B@7JW/W!
MH)VH;EM*ZTG=E*`%$J4G8=PQPR*\^J;W>F[V];M/*M[;D2`;@^9K"W0X"I24
MMIVK3M)V*]([L</1-4[%NBL7*5/::VRY2$-NN;B=R4;MHQG`QN5R]]3VJ=,3
M[E<U3[+=8]MD/0U0))>AF1O:*L@HPXC:H$JP3N''D:QBFD71QU@N&*S=5\2:
M*;T\_I2->+?`<F.R8[;[<9"TI)W@'BI1``&<D\\`X!/"HR[=(TR%T20M2-PF
M'KY,MYEMQ$YZM.U&Y:E<<[$CGQXD@<R*O+5;EV^`("'6C"9:0Q&0ELA3:$H"
M?245'<<C/`)]W'G43/Z*+=.T3'LK\Z:F>Q:_-B)S$A]E)3CFIE#H2L9X[59S
MR)K;C><93TK]#9TPK?S/9JVZZIAS+4BR3K*57-YMEB)(MKKBTC;N=6IQ,A(V
MI2%'['^4>W-?#2.L9E[U-*8?G1&8*)<B*Q&59Y+:GNJ4I/H2U.=4M7HE12E)
M.`?<35%%TTW'OEJGB2XXW;H"X333I4XHE902X7%*))PV!QR>)XU\!IVX2KU#
MDWB[,S84"2J5#:3$ZIY*RE:`''`O:L!+B@`$)/`9)XY*)_=_/]F:O#7.G:_U
MJ:4;UIN/\%&_K?K5K*C>M-Q_@HW];]:M9*2O1IZN3/C5V^HR*JJE>C3U<F?&
MKM]1D554!*])?JY#^-6GZC'JJJ5Z2_5R'\:M/U&/550"E*4`I67J*\M6."B0
MY'D2G'74L,QXP27'G%'@E.Y24^\Y)``!R::=O35\@KD-1Y$5QIU3#T>2$AQE
MQ/-*MI4D^SB"0<\#15#H9-R_Q3T]\%N?^O`JJJ5N7^*>GO@MS_UX%55`*4I0
M"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4`I2E`*4I0"E*4!YKG,;MUME37TK4U&
M:6\L(`*B$@DXS[>%1TC7<<Q&DWRV7K3<.>ROJ+C*7%V##:G.!;=<*5;$J4-R
M0/1]_"JC4T9Z;IRZQ8R-[[\5UMM.0-RE((`R>',U$VK14BQW[3=QBIG7!AMG
MJ)4:=<79/D:RC'7L]:X0/:A03^RKT>1!BJVG>?T5N$G[_'V;G1I*AS=/NOVN
M[&YV]<E9CK5.\L6TC`]!;I4HE7-6"21N`]E5E?AY'6,N(P@[DE.%IW)X^\>T
M?A43H[0W9^\>6^2:.:_LU(W6G3OD+W'_`/9UZ^'O&.-:F69B$:&HM:1+'/?C
MNV^XRFXC*)$V3&2V6XC:B0%+W+2H_94<("B`,D5HZAOS5F1#2F)*GRYCA:C1
M8NSK'2$E1P5J2@`)!)*E#_Y(%1NMK->G9^J(ULM+LUC4-O:B"4AUE"(BP'$*
M+@6M*BG:L*&P*/`C`K6UC"G2X,!R!;+J9=NE8:>A2(S<A*>K*2XTEW<TM)W;
M2ES:<9(&0,J074_EXU^W;K5YS;T_>9MO3E+CT=44=6Z'"V6BEQY*RL+&W"00
M21@FM67JRW1+_9[+)#S=RN;2WD,E()92E!42X0<#D0,9R0<<`34O8M'W&(QI
MN%,2MV(S<9=VF%;J58<4I:V4*X^D0IS.0,;F\\.%?&1H[4K>OK7=?.%MG0C.
M?D2%&"I#K32FE(0V5%\A0"2$C:@8)*B#DY/A=ST7,F+BKM=^15:>U=$O<AAM
MJ'-C,RVU/PI#Z4!N8VG&5M[5$@>DDX6$D@Y`/&J2N9:.TO<V-26N1*C7*!;[
M0R^PQ&DRV'F4[]J4I8+0"E-@)5Q>`7R&,5TVCC0NK%*4J`RHWK3<?X*-_6_6
MK65&]:;C_!1OZWZU:`E>C3U<F?&KM]1D555*]&GJY,^-7;ZC(JJH"5Z2_5R'
M\:M/U&/554KTE^KD/XU:?J,>JJ@%*4H"9UW`F28]JF6Z(N;(ML]N9Y*VM"5.
MI"5(4$E9"<X62,D<N8K^Z&A38\>ZS+E$7"D7*>Y+\E6M"ULIVI0D**"I).$`
MG!(XXS5+2BI//Z\(8O5$Z??EG.I?1U%5K2U2FW=0&W-V^8V\Z=0S=Z75.1BV
MD$O[P"$.D@>B=HW<0FMOL':.^:D^8[CX]55*`E>P=H[YJ3YCN/CT[!VCOFI/
MF.X^/552@)7L':.^:D^8[CX].P=H[YJ3YCN/CU54H"`C:#1VJN/7S-2>9?(H
MWDW^T<[_`'^]_KN3^[[/4<^'NX[JU>P=H[YJ3YCN/CU54H"5[!VCOFI/F.X^
M/3L':.^:D^8[CX]55*`E>P=H[YJ3YCN/CT[!VCOFI/F.X^/552@("3H-':JW
M=1,U)YE\BD^4_P"T<[_?[V.IYO[OL]?RX>_CMK5[!VCOFI/F.X^/552@)7L'
M:.^:D^8[CX].P=H[YJ3YCN/CU54H"5[!VCOFI/F.X^/3L':.^:D^8[CX]55*
M`@(V@T=JKCU\S4GF7R*-Y-_M'._W^]_KN3^[[/4<^'NX[JU>P=H[YJ3YCN/C
MU54H"5[!VCOFI/F.X^/3L':.^:D^8[CX]55*`E>P=H[YJ3YCN/CT[!VCOFI/
MF.X^/552@("-H-':JX]?,U)YE\BC>3?[1SO]_O?Z[D_N^SU'/A[N.ZM7L':.
M^:D^8[CX]55*`E>P=H[YJ3YCN/CT[!VCOFI/F.X^/552@)7L':.^:D^8[CX]
M.P=H[YJ3YCN/CU54H"`DZ#1VJMW43-2>9?(I/E/^T<[_`'^]CJ>;^[[/7\N'
MOX[:U>P=H[YJ3YCN/CU54H"5[!VCOFI/F.X^/3L':.^:D^8[CX]55*`E>P=H
M[YJ3YCN/CT[!VCOFI/F.X^/552@)+3&G7;'J^].L+N#EJD08:6ES+@[+/7(<
MD]8`75J4D;5L^X'/#CFJVE*`E>C3U<F?&KM]1D555*]&GJY,^-7;ZC(JJH"5
MZ2_5R'\:M/U&/554KTE^KD/XU:?J,>JJ@%*4H!2E*`XYJ.)$?NNJ[K,8:-\@
M7F`S;I!0.N:;*8^U#:N82HK<!`P#E6:['69)T_9I5W9NTFTV]ZZ,`!J8Y&0I
MYL#.`E9&X<SR/MK3JS1*\EWS*W+D4I2H05"](]OLEQ6U&E6YFZ:AD,J;M[#A
M*BR<\7P#D-!)()=`"N0!)(%758M[TIIV_242+Y8;3<I"$[$NS(;;RDISG`*@
M2!DGA4:DJ<')Y5M1$C7&XNA$O5D"_P`*"Q.6@>4%O$=.P*Y[%(4M13P!W*./
M;6GT;PX42;HB;!9::N=TM#[UT<;2$KDK`:)6]C[2@X2`59(W$5TAO3-A;N4>
MXMV2UIN$=`:9E)B-AUI`&`E*\9``X8!Y5]+9I^S6J;)F6NTV^%+E'+[\>,AM
M;QSG*U)`*N)SQKHL5(O*.N;MF4H47G\:&G2E*P45R;_Q!W=]O2=SM+;=T9CN
M6]Z0]+C07W4*P"$LEQ""E&3Q45$`)&/VLCK-?*9%CS8KL:8PU(C/)*'&G4!:
M%I/,$'@0?<::IFL+AR<9OS<*Y,:HO$B,E5U@,P56AU]DH?8"FTE.P*PM!4X5
M`C`)Y&OOIB)&:N.E+LPPTF_S[S/9N#Z$@.O-I$C*'".)2DH;`!.!A.,5U&9I
MZRS;C&N$RT6Z1/B@!B2[&0MUG'+8HC*?^U9*EZ1M&NH\81+;%U5=6G'4.MPP
MEZ0A.-^70GCR'`JR<?A6EBK^[\G+=A5X?730J:5DVO4=INMZNMIM\L/7"U*0
MF8T$*'5%8RD;B,'('L)Q[:UJR;%<MZ1H+]XU:N)(;L[MOAVA4U#=TCJ>0I8<
M(64`+3L6`$#K,DHW<`<UU*O#=;/;+N&!=K=#G!A8=:$EA+O5K')2=P.#^(J-
M2U>ELJ<7SM'&5B)=(=ZU!)AAJ]QI]L3;7'AND1VUMQBEM*SZ6%%;@5_FRK.:
MU=#Q(L>;HNY1H[+=ZN9E^=7FT@./X2HJZTCBK:X$@9)QG`Q73).G[-*N[%UD
MVBW/71@`-3'(R%/-@9P$K(W#F>1]M>>V6W3T74-P=MEMMS%X4E*Y;[$5*'5A
M9)&]P#B3M)P3GD?:*W-;X?.IEKTQ[7X-NE*\J+A%7=';<AW,QII+ZVPD^BA1
M4$DG&.)2KAG/"LE/57(>EB.Y<;Y=$-0XLM-NLOE*G);G5F"5*<VR(QV*W/`(
M5S*,;4^D,G'6I+[<:,Z^^K:TT@K6K!.$@9)X5ANM:;U/*BF5"@7&1':;F1S*
MBA:FT+XH<1O3PSMYCB"..*+--:?94TL[JK_LYA<&H[Z+I?VF$KU*UJ&&Q$D+
M0/*$LJ\GPT#G(24+62G@#E1_&M#HWAPHDW1$V"RTU<[I:'WKHXVD)7)6`T2M
M['VE!PD`JR1N(KICFG[,[>F[P[:+>N[-C:B:J,@OI&,8#F-P&"?;[:6S3]FM
M4V3,M=IM\*7*.7WX\9#:WCG.5J2`5<3GC6EBA1>4=<W;,K*^/QH:=*4K)17%
MM1QY%OO'2`A4Z7*ZV);"\X^L90TM]T.!(&T)2$9X#'M)R22>TUY7;;!>7*6[
M"C+7*;#,A2FDDO(&<)7P](#<K@>'$^^@./7&TVR/K9K3L2!$1I1VYQ1(@H93
MY,7#%D*V%'V<%265$8XG'OKPVFV6B?/OD"ZQXSMDM<2:NU!X`HC[9+@4IK/V
M2C"4I*1Z(P`177V])Z=;L[EH;L%I3:G%;UPDPVPRI7/)1C:3P'''LI*TIIV7
M$AQ95@M+T6%_Y5ER&VI#'_H21A/_`&Q1UOE$_P!:%3A1[=&WUN3Z:1=D/Z4L
MSL[=Y4N$RIW=SWE`SG\<UK4``&!P%*UB>]B;,8,.[A2X"N76^!;8]ZUZSJ>>
M_*MVZ&[(=F/%(4-F=IVX&PGAL`P<X(.3GJ-9UQL5HN;4IJY6J!+:E%!D(?CH
M<#Q3]G>"#NQ[,\JPS1RQG3D3SG98DVULQM,7:ZNO,V9YE(9;2F*K8%-'T4[E
M)4YLQP..&<U.6V%`N,'5*;TRTY#M%LD+LSCJ<F,E,J6$N,J/%*@$,@*3Q`2G
M%=H;T7I9JV.VUO35D1;GEAUR*F`T&EK')11MP2/>17VE:5T]+1!3*L5J?3``
M$0.0VU".!C`;R/0Y#ECD*VW2+RS]RX7&=UF/9W)A]#JW7-#A<@$/JN=S+@//
M=Y?(S_\`=6M2O1IZN3/C-V^HR*JJC<N3.%0DB5Z2_5R'\:M/U&/554UTAQ)L
MS3:$VR&[.DL7"!+\G:6A*W$,S&75A)6I*<[4*QE0KY=J+O\`<34GY]N_55"E
M52I7M1=_N)J3\^W?JJ=J+O\`<34GY]N_54!54J5[47?[B:D_/MWZJG:B[_<3
M4GY]N_54!54J5[47?[B:D_/MWZJG:B[_`'$U)^?;OU5`55*E>U%W^XFI/S[=
M^JIVHN_W$U)^?;OU5`55*E>U%W^XFI/S[=^JIVHN_P!Q-2?GV[]50%52I7M1
M=_N)J3\^W?JJ=J+O]Q-2?GV[]50%52I7M1=_N)J3\^W?JJ=J+O\`<34GY]N_
M54!54J5[47?[B:D_/MWZJG:B[_<34GY]N_54!55RWI)M=Q<UE%O5LM\B5(M-
ML5*CEMHJZQQ#Z"IE)Q]I;?6)`Y\:J.U%W^XFI/S[=^JIVHN_W$U)^?;OU5-4
MUIX@.JAW63F$:QS+4]>'KOIV3<6[DU;WYR>H>=;+JUR''=R&P5/)05I24`'@
M4Y&!7\T=I)=QOUNBWZP+-HCN74(CNV];,5"%JCEH!M14E*2-Q2DD\0>`(('4
M.U%W^XFI/S[=^JIVHN_W$U)^?;OU56:MW:'!Z_\`?)RNR:2F.Z>N\ZX6><N\
MQXEM\B=?867D.-H&XMY&0H<E$<<<#6?K6U3YTJ2]:M+2XDMQ%S8FJ9M\E;[V
M^.\&PN2K@ZA2@@I2D*2#M`*<`'LG:B[_`'$U)^?;OU5.U%W^XFI/S[=^JI,N
M??J7"]UR9NBM/MV'5DI-OMZX<%^TQ5.%+92AR0%N!2E'D7,;=Q/I<L^RINZ6
M4W?4"(4V$N8A&JS(EHZLJ3Y.82@VI?\`R8VHX\"01^%6W:B[_<34GY]N_55\
MQJ&Y)D+?3T?ZA#ZTA"G`[;MQ2"2`3Y5G`R>'XFK/JEW5/X(J*+_CN_?N<OG6
M5NUP[PG4-DFR+''9G-6AI$-:TPW`^Z0I.!AH%LM['#M2`D@*&>.Q:[!(O&FX
M#]QMTAQ,FY6]HLK94"(K"$I]($9V%76*X\"%>XU475]%WE1I-VZ+;G.DQCEA
MV2FUNK:.<^B5224\0#PK4[47?[B:D_/MWZJLX:9\NCG]L;3UMM4F>J@Y\WI)
M=O1$>M]GD,OHN5TCA3;*\HAEJ1U38X<&=W5[4_9R1@9-5EB8>1J;2+:6W&W8
MM@6F8E0VE`460A*A[]R%X'_*JM7M1=_N)J3\^W?JJ^:-0W%#[CR.C_4*7G``
MMP.VX*4!RR?*N.,G_P":J<7R:^1BJY]^K3^*%=2I7M1=_N)J3\^W?JJ=J+O]
MQ-2?GV[]54!54J5[47?[B:D_/MWZJG:B[_<34GY]N_54!54J5[47?[B:D_/M
MWZJG:B[_`'$U)^?;OU5`55*E>U%W^XFI/S[=^JIVHN_W$U)^?;OU5`55*E>U
M%W^XFI/S[=^JIVHN_P!Q-2?GV[]50%52I7M1=_N)J3\^W?JJ=J+O]Q-2?GV[
M]50%52I7M1=_N)J3\^W?JJ=J+O\`<34GY]N_54`Z-/5R9\:NWU&1554UT>1)
ML/3:TW.&[!DOW"?+\G=6A2VT/3'G4!10I2<[5ISA1JEH!2E*`4I2@%*4H!2E
M*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*4H!2E*`4I2@%*
54H!2E*`4I2@%*4H!2E*`4I2@/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>ex1002_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex1002_02.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``8$!08%!`8&!08'!P8("A`*"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!#`0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P``1"`#Q`D<#`2(``A$!`Q$!_\0`
M'``!``(#`0$!``````````````4&`P0'`@$(_\0`31```@$$`0(#!04%!08#
M!0@#`0(#``0%$1(&(1,B,0<4%4%1%C)A<=$C5(&1DD)2<I.A,V)SL<'2)"6#
M"!<U1((F-$-%4Z+"X564\/_$`!8!`0$!```````````````````"`?_$`!D1
M`0`#`0$````````````````!$1(A`O_:``P#`0`"$0,1`#\`_5-*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*
M4H%*4H%*4H%*4H%*4H%*4H%*B.I>HL;TW:1W&5ED596*1I%"\TCD*SMQ1`6.
MD5F.AV"FI.UN(;NVBN+:5)8)D$D<B':NI&P0?F"*#)2E*!2E*!2E*!2E*!2E
M8;V[MK"SFN[ZXAMK6%2\LTSA$11ZEF/8#\309J57<?UUTED;V&SQ_5.!N[N9
MN,<$&0AD=S]%4-LG\JL5`I2E`I2HF]ZCQ-C<S6]Y>I!/#";B1)`05B!XF0]O
MN;[<O3\:"6I6.WFCN;>*>!P\,JAT8>C*1L&LE`I2E`I2E`I2E`I2E`I2E`I2
ME`I53P'7>,S:8.6V@O8[?-!S82RHNI>*,Y[!BR^53W8`>@]2-VR@4I2@4I2@
M4I2@4I2@4JK8?J2>_P`O#;N+&-97F1K5I2+J`(2`67N#RUO7EX@CNVZM-`I4
M5U%?RX^U@DBFM+=7EX/-=$<(UXL=ZY+R)(``!^>_D:WL?<"ZL+:X4DB:)9`2
MA3>P#]T]Q^1]*#/2JCD.J+NURF6M);6"WCM3:B*XEDY+QF9U,CCMI1P]-_Q&
M^TYTYD6RN&M[R1%5GY`\/NMQ8KR7_=;6Q^!%!)4J)ZBR<^+BM)(+43I+<Q0R
M.7"B-7<+O7J3W]!6/$Y=KO*7-M++;EE+\(8AS:)5;CN1PQ`+;!"Z!UOZ&@FJ
M5KY&X%IC[JY+PQB&)I.<[\(UT"=LWR7ZGY"N='VBW0N!$JXUXN%Q/%=%^*7*
MQ&$")5Y$I(_BMQ!V?(?*?D'3:5AN)C'92S+X:LL9<>,W!00-^8Z.A]3HZJE6
M_64TV,-R+K$-&MQP:YB?G&4$98A%+JSGD.*D?>WO0%!>Z5BLYQ<VD$ZA@LJ*
MX#*5.B-]P>X/X526ZRNQF[C'2OBH85:/CD/&\2&/D)248;'F'AJ.Y79<]M*.
M07NE:>%O#D</8WK)X;7,"3%/[I90=?ZU5LKU9>6=]=6T0QDG%PJN+E>,`\9$
M)E)8=PK%RIXG:\5YGO076E1]GD5DPQOF+SJB.S&&%MR<202B;).]=@"=[&M[
MKGUI[3;J[NKVW;')8FWFN@LEX'1)1"P"P[.M2N&WKOK3=CJ@ZC2O,+^)$CE2
MO)0='U'X54>J.KKC&9)L?C\=)-<&TN94DN5:&%I8U4HGB$<>)+=VWH?B307"
ME1/3&2DR>-\6>:VFG5@LAMA^S#<58JK<F#:Y:Y`ZV#V&JTLWGWQV8]VYVZQ)
M`DOA=I)[AF9EXH@<,-<=EBI'?MZ'06.E5KI#/RYFXOXI9;"=;80LLUDY96YJ
M25/<Z((UZ]_7MZ59:!2E*!2E*!2E*!2E*""RO35ME<_9Y2]N;S_P4+Q6\$,[
M0JK.1S<E"&8D*JC9T!OMWIT7T]]EL$F(BO9[NSMW86@F[M!!OR0\O5@@[`GO
MH`?*IVE`I2E`I2E`I2E`I2E`KS-(D,3RS.L<2*69V.@H'<DGY"O51/5V+.;Z
M6R^,1$=[NUDA5))&C1F92`&902%)T#V/;?8^E!R##2"W]I4^/M\3[K"W44U^
M(DO$9?&97C>Y+@\MNA)\/8XEN!4ZKNM?GWH+J.YQ7M&R/3MMU'A#:S9Z[:6T
MFNRUW([2L6TJVX79/R#C7<;[5^@J!2E*!7"_;7D89NH[2..&:ZB:SN+66&WG
M>W9VTZ\9_.O.`.8R1Q<$<_*VP*[I7)<UT?';]:RS)'E+:&YAEG:\L)L@(N;S
MES%X<%P"K'D78C2LQ)T":#HO288=*X8/'8Q/[E#M+!"ENIX#M$K`%8Q_9!`(
M&JE:U<3$(<591!Y7"0HH:7Q.;:4#;>(2^_KR);ZDFMJ@4I2@4K1SUS<V6"R-
MU810RWD%M)+#'-((T=U4E0S'LH)`V?D*A.@^KX^K+,R+9FV=(8Y21>6MPD@8
MNI9#!-)Y0\3KMN.RI`V0V@M-*4H%*4H%*H/1?M`DS4MC99'&)#>RS2VLEQ:Y
M*RGMO'C0NR)QG,K'B`=>'R&P2`-D7Z@4I2@YKTC[)\=TRF$6Q>QBEQCAS>6U
M@L%W=`!APEF#'DIY`D:[\172J4H%*4H%*4H%>)G\*%Y#Z*I;^5>ZTLVQ3#7S
M#U$#Z_I-!4OMQ-^Y1_UG]*'KF;]RC_K/Z5SF[P\ES?-<?%LE"IU^QBD4(/\`
M]N_]:E==@*"V?;NZW_\`<(=?\0_I7M>NK@^MC$/_`%#^E4[CWKTHU06N?KN\
M4?L<?`Q_WI2/^E8+?K_)LY$^)MT7Y%;@G_\`B*K9&S\Z`:H+:>N[H?\`Y?%_
MF']*+UW<[\UA$/\`U#^E5(C\:`4%LN.O+I$W%CX6/T,A'_2M5?:#DR>^)MA_
MZY_[:KC+L5Y"'?J:"XGKNY";-A%OZ>(?TKP.O;L^N.B'_JG]*JA';6Z:_$T%
MN?KJY$99;"(M]#(?TK37V@Y(GS8B`#_CG]*KQ&QJO`0[^\:"XKUS<&/9L(@W
MT\0_I6`]?7P/?%P_YQ_2JR!VKX106Z+KJX9=O81*?IXA/_2O7VXG_<H_ZS^E
M5`=J4%P^W$W[E'_6?TI]N)OW*/\`K/Z53Z4%P^V\W[E'_6?TI]MYOW*/^L_I
M50I07#[;S?N4?]9_2OGVWF_<H_ZS^E5"O#DJ1KT^=!>L=U?/>7T%N+2-?$8+
MOF3JKC7*^E!RZ@LO\9/^AKJE`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E
M`K3S.2ML/B+[)W[E+.R@DN9G"EBJ(I9CH=SV![5N5KY$S#'W)M;>*YN!$WAP
M2OP21M'2LVCQ!/8G1UOT-!P'H+J-NI_:7++]J;+&0K="ZM[!LO+<27D<C2<8
M0BWTL&P`>2J@*^72J"*_0NSR`UVUZUS['VO4:7>)N/L/TMCT>:,W+P7WC3V\
M9'FT/`C7D/38<_@&KH5`I2E`KAGM*6RZMZP;&]1=-Y^/$P"2R]^M,+[VY!3D
M7!:RD*H3M0T4W('1XC[P[G7/\UA_:$_QNXPW4N/CFGEE2PM+BW4P00F,"-N8
MCYB57Y,>7B*1H:'K07#IZWM;3`8RWQZ2QV4-K%'`DL1B=8P@"AD(4J=:VI`(
M]-#TJ0J/Z>BR,&`QD6<GBN<M':Q)>31#223!`'91H=BVR.P_(5(4"E8;Y[B.
MRN'LH4GNEC9HHI)/#61P/*I;1X@G0WHZ^AJE?%O:')D\`&Z8PMKCKB8?$63)
MM<RV\97?H4B&P>VU,GY:[T'KVO7^0L>E;T6=C97MC-8WJW<5TRJK*+:0JO(R
MQD`D>;6SQ#:UZB#]B=KBA<9:;'9+%Y&5%52;&X:7PA)))(VP;RYUR<LW]C9W
M][^S?.L+>PEZ:RCY0I';1V<Y>=G,9A0QL'82`$IY2?,`2/QJE>Q:ZLYADTQ=
M[<9*R6.#P[[PX3#(09`566.VAY.-#D&Y'N#VV=ATZE*4"H?JR[R5EA'FPD,$
MU_XT"(DQ`4JTR*_JZ#?$L0.0[Z['T-/M,E[3X\4+C(X3"37-PZA+:RF*R68Y
M]_$+OPE4KZE&4CY*V_+T2>"*XB,=Q$DL9()1U##8.QV/T(!H.$^R^7&W76&(
MW>=.Q7-O+<^!B[>;G+;'PV0A%]_<*0B`=H.R@@!1LCO5<.]GUWC$]HEICL%D
M+_+P0M<>-+$(+J*T/%^*3S>ZK,I/FXEI?-P(+-Z'N-`I2C`,I!]"-4$5-U#C
M(;*XO9+DK8P0&YDNO#?P?#`V6$FN)&N_8FMBUREK<@>&TJNRLZQRPO&[*NMD
M*P!(')>X'S'U%57(]'96]Z7R?39SELF%GQ[X^V46!,\2M$8P7D\7B^M[T$0G
M0[U(VV`R<C0W.5RMO/D;>&2&WDM;-H(HP_'9*&1V)TJ_VQ\]:[:";Q^1M<@)
M?=92SQ,%DC=2CQDC8#(P#+L$$;'<$&MNJMT]TF]C;7'Q3)3W=U<2^-(]M)-;
M(#KB-?M6D/8#?*1N_IH=A"7?LYN,A-FS?Y.R$>1:-P]GCV@F7PW#(KOXI#IZ
M[`522=[[4'0'GACFBADEC6:7?AHS`,^O70^>J]R.L:,\C!44$LS'0`^IJA8[
MV=I8C&3QW%B;^UNVN'=K222(JRJK+$DDS&,Z12#S8!MDJ=ZJ1Z;Z2GQ'4]_E
MYLE'<"Y5T\*.W,6P7#*7\Y5F7NNU500?3>R0E9.J,"B,QS6-/$$Z6ZC)/Y#=
M:=_GL7E>G[\XV_M[AO!.T1QR4'MW7U%6.1!(C(V^+`@Z)!_F*K_5,,%CTY/'
M;1)$C$#2#6R?F?J?QJYGQ7(FTQJW'7Q9^)>\'-9!27#"W\2/A_AUQWK^.ZS9
M7.8S%,BY"\A@9@2JNVB=?A6"[Z5PEW?M>W.-@>Z8@F0@[)^OYUL9?!8W,1JF
M1M(YPOW2WJOY'UJ%(U.MNGFW_P"9P#\R16Y;=386XC=XLG:%4&V)E`XC\=U%
M/[/.FW]+$C\I7'_6MRTZ+P%K"\<>.A(<<6+[8D?F:#,.K,#_`/Y>Q_SE_6LD
M?4F$EWX>6L&T-D"X3L/YU&_8#ISF&^'+^7-M?RW6];=)8*V8M#B[4$C6RF^W
M\:#ZW56!'_YQ8'\IU/\`UKU%U/@Y6")E[!F)T`+A=G_6L+='=/LY8XFTV>_W
M*S672^%LWYV^,M4?^]X8)_UH/%SU7@[>9HI<I:AU.B!(#H_0ZK&G6'3[G0RU
MH/Q9P!_K7JYZ0P-S*TDV+MB[G9(76S_"OD?1W3\>N.*M?XIO_G09&ZIP(&_C
M&/\`X7"?K1>J\`2?_.+`?G.H_P"M;$F!Q4BA9,;:,H]`85[?Z5]3`8E""F-L
MP1Z:A7M_I0>KC-8RWM4N9[^UCMW&TD:4!6_(_.M$=8=/G7_FUI_F"I>6RMIH
M1%+;Q/$!H*R@C^5:(Z:PHDYC%V7+Z^"OZ4&49K&>Y>^?$+3W7>O&,R\-_3>]
M5K?:G`[U\9QW_P#L)^M2*V-JD/@K;Q"+^X$''^5:?V<PV]_"[+?_``5_2@V;
M/)65[$TMG>6\\:^K12!@/XBL+9S$J_`Y.R#_`-TSKO\`YUFM<98VD#0VUI!%
M$WJB(`#^8K3EZ8P<O^TQ5D>__P"BOZ4$I%-',@:*1'0]]J=BCRQH"7D50/F3
MJL=K9V]I$(K6".&,#05%`%>9L?:S=I;>)Q_O*#09HIHY5Y12(Z_53NM>XREA
M;'5Q>VT1']^55_YFLUO;0VZ<((DC7Z*-"L<F/M9'+/;0L3ZDH":#[:7]I>J6
ML[J"<#U,4@;7\JPW62QT.UN;RVC(]0\H%;-O:06P(MX8XP>YX*!NO36\+[Y1
M(=_510;O1&6L)>K\7;17"223B5HPGF!"H2>X[5U^N8]"V</VC@E$2<HD?BW'
M[NQKM73J!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!7F9/$B=.3)R4KR4
MZ(W\P?K7JM?(S36^/N9K:)9IXXF>.-F90[`$@$JK,`3V[*Q^@/I0<KZ,P-W9
M]1W45\O4)MX,O/-";S(3RQS@DE9=+;JH&R=*7^7JPT3UROSMT;/99OVH7.7Q
MW3N3BMGR\T,ID-WQ,B2-_P"(?=EY3L#]F]P.'W>(UJOT30*4I0*_/OMRQO'V
MB6;6JQ";(8V1F6.&.XFE\+;/M)+J$<1&H/8'[I]?E^@JX![:8,DO42#)9VVQ
M<)AFEMIR\=H+L!CP@\UY%SX+*RDMVW(WE`;N'9^C2AZ0P9C,!0V,''P$C2/7
MAKK@L;,@7Z!&90/0D:-3%0O1#%NB\`Q6V4G'VY(M1&(1^S7[@C+(%^G$E=:T
M2.]35!YF3Q(G3DR<E*\E.B-_,'ZURCHK$7`RME)E(.HS)9W4ZP?$,C<R:\[`
M2GA"L;<E[\6;6FT>]=/RLUS;8VYFL8(KBYC0LD4KLBN1\B51V_DK'\*_/?L]
MM[:\ZSQM_C^F,G'8W>2>]5F>[6.WD`E4RNS6**Q(=AIIV^0)[:H.Z=;MQZ+S
M[&2>(#'W!YP(SR+^S;NBJRDL/D`RDGT(]:X_[!H;Z;J>^DM.KK:_LH;>%KJT
MM[>-XI%;QA&><=S(L<NQMAKT"@$C9'9>K#>#I7,G%K*V0%E-[NL3<7,G`\0I
MT='>M'1KEW_LVS2RX[*&6XMYA+';SAH;BXEYDF5&D)EGE4[:-EY(%!*$'?$!
M0[-2E*#D7P"]MNO,X)#U*]C-<6TZ3MDIS%.0J[55CMSP"E0#M^_U'<#KM?FW
M-7=OU)[3;^X7IC)>^64MK!?B&2]XW#&*,E3_`.`9DC79`\\(<#GKSDU^DJ#\
MN]&)DLI[0+./IKKB>"XE>[F5%L1=$(-AA?(+MG71;2&0=VUO3$"OU%7YZ]D_
MQG_WE#W]M3O<79O$-W>2R;13VD_;B!BOC1?_`("@>(FE0LM?H6@4I2@4I2@4
MI2@4I2@57.O6U@@/K*H_YU8Z@>LK*YO\9%#9Q&1Q,&(!`[:/U_,4'-:5,?9G
M+_N9_K7]:?9G,?N9_P`Q?UH(>@J8^S.7_<S_`)B_K7W[,Y?]S/\`6OZT$-2I
MG[,Y?]S/^8OZT^S.7_<S_6OZT$-0U,_9G+_N9_S%_6GV9R_[F?ZU_6@AJ5,_
M9G+_`+F?ZU_6GV9R_P"YG_,7]:"&K[4Q]F<O^YM_6OZT^S.7_<S_`)B_K00U
M?:F/LSE_W,_UK^M/LSE_W,_UK^M!#T^=3'V9R_[F?ZU_6GV9R_[F?ZU_6@A]
MU\J9^S.7_<S_`%K^M/LSE_W,_P!:_K00]*F/LSE_W,_UK^M/LSE_W,_UK^M!
M#TJ8^S.7_<S_`%K^M/LSE_W,_P!:_K00]*F/LSE_W,_UK^M/LSE_W,_UK^M!
M(=`1\LI,_P#<C_YU?ZJG1>*O,?/=->P&(,JA3R!WW._0U:Z!2E*!2E*!2E*!
M2E*!2E*!2E*!2E*!2E*!2E:E]DK.Q91=SK&6[@$$_P#*@VZTLYD%Q.%R&2DB
MEF2SMY+AHXEY.X12Q"CYDZT*P_'L9^]K_2?TK!==48:U0M/?(BCOO@Q_Z4'$
M^A\C@\Y[1;:]N+S/VN4:\>Y572ZN(+GQ"Q6(/)!&(A&!K177$J`YUL?H:JA)
M[2ND8VT^9C!_X,G_`&UB/M1Z-#<?C<>_^#)_VT%TI57M>O\`IFZ91!E%<MZ?
MLG_[:WQU/AR-^_)_2WZ4$S7&NLNELYU3UO.V<Z7MKCIY]V2SVTR+>+`J,RN&
M:;B0SEE*<`>,G<GB#5_O>N^FK+_[SE(T/_#<_P#(5'_^]3HSEQ^.1;_X4G_;
M06S$VT5EBK*UMXI888(4B2*60R.BJH`5F))8@#1.SOZGUK:JH)[2NDI/N9F,
M_P#I2?\`;6_;]98"Y_V&1C?\D?\`2@DL]D5P^"R.3>":X6RMI+DPPC;R!%+<
M5'S)UH?C7#O9_>X#.=>V4XR&>L\BKLPAGAFFBO'\T@/CRPIP`#.A4A2W"+BW
M8\^TCJ+$D;%XFO\`"WZ5Y;J;#JNVOD`_PM^E!'^T;-8_"]-2',1>-97K&RDC
MXSMR5T;8_8QNX[`]]`?B#K=(_P#9\?#7UG>7V/L+ZQR`B19X+R6>1H!))+*4
M!>*--%V=CPY=SWUVKH)ZOP(]<@G\$8_]*+UA@6(UD$[_`.X_Z4$]2H=.IL.Y
M`6]4G_`WZ5];J3$I]Z\4?_0WZ4'`!U!@>KNL8,CE+KJC%W%S/'/$/!N)XX57
M@JVQ3P%6,L=MY3(FPY+>8"OT-U!DX\-AKO(SC<5NG-O*[=OR168_P4FM-^K,
M(@!:^`WZ?LW_`$K`W6W3RMILB`?^%)_VT')_9%D>E[OJV"&QP]U87$=U<^XP
M3-=O&@$94SISMU0%XTUYWY:.O4Z/>ZKT?6G3\GW,BI_])_\`MK,G56%=>2WJ
MD?\`#?\`2@FZ5KV-Y;WT`FM)!)$21RT1W_C6Q0*4I0*4I0*4I0*4I0*4I0*4
MI0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4
MI0*4I0*4I0*4I0*4I0*J'6O>[@&]'AO_`%-6^J?UM<I!>0!V"DQ[]/Q-!60?
M*5V"=[[U"]0VS^ZN1H;&_P`*EQ=1N"Y/'_7=1EWD+6([ED5=_P!XZH.;WF,N
M"S,`I!._SK0]PN%<DP[WZ=JZ)/E\7LD21$_XO2O$=]82-VDB[^AY`T$9TW:N
MKQAH@"-[U5N9`D7+N0!LC5:UG<0,I","WR4:[_QK+/<*@')^/;T-!3NK"CG;
MKZGL15.AMXFDV!IOH=;KHUZ]C.&69XSWWLU$G'V83G^S`)UL-01F-QZ,P9D;
M6N_TJ[8"STIX*5``]16ICX[:.,)&R-H#YU8[*9=*(M?B10;<2=@"I+#Y$:K!
M>VX=CY1RUW%;JN>7F8L-?*M5S&S%@300<EGQ8A8R>]>X<>2X.QV]14X@CUYC
MO\*R!8RXUHCZ`4&.QM/#C77?8_E6W/#L#D0/PKZK:'`:T*],&9/(RG7X4$7-
M;CD25(8>G>L+0^(/N[%2BP@>9_G]*R\8F_#\A01,%DH/^S['YZK<2R^05N/Y
M=ZW0I`TJ[`^=9HET-MWW06GI&/P\,JCTYM4S49TX0<8O'L.1J3H%*4H%*4H%
M*4H%*4H-4Y*Q4D&]M@1V(,J]O]:J&>N[V7)7Q@OI3#X<?N#V-W`@B?OS,H=@
M&V=>H8:]`#4#>'_Q<_\`C;_G6#8H.I#)V.AN]M=_/]LOZUK93(6LF-NTMLA"
MD[0NL;1RH65B#HC;`;W]2/S%<U6174%&#`_,'=>@>U!?.G\A;QQW*RO[M%X@
M,2W5^)Y".(V2>;Z&]Z`/\*U^I[NZE>RDPF6M4\-V\2(R1A7VC<2Q)WH-Q[#Z
M_.J7NFZ"W]&7L\-M.,Q=A&/AD+<7<<C<^`\0J58Z0MW`)[=^P&JG[C(VCP2+
M#D;6*5E(5RZMQ/UUOO7,MTW063%SW<-_CIK[(2W3BRMH9`UW$D,<BAO&D8*^
MW=N0[<"H*#6MDU;?B=A^^VO^:OZUR[?>OM!)YNYRDN4N&Q]U?1V@EC$G&_MM
MW,9FC+>&"X\+2!U&M,P8DD,%-6SI[(JF'MUR=[![R.0/.=&<+R/'D0=%N.MZ
M[;W5`I035Y<7LV6O_=[S(06Y$H$[7MNX<,NE6.,2*$"GNK'S['?MZV7`Y*);
M$K>2P6Y61A&DEZ)GX?V2[%CYOJ`2/QJ@5]H+#U#>9+X]#-@KT&,B193/<Q"W
M`\%^'%>7+8DX$[79W]X*-5*]+7RQ6,JW]T8SX@,:W5W'+(%X)O;*S#N_,^OS
M^0T*I%?:"W9^]F.4LIL7>\@A7FOO$0AX[\VQS!+:^JL.PUQ))KYT;<^Y6?@9
M&\DD=(8E:ZO+Q'DN)`"'?@KLJ`G1TI'J>W:JC04$AU'=]52YEWLKW'_#&55,
M=M?(&X"YA+ZY!2)&@$H!WH'T(.B;9TW?K%B(DR-[$)@S\1-<(\@CY'@'9206
M"Z!()[_,^M42E!;NL<CDY,=-'TW=8OQ#$QYR7@23G\E4<2O?ZDC_`*U]P%WX
M.2NVO;IF$C2.99KQ#&NV'!(T#D:`Y>8JI/;MWT*A2@NO4]XEQ'8BTOB84N.5
MQ%:SHCRQ\'`7F9$*#D4)())XZUW)$-A[W*MG;&;)3+;Q\?\`Q*Q7\<ML![NG
MD`9N9(EY^;B"?F2-5!TH.IPWMK._""Y@D?UXI("?]*SU0>C?_C:?X&J_4"E*
M4"E*4"E*4"E*4"H7J7J7'].BT&0,S2W<AB@BAC,DDC`;(51W/;OVJ:JJ===%
MV_5TN(DN;EX#CIVG0!20Y*ZT=$'^1H)7'Y^RN[#WN4RV,7?M?)X#=O4Z;7:M
M#-=;X3%7%O;O<FZNKA/$C@LQX\C)Z<N*G?'?;?IW%5CJCV8R9B#!6MODHK>#
M'/+(S/;^*6Y%"`%<D?V#O9K+T?[,/L@MB<'FYHW@M?=9#+;(XF7D#OZJ>P]#
MJ@F[OVA=,VF"L<Q/E($L;R=+:)S(O^T;^R>_8C1W]-&MB+K;`R]06&&COXFO
M[Z'WBW0,/VB<.>QW[^7O^55C.^R:RZHNH9NK<K=Y00V\D,:)&EL%9QHR?L];
M.BW8_7YUH7/L4L9L:;5<S=QRPQI#9W`B7G;1H0%4?WO(H4D^OK07_!=4XG.Y
M+)V.,NDGN,=,T%PJD'@ZZV.Q^6]5-U0O9Q[-;+H>3)/:WUQ=M?A3,9%"DMQ4
M,W;YL5+?ANKC\-MOI)_F-^M!N5SCVH9%;/(VT9WR,(._XM5PRW3MAE,;<6-U
M[P(9T*/X<[JVOP(/:N1>T/I.WP4EC:XAKA;5+=5_;2M,Q(V/5B3Z`4%/ZNZO
MCQMN7+>@]-BN!]6]=7^6NW%O*\40V!W!WW_*IOVJ8[*"XY+%*UOQ\P"5S%E9
M3I@0?H10;YS.1/\`\W+_`#KZF;R4;<DO)0?KNHZE!TCHSK^]MY4@O)9)`-G>
MQ^%6G.^T98X"ZB0R!?+IA7$8U=F'AJQ/X"DA<M^TWO\`&@L>1ZTS%Y*S"Z=%
M))`&NW^E:D?5&737_C)3KZFH2E!;+/KO+V[`F9G'S[@?]*ZCT7[09;Y0DCN&
MT!W8=JX%4E@9KB*^06X)V>^A0?JR/JU%@U(Y8`=SL"J;G_:K!CI!&BNS?,AE
M[US'+Y:^M\=Y8V.QHMKTJBS2O,Y>1N3'YT':D]M`4$""<?CL58,![6X[^2.'
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MTY'=!W8^T[IU#J-[A_\`#":G9NI[*+$-DF$ONX7EV7S?RK\W6MV8IMLO('Y`
MZKJEE+KIGG=G:.NN*GL.]!-1>U+"RZ/@7P/T\/\`_NINVZRQ]SBY[Z-+CPH0
M2P9--V&^PW7-[:;%1NNXNY'TJVCW*+`3RA%6+PR2-?A0?%]J^"+`&.\7\XQV
M_P!:M.!ZCLLY9>]6/B^%R*^=>)[5Q=+[#KLK;*?_`*174NDF@;#1-;H$C(WH
M#5!]N?:!AK:YDAF]Z#QL5)$)([5OX+JW%9MI%L99"T>N0="NOY_E7/,WG,>E
M],C0`L&()U5BZ,%I<V\LT"!-D;T-?6@L%QUEA+>^]UEO5\8>N@2!_&I+'Y>R
MR'/W.=)>'WM'TJC7\^*MKMFFBB\3?<\14WTO=65TD[6:(O$@$J`-T%BDREG&
MY22XB5P=$%ANL\5U#*-Q2*W^$[JF95<<UQ*9TAV#W+**W.G[:QC=Y+-8E)&B
M4`'_`"H+5XBCYU]$@/H:I?4-U;1&4O<\&`[@/JO71DT<]FDD4S.3O>W)H+GL
M5]W6HOK]X_SKV#H^O^M!GW7W=:Y)]=FO49W\Z#-NFZ\U]%!]W2E*"=Z-_P#C
M:?X&J_50>C?_`(VG_#:K]0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*4I0*I'7]N
M+B]MPVM<!W/YFKO6M>6%O>%3<1ABOH2*#BV5Z=BO`4EC1@P[;4$52,O[*L=>
MLQ,<*L?[L8-?I<X2Q/\`^"O\A7P8+'C_`.73^0H/R)=>Q*%]^')P.]_<]:QV
M_L1B23<L^P/DR"OV#\$L-:]W3^0KS\"Q_P`[=#^:@T'YAL?9796NM+'_``C%
M:&9]DUM>*X3C&Q!T1&-U^KC@\>1KW:/7^$5Y.!QQUNVC[?[HH/PS>^QN^CE(
MAN#K>AM/_P"ZTS[(<J&T9?Y)7[P^SN+Y;]TCW_A'Z5X^S.*WOW6/^D?I0?B*
MP]C=V6!N)SKUUQJ[X?V:062H.,>^WF\,;K]3MTUBV&C:I_`#]*^KTYC%]+9/
MY"@_-=[T#'>6S1A.VM'R=C5#RGL9EED+6TK1_@$[5^TA@,<!KW==?D*?`,:/
M_ED_D*#\*GV-94,09]?FE36$]C,B31O>2E@#LCAL5^SVZ>QK,";9-_X17T8#
M'`'5N@_("@X/TST1:XVUC153RKK[@K=RW1%EDXBDL43`C6R@/_2NV_`[`+KP
M%U^0KT,-8CT@4?P%!^7[SV(XR1BRN$W\O"%><;[#\=$^YB'`^31@U^H_@UEL
M'PAVKZN(LEWJ%>_X"@XMT][/\5BD40VT0*_,1**N%O:Q1V_!5XG\%J]#%6@]
M(A_*O0QMJ!_L5_D*#3Z4C$6)"C^^QJ8KQ!"D"<(E"KO>A7N@4I2@\R.(XV=@
MQ"C9XJ6/\`.YKFT>(SF7P-GBIK1X88VFN99;BY:%R[22>$JD*WW00Q!']T?6
MNETH.:7D?4V2D%[=6%Q"@M(4OK*"7BT_">7FL3_+:\6UH%E(7DN]UNW-M<S=
M2X>ZP^/N(%64&8/`\+)"4UYI"Q5D';]B%#;&]KH[OU*".N8,F]O*B75KS9"!
MJ!U[Z^H<Z_.F&@R4$/')W<-RWRX1%2/P+;\W](J1I5:FJ9GMORA"S9B[SC_!
M#CO"N)$!=->+HGS#RC=<>F3C-(&\K!CL?3O7Z5L+K(Y?.9"UDZ6ZALO#=RL]
MQ8NL4H#:\K:_C^5<PZOZ/S]QG;A[?IG,R1<CYDQTI!_CQ[U+7-2NR.)VWR%6
M;.9._ALK>Q(\*'B#O7=JMO1W1V<CR2>\=-9:)/[TF/E4#^)6K9UKTQEI+&..
MVP=_,V^_"RD?7\A0<&%Q,K`^,=_C5BR6?R;8.WM)(O"A==>)K[PUJKA8=)Y]
M)%_^SN44;[DXZ4?_`,:L76'3V<?IY$ML%D9I=`<$LI&/I]`*#@X+#TDKI?2N
M>O[;HRXD6#Q3#R"-Z;&MU$KTIU6(Q_\`97,@CZ8V;_MKI&`P>=3IQ5FPF3CE
M"':-92`_RUN@X3<WD]Q,TDDH+,=GM5IZ,Z@R=C%=I:V_O2",N==N)`-3<?3'
M4AG<MTOEM<B=_#IO^VK[TIA,S'CY!-@[^%ODILY%)]?J*#A]YG[VZG,DH0,?
MD%J^>RK)7<OOP>WW$BAN8[;/?M5T^`Y8SES@K[?U]SD_2IG#8?)I!(&Q-]'W
M]&MG&_\`2@XKF>M)'OKE&QZ#4C+WD[]C^56+V?=6K?9`V361C9EY!E;D.VOP
MJY7'3V4:YE+8*]<%B03:.=__`+:E<'T_?P(Y^#74))_=F&_]*#B/7V;%QF;V
MV6VUP;AS+>NOPU6Y[+<]'9Y*.QEB?<N]/R[#L3Z5T3JSI.^NGE?[.WEPQ'WE
MM78_\J^="='7EGN5^G[ZVE].4EJX/^HH-_)96SLKW5S<"-F'8$ZK+C<I97$Z
MI#=I(QWI0PV:FIL+?O(.6,NV_$P,?^E>X,%>+('&,N58?/P&_2@UKKCP\S\!
M6*WX*XU-RV?2I:7#WSZY8^Z;7UA;]*^+B+X,-8ZZ_P`EOTH-=DY%3LC59@-5
ML'&Y`>EA=?Y+?I7H8Z__`'&[_P`EOTH-4TK:^&W_`.XW?^2WZ5]^&7_[C=?Y
M+?I02/1A_P#.T_P-5_KGG3.'N%ZHL[RXM[J+P(Y5!9"JGD`.^Q^%=#H%*4H%
M*4H%*4H%*4H%*4H%*5AOI6@LKB9`"T<;.`?38&Z#-2N9=.]=9.[]E5]U/D,5
MDK:ZM<*,D#<+"D-R_@&0^"49V"$C^V-Z8=B=ZLK=3W$V<NL?CL?'.MID(["X
M=YV5AR@29I%548%0)8QW*]R?30Y!:*4JG7.=R=OUICL?/;3V>-N)I8O>+Q83
M'=-X;,D<!CD+J_E+'Q%T51_0ZH+C2E4[IWJE6Z"P^?S=TD4N8CCGACXE@C3+
MSCA4(O)N(.B=;\K$]O0+C2H+"Y,Y>QN8+>]3W^T98Y)EBT&;08-P)WP;T/IZ
M,`>P:MO,WES#@;B^QMO+<7$47O$=N$*R3!?,8P&UIF`*C?H3W]*"2I4,<J_O
M\4RRVC85XN\VR'23B9.1)(7P^`]1L[(^6]8(LS>'%VDJ6RRWEU$URD4D<L(6
M,G:*Q5'TP#*K?CLZ^5!8*5`V6>N+JXQR/B;NSCN[2.Y+W2E?#9_6%N(8+(O;
M88KLL`I;S<<MOEIUES!OHH8X+2Y6"$Q,[L_*.,KL!=[)DUVW_'U(3-*JE]U9
M-CK>ZDO<3/RBN+.",0\^,OO,ZPKQ>1$')6.RHWH%=D<NVY>93,Q3V5G!BK*2
M^GM9[A^5^RPQM&T:A.?A%CR\3>^';B?J*"?I5>3/?$_9\.H<<'@]ZQ?O\`D`
M+1\HN:['<;&Q]17F_P`OD(L+>RS6L5I<>X374#13B;B47T;:@;')?3D#W[^F
MPL=*B+G)W;7EY!C+*"[]T5?%YW/A,7(Y!%'$[\I!V2!Y@-]CK6Q^:O,E=%K"
MU@:SDL+>\A\>1HI-RF3RL`K:[(/R[^M!8*52.E>K<AD\?T5-D+.V23/8\7;M
M;S'BC>"LF@C+O1Y'^UV^K5-8[-7=S\*EN+*"*TR(_9.ER7=28S(`RE`-:5MD
M,=$#UV=!.TJOXG/W.2R=K'#8(<;<6KW'O:3\C$P9`L;KQT&8/L:8_<;\"6>R
M-U8Y>`EBF-BLKB\F,3`R.8S'Y>+*1K3'T8'O\M=PL%*@[7,7HN\?#DL?#;B^
MY")H;L3%6"E],.*_V1ZKR&^WIHG9Z:R%UEL'9Y"]LTLGNH8YA`LWBE`R!M,>
M(&P21VV.V]]Z"3I5:Z:R^1R.2O8[O&9.WMH9[B..ZD:V]WE"3,BA0KF7>AOS
M*!V/X`_,7U)<W(PLMYCXK:WRSM%`4N#*X<1/*.0"``%8W[\NQXC6R0`LU*KF
M!N\AEL999-\A;0B2<EX(XN2"/DR^"22&\0'0+=AR4CCKM5&N?:@(NO45+^RD
MZ9-\F)(5"2'*$FY\7[O`3%8>._DS?2@ZY2N/8'VBY>/VC=1VF=:U'2UKD3C4
MN>`C-G)X7B1M(^]<'TZ[([-P']JIGHCJW,9KKZ[M+T+%BKC$Q92RMVAX2Q(\
M\D:<R>Y+)&KD$>4N5[ZV0Z12J'U3UO/T]'U+<>YB\7&S6$,<)E\,,;AT0GEQ
M)&B^_0[U\JGNF\U>9&^R=AE+&WL[VP,7,6URT\;!UY#3,B'ZC[M!/4JIV75E
MQ>7&=GCQJ+B,1/+;S3O<ZG=HH^3E(@FM;*@<G!/<Z`URC^F^N[S*KTM<7>&A
MM;#J,-[G)'?":1#X+S+XB<%`VD;?=9M'0.MT%\I7/,)U[F<CB.F<A-TNENG4
M,,C6<8R2NXE%N\\:OY``KK&^F!)'EY*"2%Q3^UC&)BEOX;.>X2#&39+)11.#
M)CS'Y?!<?_J-('378#PV)[#=!TBE4"[Z^R%A;Y^3(=,W:+C<3-E8[A/%%M-X
M:[:`R21(4DWZ`*P*]][!4>[GK3*PW^8Q<V&M;?*V>)7+1@WADC,;-(O%R(P0
MX,?H-@[^]07RE<]DZVOL;[G?9RUB2Q/3MWF94LY?$+>![N2`K(NB1,VAR(^O
MUK+;]=WJ0XV;)86""+)XV;(6G@7XF8>&@DX2#@O$E&7S(7`.QZ:+!?:52K#K
M*]\7#G,XFVQ]KE+&2\CG]_#B`I&DA2;:*%'%F\REAY#]15?SWM(O5Q74%I#9
MK99.'IFZS=I=PM)+&&C7782PQ\@&9"#HAAO8&M$.JTKFMMUKD<?B\SD[Z)LA
M;6%OCIY8TXQM'%)&IGE&E[\06?1UV4@$5<>G<X,Y/E6MX`+"TNC:0W(<D7+*
MJ^(RC0`"N6CWL[:-O35!,TJAV?7=Y-=6S3X:&/&W&:N,(LR7P:4/')*@D,90
M#B3%Z<N0Y;T0-G?AZS22PL[CW50UQFY\-X?C]U,<\L7/T[DB+EQ^0;U[;(6V
ME<W;KO)WV&ZBO[;%Q6=EB;Z;'B<W8>6:6*Y$9(C\,J(V7OLMR!V`NM.8W*]6
M=3+U'UL4D@BQV"EM;:*&%U!82QHYD8M$Q9OV@T`54:UIO4AUJE<]R?M$N8;K
M/C$]/W.5M\-=+:2BV$[3S2!$>01HL+*2OB*`"XV0WH-%O'4W6&9?%Y^?!V5M
M!;8R]6R>[FNAXI8%.;+"(V4CSJHY,"=L=#0Y!T6E5KKKJG[+6N+9+"6^N<E?
M)801(W$!V1WY,=$\0(V^ZK-]`3VJ#O\`VC/B+&._SN#NK&P&2..GE;F7T8P\
M<T,9C#S(V^)T`RD-Y6"D@.@TJCVO6>1O[A+?'X2V><8J/+2";)*BK'*T@B16
M5&#,1$>1^XN^S,-$^H>N_>$P-W'C'@Q&4L(+_P"(7DACAA$K(!$65&42`.#I
MBH)(`)[\0NU*Y_+[0+L664RL>$B.%QV3;&RRM?J+ARDW@O(L04KH/K2LZL1L
MZ^[S]WW7&4@@REU!@()K6SRT6)3ED.$D[R2QQ!U7PR`.4JC18>C?AL+[2J+?
M=>S8JTS'Q?$^#>V%W:VBI;SM/#*;DHL;\Q&&50SD-M-^7L&)`.1NL\HMM<-]
ME<BTL-]#:\E27PFCD&_&&XA(54^5@(SH_P"[M@%VI4&.H;8=*39N6YQT<$4<
MC-(UT1`K*2I5Y"H*Z8<6VNU.QHD:JKW_`+1Y+%\];S8<M?XVQ@OH8%EDC]Y2
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M:]3I5&SWT`/E6&/%8^.:UECL+1);172W=85#0J^N80Z\H;0WKUT-U$VN,R`N
MKRYGNKF-7OA<6L$=P9`BF(1E9`VAQV6<QJ=`@%3NL5C:]1&6TNLP;264XXP7
M,%C<21Q+<EUVZ;&RI&_,3R0+Y0W,T%AL[2VLH/!LK>&WAY,_AQ($7DS%F.A\
MRQ))^9)-:>&PUIB;**TM@SV\$KR6ZR:;P.1/E3MV4!F`^@.MZJ!Z=Z?SUHO3
M2YK,O?>Y8J>TOW29T-Q<.T'"30URXJDHY'3>;?J3K+A,+F[##='VT^2,UU8:
M^+RO<22^];MY%?B6&V_;M&PWQTJZ&OND)^]Q\-TS2#<-PRB,W$("R^&&#%`^
MM@'N.VB-[!!T1N5!XW&Y`R6TN1R-T);::1BD4B&*Y5@P'(<`0/,"%WM2H')A
MW:2LTN8WD6:7Q(``(^:CQ-[;?(CL1KCKL#Z[V:#7^`8?X*N'^$X_X2NN-E[L
MG@#3<AJ/7'LP#>GKWK/"]C?S>-%X%Q+:2/%S`#-"^M,H/R.CHUI9#%3W]VOB
MWU_;P1W$5S'[K<!`W`J?#?2@\&(.UV003O785I8?$Y#%->,G@2BYRTEVRK*5
MU"XUW\O=AZ\?3MZT$\EG:QOSCMH5;@D>U0`\4)*+^2DD@?+9UZUB;%X]FO&:
MQM2UZ"+DF%?VX*A#S[>;RJJ]]]@!Z"M);2^?WR2ZBMYW-\LUM"UR_AK&H102
M>'KV9^.B`Q'??F&`8S+2Y3+"ZREPEA/-%-9FV**T`5$#1D%#L%T9M[((<J0-
M>8)6\M['P$6\AMC")(N(D0%0ZN#%K?S#\2OT.B.]?;Z>TLE6[O7BBXE85E?6
M]R.JA`?7;-P``]3H>NJB,AC<G>>^I(\+1?$K2YM0;AEXPQF$R`@)V.TE(7;`
MDC97?ED<W8'(VD,2\=QW4$_F)`_9RJY]/4Z4Z_'7YT&Q!9VD6.CLH;6&.Q2(
M0I;K&%C6,#00)K077;6M:[5YM\;8V]HUK;V5M%:LI5H4B54())(*@:T2S$_F
M?K6F]A>>%F_!NF6:ZW[JS2,PA_9*H['LOGY'M]1^0S65M-XMK<3!XI%MS#+"
M+EY4#;71&]!O1O.0&((WKT`9)\7C[B\-W/8VLMT83;F9X59S$=[3D1OCW/;T
M[UF-K;F\6[,$1NEC,0FX#F$)!*\O76P#K\!47B,/+:#$27-U<RW%I8BUE+7D
MKK(VD\[*QT[>5O.PY=_7N:R=/6-[;=.6UCF;DW-VD9BDF25N3#9`//LV^.O-
MZ[[[WWH,T-IB[;W+P+:RBTS^Z\(U&F<%GX:'8L`Q.O7O6RUI`8(X5B1$B&HN
M"A?"\I7R?W>Q([?(U6>ENF;G%]+=%8VZ:`7&#BB2<P2-P=EM7A)'8<@2^],/
MQ]0*^Q8SJ*U>+AD!+:ID;B=HQ+RE:V9&*(&=3M@Y'E.AK7F`4`AM8?H_%8B[
MLKFSB"2VD301LL42$HP`(9E0,P\H[$Z)`)!(!$J+W'/:VN2%S:-;S*BV]UXB
ME'$K*$"/Z$.Q0#1\Q*ZWVK)C;4V5HL#7-Q=%68^+<,&<[8G1(`[#>AV]`*I=
MGT9DX/9WTQ@7R*R7>,;%M-LKX3"VFAD<*1&&(U$P7>B3QV?6@N-ABL?CEC7'
MV%I:K&AC000J@52W(J-#L"W?7U[UM0QI#$D4*+'$BA511H*!Z`#Y"H%,;D9[
MJ9+^]NUA][%U#);3JHX*ZLL3C@"`1Y2`6#`,202!6OE<!D+K#F"VR$\5X^6B
MO7E%[,G[!;I6>,$'8!@!3@-+L_B6H)"RZ7P%CEY<K98/%V^4E9FDO(;2-)G+
M';$N!R))[GOWK-A\'CL1!"EC:01O$G#QA&HD?80,68`;+>&FS\^(^@K''9WM
MHV3D@(N6N;R.:*.>[D58TXQ*X!TW'7%V"*.))[ZY$B*SECDH['(3V3W+O=7=
MG+%:M=R(8R)8PX,B\BB$#15`5T&.CS:@W[SI+IZ]R"W]SA,<]\LZW0N?=U$G
MBJI59"P&RR@]CO8T"-$"LR]-X=>FOL^,=;_!?!,'N97<?`_V=57NM,)U%>XO
M--@[Z2WNKEK%X(H[MUX&*96F*L=<.:#AQ&E/'9^^U:U_:=59F3J.9(;G%0W5
ME8PV$#7P$J.DDK3LWADK&Q#JOE9MA%[_`"`3E_TWTN8LK;9#'6!BRI-Y?1SJ
M"D_AE3S??;RGAW_*L^*N,%DLA;9NP\)[R_M!'!<E&1I[=3S''D!M=R<@1Z\M
MU&=0]/7UQ)':X^>Y.,^#W]HZ27DC,\\C0&$LS,68@+,.1)(#$>AJM8KHSJ7&
M8SHZUQF0GM&LL#/97X:^DDB6Z,$20L(R2I"NLA&AV^E!T'(=/XK(I=I>V,,R
MW;1/.&'^T:)@T9/^$J"/RK%E+_"=.22Y#(SV]E)>-&CRN>\A!")_JRC?^\/K
M54Z5P6<@Q5V;NZZCCR;8WW8I?7\,]NTY0'Q(F4F0$,2`QX[&R1]TB:7HW'Y#
MIBTQN?BEOG$2F8W5P]SN3R,V_$+!EYHK<6!7:CM0;-AC.G,U=QY^TM;6YG>1
M9A.%/>5%*+(5/;Q%4E0Q'(#MO5:'1>%Z,+C+=)8['A%YQPW-K#J(`GS^"=<.
M)([E.QU4]A\'88?$#&X^)H;;B02)&YL2-%B^^7+\=[]->@KFW2'0>=Q.`]GN
M,FN;J"#'&4YB*WR4J*_[%Q&!Q8;`D*'0T/PH.EP8;'6]MB[>&TB2'%\?<D`[
M0:C:(<?_`*'9?R-:UGTM@;(Y<VV'L(_C#,^0U`I][+`@^)L>8'DW8]O,WU.Z
M=U%ANK+F3J"WLVN_>+F:'X/D(<BT,-E$%B!\6+GMV5A*Y\K^)OBW$:`D,UTY
MF;Q.J)8;V^2ZN+Z&7&^'D9HECA6&W#+Q5@H!=)B1KOR._6@G;3I+!VF/N[&&
MP7W2ZM%L)8GD=PUNH<+$.1.D`D<!1H#D:WY,1CY,E-D)+2%[R:V%G)(R[+PA
MF8(?D1MF.OQJ%Z:Q65QG5&>\>YGEP,L5K[@D]R\[I(%<3=W)8`_L_4Z[$_,[
MKW4V,ZOO.IK*?&&ZMXH<O;22/#>\+:2Q!'B!D+$M(0".(1%[[V2-D+GB.G,3
MB#;''620M;0M;PD,S&.-A&"@))[:AB&OD$4#L*C[/I/I7I\R2VF*L++WB/W$
M%4UJ.20L84']A&=RW!=#9WJJ_E</U:][FH.GKJZMH;NUO!'>92ZY^#<,083`
M$=@(]EAYD#*%&B?0X8\-U+)A,);VL63L+ZUO,9)?2W&7><7$<;[N%4\V)4C8
M.PI??<=A07OX9B[CP(S;V\ON*M;HATPB5D`*$?BA'8_(BHZ#HGIR&)HTQ4!5
MK%L62Y9S[HVMP`DDB/RC2CL.^@-G=8ONELS&.M4P\U_9W.3O(KJUNTO208EA
MM4DC')CPD;PI5#E?*".XUJMFVZ=O4L,RZ7G6JR7"Q<8)LA;N_)'V&A//2;``
M8%E#*?3>S06X82QCM;R&UA6V-U"('=%5CQ5."]F!4Z'H""/J#3IK"V?3G3^/
MPV,5EL[&%8(N9VQ"C6R?F3ZG\36A@(,VG2#P7K)#F-7"Q.SE]>=_!9RS/WX\
M"PVP!V!VT*@,!A\_)>8$W)R6.@MK22/*K/D#<B\D:-5"QGQ"5`?D_B:1O(`!
MISH-_I#IKI:&\GRN'M4N+LWES<&^>+NTLLLC.R-Q"MKFT8<;/`!>1%?;'%]$
M97J%;ZP7#7F75S?HT,R2.C$(C3*H)XDA8P6`[Z7>^U;WL^PLW3_2MIC[GEXZ
M,[/N9I0"7)&B2=#6NP[;W^-1>`QN2O\`JE,[U1CYH;Z".6"QB22-H+2)F[G8
M;D\CA8^1*@#CH`=RP6).G\5'8W=DEC"+6[G>YGCUVDE=N;,?Q+=Z2=/XJ5\D
M\EC"S9)D>[)'^V9%"H6_(*H_A5>ZGQ^;?JOWR*.^O\(V-,"6=G?FT:.Z\3?B
M,0Z;5D(&]DKP[*>50S]/]=6F#Z=BM\N;K)2V"XS,S/<$"'EH^]0@C32Q[<;[
M%]J6WH:"X7W1^`O<I<Y*XQD/OUTJ)<3(6C,ZIKB).)'/6AKEOT'T%8<WTGTS
M=RW62S&,M93R6ZFDE!*\XTXK*5].:J-!M;`[;U53SN"ZJGFOH+!LA#X5Q`<?
M<0Y1^#PQB'9G+R$ECQD\JQ@-VY,>3,9C%X#-)]KKB^O;MKNYNYSBM7\O"*!H
M5"#ARXJ0YD/IL=OH-!:LKC,=G+#W;)6MO>VC$2*LBA@".ZNI^1'J&'<>H-:M
MOTUB(+Z"]2R5KR&5YTGE=I)!(\:QLY9B26X*J;/<*-#MVJ@]5X#K&_Q%[9V$
ME_%?>X1"SNK?*O`OO"Q@,96YL?O#8"Q@,>S,`Q-;/5/3/5=\G74N-R-W%=7+
MV\F"X9"2-82L,8?:AN(!=6)!!!V=CN:"UY#HCIK(QPQWN&M)DA5T0%?1';DR
M?BA)WP^[^%;5[TSAKZ57NL=!(%2*/@01&R1,7B5D'E8(Q+*"#Q))&JU>N;+*
M7V-LTQ#2GA>PO=1PW+6\DMN&_:*DBD$-H@^HWK6QO=0N7Q^8N[:!+.QRUM:,
MLQD1<JPO`Y$?A^?Q2BJ2)`>[D:!4;8D!.3=&=-S9GXM)A;$Y#QDN6E\(#G,G
M+A*P]&D7FVG(+#?8U(-AL<T,D+6D1BDNEO7779IE=75_S#(I_,"J;@NG>HWR
MO33YZ_NWM+7IU;6_6+(2)XE_RBW(0C#D=+)YC]?QJ'Q&"ZX@R'2]UU%/?9*S
MM\,;.^M+'(&%Q>>(-7#'F@EV@T=MVT2!L]PZ3>8/%WL>0CO+"WN(\@JI=)*@
M99E4:`8'L="M?[,XD^8V[M-XPG%PT\AF#A"@82\N8\C,O8^C,/F:I=]@^H+G
M,7_OK]3QVD_@BS;$92$+:HL"<@XE*EF\42'EI^08<NPU5KPN'NX>I>H,ED+J
M[>.>[1K&(WDABCA%M$A`BWQ!,@E/I\P:#>7I_$+@6PGPVU.)=61[1HP8V#$E
MM@^I))))[DDD]ZU8^C\`EQ>W'PR%[F]54NIY"SRSJI!4.[$LVN*ZV>V@*J75
M\.;O.L\_;8ZUR=S!\`MUM?=LI):+#=/+=#EH,JG8"EG!+*$72MR[:.=Z?ZXG
MZ>7'B\NILJF#AB3(V-^T`;(+XG,R;<#AWC((BY-W#,H`%!T?(8[%7LMW[_!;
M3/):&WN%DT=V[[VK`_V3IO7Z&M3`=*X#"74E]A<;;6]S<1".2XC[O*@.QR;>
MV]>Q.^VAZ`5`9?IF\EZMSU];+?A<AB8+>WGAOWC$4\;73'D`X('[6/6@0#R[
M#N3'9'IKJ2?(!K_)9Z;'28RWMDCQ%^EO+;SC8F9N94/RVK!^18<6&O38=-KR
M)$,K1!U,JJ&9-]P#L`D?0Z/\C5#EZ;S=UE.IVN+_`"/N4^.MX<8%R,D3).(Y
M!*Q$;``DF,['S!(K-AL)D['K4Y:]AGN5N</:6TLL=X?+<0F<N&C+!65A*-$;
MTP)T-EJ"\4JC](V6>PEK=1/#D,A;I[M';ME;X-=N.;+,SL'>,Z3BXUQ+G8('
M8U>*!2E*!2E*!2E*!7F:188GDD.D12S'Z`>M>J\S1K-$\<@VCJ58?4'UH*+<
M==W45[T=:C%0Q2]16D]X1?71MC:K&D;B-AP;;ZE`([:*GUJ2M^JY),?AKV>R
MBAAO,@^/N&:Y&H&#2(CJ2!S#R(BJ-*W[4$@$$5DQW2%M;1=//<W=S<Y'!VKV
M=M>DZ=HW"*Q<'89B(TV2/4$C6]5M3=.Q.;%%N',$-\U_.DJB0W$FF*@D_="N
M58<0-<%`T-B@SYG+_#<C@K7P/%^*7K6?+GQ\+5O--RUKO_L>.NWWM[[:.O)U
M7B(IXH9)KE'FNWL8N5G,!),N^2*>&F^ZW<;'E;OV.I&^QMM?76.N+E"TMA.;
MFW(8CBYBDB)/U\DKC1^OX5K7.`Q]RV/:6)B;&]>_@\Y'&9A("WXC4K]CV[_A
M08%ZKPKQVSI?!Q<WTF-C"QN6-S&)"\1`&U($3^NO3\1OWC^I<9D?&]R>YF\&
MZ-E*%LYMQRA@I5O)V`V#R/;1WO7>M>VZ/PULT+16[@Q927,)^U8ZN91(';U]
M")7[>G?\*F+.R@LVN6MU*FXE,\FR3MR`"?P[**#'D<I9XVRN+N]F\.WMV"RO
MQ8\2=:[`;/WAZ?6O-YE[.S\8W!G"PE1(ZV\C*F]=RP4C0!!)]`.YT!6KF>GX
M,N)XKRYNO<I^)EM4951V4J0Q;CS!\@&@P!&]BI"YLH+FVN[>528KI2LHV1L%
M>)_+L*#4R&?Q>.G:&]O$BD7CRV"0G+TY$#0_C^'UK=O+N&SC5[ABJLXC72EB
M6)T!H#=8)<>[78G@OKJV!?Q)8H^#+*>(7OS5B!H#[I7T_$[R9.S-_926WO$D
M"R=F:-$8E?FI#JRD$=CV]#09(KJ&6X>!&/C)&DK*5((5BP4]Q_NMV]>U:;9N
MQ`LRKS2"\A-Q#X5O(_*,<=D\5.OOKZZ]?P-:N-Z9L,4+(8LSV@M;=;1`C\@8
ME.PA#`C0).M`:!T-#M6-^G^-]BFQ][<6EOC[&6R41R!VTQ@*[#JP8@1>I[]_
MQ-!)7>4M;6YMH)?',UPCR1K';R2'BO'D3Q4\?O+ZZWOM7@YJQ%U9VWBO[Q=Q
M23PQ>$_(HA17)&MKQ,B`@Z()_.M7(X6>ZR^/NK?(75H+:UFMRT3*S-S>%NX=
M64]HB-D;'(Z]36X,39KDK3(%#[U:6\MM&Y8_<E:-GW]23$AV>_8_4T&!^HL2
ME_'9/>QK<R3^[(K`@-+HG@#K6]`_/U[>M>H,_C9L7>9&.X/N-IXOC3-&ZA?#
M+!_4=]%6]-^GY5FM\?[M<%X+J=("S.;<<"G)F+,VRO+N23][7?M6M;8&"#*7
MV26:0W]V@C:?PXE=4'HNU0<@/ESY$;.M`D4$@EU'(L+(6U*W%>2LI/8GT(^@
MK53-XYQ;D72`3PR3H6!4!(R`Y;8\O$LH/+6B=>M><+A8,59Q01R23,DAF,CJ
MB%Y"-,Q5%5`3LD\5`)).MDUAM.F<5:_$Q#;D+D2YG4NQ'G+,X7OY0S.[$#7F
M8GU-!GQF=QV3G\&RN/$E\(3<"C(>!.M^8#^/TV-^HK)D<K:8YHA>/)&)9(X4
M80NREY'"(.0!`VQ`[^F^]?<=8RV9E\3(7=VC$<$N/#/A``#0*J&/IO;%CLGO
MZ5J773]K<YCXB\LXD*QADVI5N#JZ]R"R@,H.E(![D@GO0;*9>RDO[FRB>26X
MMF5)A'"[K&S*'"LP'$-Q*MK>P&4G[PWJ0=16MQ`DT4=RB-=&U)GMY8],)#'Z
M\2.[#MO7KW(K=]P87YN$O;M$9N3V_)6C8Z4#U!90`OHI`)+$@DDUY3%0+`\)
M:1X6N/>0A(TK^+XNP0-_?[]]T"/,6,B6S)."+BX>UB\K;:5.?-=:[$>&^]_W
M36"VSMM-/C8"DQEOK7WJ-HHG>(*.']OB-??'J!V]==J]66`QUEF+W*6\!%Y=
MD-(S.S`,!HE%)TFP!RXZY$`G9[UDBQ%M!)CW@,L;6,!MHN,A(\(\-J0>Q_V:
M=];&CHC9V'V#,6$_N@AGYM=/)'$H1N19-\PPUM>)4@\M:;2GN0#[N<E:V]RU
MN[2/.L?BM'#$\K*FR`2%!ULAM;]>+:WHZC\/@A89_-9(LI%](C11*21&!&H=
M@#]UG91RXZ!X(=<MD[%[AHY\H,C;75S97A1(I9+?@?'B1F98W#JPT"[D$:(Y
M'1[T$'E^LHHNH^FL/C09&S*SRBX-N\B(D7$,I`T0W)P#L^71Y`=JGLEG+#'7
MUO97,LIO+A'EC@A@DF<HA`9BJ*2%!91LZ&V`]36%^G,:V5Q61\%A=8Q)X[=@
MY[";CXG+?WB2H))V=[.^YK'FNG(,EE+7*0W=UCLI;PO;I=VGA\S$[(S1D2(R
MD$QKZC8[Z(W0><?UA@<@EB]KD4,=]!-<P.Z-&K)$P6798`*RD]T;3#1[>4ZU
M;OKSI^SQ"96ZN+N'&O;QW0NGQ]P(_#<$J>7AZWH;(]0-$@;%8<M[/,!E<!:X
MB\BN&@MY)I1*L["5FG$@G+/ZGQ!+)R'H>7;6AK5ZB]F6!SN5GO[KQXY9K+X>
MPB6(\+?@Z>'&S(6B!61P?#*[Y=]T%BDSUH<K<XJV\:;)0J"R>[R^&I8;4/*$
M*KO\_P"%1GVXQ%OTS8YK)2O#:7-C%?&:"VN)H>+KR'%_#!/ST"JMK6U&P*G+
M3&6]KDKZ_B#"XO?#\4D[!X+Q70^7:JM/[-<+)\.\*6ZA]PQJXF`@1.R0*C)Y
M7=&:-BKL"R%2PUO>AH)3)]:8+&M/[U=3\8+),C-)%:32I';N7"R,R(0H/AN>
MY]%)].]2N:REGA<;-?Y.;P;6+B&8*SDEF"JJJH)9BQ`"@$DD``DU%W'2&*N+
M+)6LB3>#D,7'AY]2=S;H)0H'T/[=^_Y?2I'.XFWS>--E>&58_%BG5HFXLDD4
MBR(P/U#HI^G;O08FSUDEN\[QY!8T?PV)Q]P"#Q+;UPWQT/O>F^V]]JU(^L,)
M+8XJ[@N9YX<HI:T\&TFD:0`;/D5"RZ^?(#7SK1RG0UOF;2QBS>6R.2FLKE;J
M&>ZCMFTXY#O&(1$>S$<N'(>H(/>I+&],8_'IB1#XQ.,$H@9WV?VGWBWU]:#7
M7K?IZ1,:T%^;ALD)#:QV\$LLD@C;C)Y%4LO%NS;`T>QU7G*==].8J5HLAD#!
M,L"W+QM;R\T1@2.2\=J=`^4Z8?,=ZT;?V<86R.,FQ<E[87^.-Q[M>0R!I%6>
M1I)4(=61@6<GNI(^1%24G2_&_:]L<SE;&YE6%;EXC"_O(B!`YB2-P"0>Y3B3
MH4&Q8]48B_R7N%C<2W-P(HYB8;>5XU21>2,9`O`!AW&S]:U>I.M^G>FKWW/,
MY$077NS79B6&25A$#KD0BG6R"`/4Z.MZ.I:RQ=O9Y"]O8R[7-X(Q,S'[W!>(
M.O0=JT\ET^EUEAD[/(7V-OFB2":6U,9\:)&9E1ED1UT"[]P`WG;O08Y.K\%'
M>VMHU^/>+N&.>U18G/O*.0`T6A^TUL%N.^((+:!W6`]<]/B$W'OLON8NA9^^
M>ZS>[^*7$>O&X<-<SQY<N/+8WL$5]RW1V.RV=L,S>RWK9/'@"SF6<I[OW\Y5
M1Y?./*^P=C0]*U6Z!Q9L5QIGO?@:W/O8Q@9!#XGC^/LGCXA'B'EQYZ^6M=J"
M1M^K<)<+D7BO?V..:9;N9HG6*`Q%A)R<KQ'$JWS^5>(>L<'*T:F[EB:6U>\B
M$]M+"984`+,G-1ST""0NR`1V[U'W/L_Q5]G[W+Y26YO;B[M);"576*)6MY%`
M>)C$B,Z^4$<V;B?35(N@\3/-8W5_<W>3>RM9;6Q>=T`MHI4".$\-5!)4`<FY
M'7SH-NUZWP=W)8I:RWTQOK<W=MPQURPFA''<BGP]%?.G?_?7ZC>*Z]H73%K!
MCY9\GQ%_"]Q;H+>4R-&I`8E`O)=$@:8`[[>O:I#$],X[%?!?=%E'PC'MC+7D
M^]0MX.P?J?V$??\`/ZUHKT9:6WN;XF_R&,N+6%[99K=HV9HWD$A5A(CJ?,.Q
MUL!FT1N@R8WK?I[)IC&QU^;H9*`W-J(8)7+QAN)8@+M='L>6M:/T-9NL<Z^"
ML[$6T<,M_D+Z&QM8YG*(SN=L20"?*BR-Z=^.OG6'J#I.'/C')DLC>R164R7"
M)X<'FE0DK)R,7)'&^QC*'^9WM=48!,]'C"9O`N,=?17\$A3F`Z;!!&QV*,Z^
MHURW\M4&&XZPPUN+II9[D1VUP+6:5;*=HXY.071<)QUMAL[T/4FOESUE@[:X
MDAENIN4=XF/=DM9G1;ABH6,N%*[)=1Z^I`K/-TSCIL;D;!UE]WO[@W,P#]RY
M96.C\AM15&G]GV6;KRYS$8P>I[Y;M<H]O&]Y`B@#P@KPL3L*$Y"9>(8D*-`4
M%SO,U.W65AA,<L4BK"]WD7*EO`CUQB78(XL[[(V#M8G[#L:U;/K_`*>O&QBV
MUQ?.V3A-Q9#X;<@W$8`)=-Q]P`RG\F'U%2/3V$;%W&4O+FZ-W?Y&Y,\LO#@J
MJ`%CC5=G05`!Z]V+-VY:&O8](8JQEZ<D@28-@+-[&RW)O43)&AY?WCJ)>_YT
M'RVZLLKZ[P2XLK=V>5\?A<*Q7@8AY@5(WO8*D'1!!W65<W*G7#X&XAXQ38\7
MUI,%/GX2<)D)]-KS@(_QGZ=]2PZ)QV-L\;;XR>[M/A\MQ+!(CJS`SNSR;YJ0
M02Q^7:MM,`WVO@SD]]+,;?&MCXH677=Y%>20D'CMO#B&@HUQ/KL`!K=1=>=-
M=.WDUKF,HD%Q!")YD6-Y#$AWIFX*>.]$]_D"?05CEZSL+*YS4F2FBAQ=@UHJ
M7*!I/$-QH)V4'L690".W??I6S<]*VQS]QFL;>76*R%VL27DEFL6KM8^002"1
M&!(#D<AIM`#>@!3-](8K-096*]28KDF@>8I)HAH6#1E?IHJ#]#KO08NK.ML3
MTQB<Q?WOO4XQ2H]S#;0,[KS&U]=+W'S)`'S.]4SW7?3F`!^,9`VK"V-VT;V\
MI=(@2.3*%VN^+:!`)XG6]&O$O1&.N\5F['*W%[DAF85AO)KAD5W"IP!`1553
MKOV4=^];-QTUXF3^(V^7R5I?O#%;SSP^"3/'&[NJLKQLH[ROW4*=-Z^E!$]3
M>T7$8[IS+7^*F.1NK3$_%8XX()94*-&S1%W12$#\2?,1V!/H-UDDZS>#V1Q]
M936G*9L*N4]VC#,O,P>+PV`2%WVY$=AW-9<OT)C\I=Y">>\R"')V26&12)T5
M;V)0X'/R;!U(XVA7L=5)_9G'?8O[+<9?A/P_X9QY^?P?#\/7+Z\?G0>+?J*T
MBOK'%WD\LN5NHC,J16$Z#P^7'DPTWA@'0)8CO]-UXMNL<'<QV4L-W*;>]E6&
MVN#;2K#,S;XA9"O$AM=CO1[:WL5)_#+?XU\5TWO?N_NV]]N'+EZ?7=5ZPZ#L
M+2WQ=F]]D;K%8N2&6QL+AXVB@:('PR&""1N.P0&=@.*_2@ROU]TZAQ_*ZN@,
MA,T%JWN%QQFD4$E5/#1/E;\]=JF\/EK/,6\L]A([I%,\$@DB>)D=#IE*N`1_
M+N-$=C48W2&*:RPMJ4F\'$7@OK7]IW$NG'?ZC]HW;\JE,7C+?&>]^ZAA[U</
M<R<COSMK>OP[4&[2E*!2E*!2E*!2E*!6*\B>>TFABN);:21"JSQ!2\9([,H8
M%=CU&P1]0:RTH.7]+XCJ!L#T*F2RN9DR*(6OI[N"-IK9C9E3&&\,#0D.P[AR
M3L%FWVE,A+U9!C[2SCN7D/O<UO-D%@XSF,`^"P40R)R/;D_`)M3I5Y#5Z5T=
MG565BAXL`=\3H'1^G8@_QJ-PN=M,W@H,QC!+/87$8F@<)HRH1L$*>XW]#H_A
M0>>F)LA-C&.6,9N5FD4%$=?(&/'?-%V=:V0H!]1VKE^(PO62>S#HNVOI[!K>
MWDPAEQT>(F2ZB2.YMB0\AG(!0+MR8P-*W9?4=-Q74-MD[^[M+:WO1+:3>!<&
M2$JL3^&L@4G_``2(>W]X5)75Y:VCVZW5S#`UQ)X,(D<*99-%N"[]6TK'0[Z!
M^E!16O>LKC-3RB(6$4&0%O%:N?$AGM?&4>,2D#,':/D1J10I(Y#RG>3H^\ZL
MSOQ\Y21\2V/SUQ:V0DL-+=62L"KL&T6VK$*Z%1M03RT0;V702+&64.P+!=]R
M!K9U_$?S%1]CFK&^BBDMI&99;N>R4E"-RPM(L@_@87[^AU^-!YO??+#&,8);
MB^F\9-LZ(76-G4.0%"@\4+$=B>WHWH:YU%E\EA^E<O>VES<S&U$317%[:\7+
MM)YTX!$Y*%*@$#9V1O8[7%KF);R*U8GQI(WD4:]54J#W_-UK[=6T%W`T%W#%
M/"VN4<J!E.CL;![>HH*\T^0M<9G3!<Y&]>&V:6WDN+15D\4B0\$547F!Y`!Q
M)^1+'>MZRR,U_E,E#;+/%##;Q>$]S9R1IXK&3EKD%Y@`1[`/;TV":W'RF/3'
M-D'OK5;!1LW)F41`;U][>O7MZUM/(B-&KNJM(W%`3HL=$Z'U.@3^0-!59K+(
M)U?BXFN+F>-L9D0^1-O'S@D::U,:*P3BHUSTI!Y",%N14FHCV<])S=-3XUEN
MKR2*ZL))KF&6RM85CN&,&V+10HQ<Z(/-B3Q[[(W5^]Y@]Z]U\:+WGAXGA<QS
MX;URUZZWVW7R*[MI;J>VBN(7N8`IEB5P7C#;X\AZC>CK?KJ@JW2<G4<N5\7+
MS`6DUNS26SJS>!,"@"Q-X$7D_P!IOF7)\I!`!WO6V,N<MT[9_%;R[CO9!%<N
MT8$+P/P4.B<0&4'SCN2PYD;UVJ;O;J"RM9+BZD$<,8VS'O\`@`!ZDDZ``[DG
M0KQ:WL=RVHTN%VO(&2!XQKM_>`T>_H>_K0?,99+C[&*U26:8)O\`:3/R=B22
M2Q^9V:KO3-UEI\T\EP^1DQEW`]Q&E[$L;VK;3C'Q$":[,W9G<^7UJV4H(/IN
M'*^[V=WDK^:9I[2,SV\L*((IN*[*!5#`$\]ABW?6M:J)P"Y)^HL9+D;J^FE^
M'7#7*367AQ0RN]OI(W"`:!230)=B._(ZV;4+VU-E'>"Y@-I(JLD_B#@P;7$A
MO0@[&OKL5G=E1&9V"JHV23H`4$)EI;OXLD?O-[:64<:2JUI:^*9FY,'1R4?2
MZX>@5CLZ/8ZCLK<9CXGD#:W%_'+;,!9VB6:M;7:M&A!DD*D@AQ(.SIQ&B01H
MM9Y+J".\AM7D"SS*SQH?[077+7Y<A_\`\#7WWF#WKW7QHO>>'B>%S'/AO7+7
MKK?;=!&9R[R]K97\F/L(+AHXMP`3GF[=O5.(&AMCH,2=`?/M%WLN4L,78/97
MN4R/'(Q>]2W%H@E\!CY@$2)=J-KW5=@;V>QU9;B[AMX1+(XX&18=KW\S.$`[
M?[Q`KSD;V.PM#/,KL.21JL:[9G=@JJ/S9@-G0&]D@;-!"7$USD;2\(BN3$F4
MM?`62W:-O#5X"QT0"0&\0[/T/R%1$:9[%]/]036^2R^3R45RSQ07=M&52,3,
MVHN,2F0-&1VV^M!5XD:J\LZ(R*S*I<\5!.N1T3H?7L"?X5]9E4J&8`L=`$^I
MUOM_(T%>R=[D)[;/'&>\QM'C@UHS6I!$Y$O=59?,>T?;N/E\S4=G/M#!D;2Q
MLKV\:U*-.;P*@D=O$),3<;:1`H5E`\J,0/O,>1%SK';SQ7,*36\J2PN-J\;!
ME8?@1ZT%/N[K.31V*7M[=XYQ8PS-/C,>TR37)#B5&1XW9(UTA`/%CRUR[&HK
MV:8S-VOL(Q./M!-B\_'C66$7,/%H9O,5#HX]-ZV"/0_+UKH\LB1*&E=44L%!
M8Z&R0`/S)(`_$UAO;VUL5B:]N8+=995@C,T@0/(QTJ#?JQ/8#U)H.4R=4]>W
M<]_>6V&NK3'Y.$6&(MY+,^-9W7%-W%P""1'S>4;;B.,":'[3D8;J?'=5OE_:
M8N(&5L72ZPT]ID;*S6.>_18T6=?%$>Y0H!/%?0[7[K,I[J\B(T:NZJTC<4!.
MBQT3H?4Z!/Y`T>1$:-7=5:1N*`G18Z)T/J=`G\@:#F]WCLT_4F<OL9DLO`$Z
M=L4BN/<HQ)>3QRWC:(>+CR[CDJH#^U&N/:K5@,Q=?8O"Y+/VMS#D+BR@ENH(
M;.5WCF:,,Z^&H++H[&B.WIZU/12)*I:)U=0Q4E3L;!((_,$$'\17BVN8+J,R
M6LT4T:N\9:-PP#HQ5UV/F&4J1\B"/E0<[Z&N\M@,1TEC\E99%;&+IFV62..S
M:0QW2*BLC<5)5M;&CH=C4;T5>]=YJXZ4@S5WD\;%+A7N\E-\.C1C=+.@6,EX
MRJ$HQVNMZ!T`>XZ#)U/BEDPWAW44]KEW:*TO(9$>"20*6"!P>Y8*Y&M@\2-[
MUN:H./=!'J+$9K,Q7MED;7#SYK*W$`MK,R27,C2R,OB%AJ./CID8#3MK;J!Q
MDVK*\ZJR3WEO%==0):Y##W-S$]S:I%-93@Q>%$I]VC56(DD!!,A\G8C1)M.+
M]H6"O[#WXF]M;`W)M4NKFU=(6<2&+_:`%5',<=L1WT/G5D^)6/Q7X9[[;?$O
M!]Y]T\5?&\+EQ\3AO?'EVY:UOM00'2-D<CT%;V6<GR.3%W:^%=#*VXAE8.@#
MQLHC0Z[D;(W]2351]C_L_P`1T_G^J\A'@%L+F+,30V$S1,A]U,,.N&_5.7/N
M-]]UTW'Y"UR'O/N<OB>[3-;R^4CC(NMCN._J.X[5ZQ][:Y&RAO,?<P7=I,O*
M.>"02(X^JL.Q'Y4%.RE[E_MG?07=[F,?B(8;=[,XW'"X6Y+%Q*)',4FM'AH#
M@0._<=ZBX\GUK==32GBUC;Q9;W;W::!W@ELA(H\566W)\1DV03,%!;3`:[=(
M]Y@]Z]U\:+WGAXGA<QSX;URUZZWVW7M)$=I%1U9HVXN`=E3H'1^AT0?R(H.&
M8;#Y>UZIP]TV.OHHX.J<_=-*UG(ZI')%/X<A``)5B1QT?-L`'O5PZ9ZJO<39
MW[];R9!!:0P-+?R6I2T=W<IJ$>#')R+,!P(<CR]SO;=%J#S.;P$++#D[NRD>
M*^MK;PB!*T5S(R^`"HV58EE()`T/-L#O01'M<PUQG^D$QUM->QK-D;%)UM8T
MD,D#74:RA@Z,.`1F<]M>3S;7DIKEU-U/C<;F+3&29.SNL./=L+90XR.6UR$:
MV\8B:5DA"IRDYC2-$J#6P`._5'D1&C5W56D;B@)T6.B=#ZG0)_(&O'O,'O7N
MOC1>\\/$\+F.?#>N6O76^VZ#D<6+RTG7>?NY\7=1I/G\5<!A&S(56S1797UI
ME5MJ6';8^52TF4ZI;*2R129-+M<R+-,6^.W9O9^.-S>\"+8)@V_+Q"H/DXE^
MU=+KR\B(T:NZJTC<4!.BQT3H?4Z!/Y`T',LWG^L;#-RVMK8WUS9XR^:\N9DL
MN7OE@W#C#$P&FD3Q9-*HY'W8`GS[?Q>7_6IQ^&Y?$(!EIKJZN9H84,N-C[&W
MM@ON\GJA\S.C'DK#D-J!T#XS`W4+X:**>2ZCMTNIF51PBC=I%0L21LL8G``V
M>W?0[UH9+J['8_J08.2*_FOA:B]D%M:/,(XBS*K-Q!/=D8``$T%;N<EU.;?I
MQ,C/=V4,T5U[_=XG'O<2"6-D\%>,D)*!T$A8F+7(!5(VI.QTG8WT/L<%G=PS
MG(&QN%:-H&C=W//7[,]P3OL/QJUV&>Q=]@OC-M?0'%!'D:Y=N"(J$ARQ;7'B
M58'>M:.]:K=N[B*TM9KFX;A#"C2.VB=*!LG0[^@H.2^S->I8,'TKB([W+QHV
M$,5X+W$^`N-D2*-(A&S(G)@W(%6,G+1/E%6;H'.9W/W\IRD(M8L7![A>JJ@)
M<9`,/%:/8Y>&JJI4@@'QF!V5[;^)Z]P>1L\3<O)<V$669%L6OK=X5N&=>2*K
MD<"S#NJ[V?D*GK1<?9SO96BVL$SE[IX(@JLQ=B6D*CN=L22WS)/SH.<]9XK(
MGJ3*X2RL;N?%=7K;^]3H&,=N4*Q7?)P-1E[54"[(!9.VR=5#X.'JR:&RL,Q@
MY;F^Z*LKEX'=#';Y2\">'9O&Q)#;B\0MH^5W&PI&AVJM<7MJ<@UB+F`WRQ"=
MK?Q!X@C)(#E?7B2"-^FP:#FN(R'67N=Q(]Y.[S8R>;5]92EK:YXIX0C6.TCY
M*&+!D)=R-$$\6WI=4/U1E.FL5-97G5>/NK/.VT%YX$$9::`O%SF4"`,\:J2>
MZ*">8=&4"NE6G4&,N,''EWNHK;'R-Q$URPB4$OP`))T"6T!]21]:D+BY@MO#
M]XFBB\5Q&G-PO-SZ*-^I/TH.99K(=:29'+1XZXN;-K1PN/\`&M&D@NT,$9#S
M<+9VWXGB;"/&1VVO8<I#-R=5K![0+^ROL@K6$4J86QBLXV65O<8G5UW&6E/C
M,X`!UR#*>78"R]7=36_2^/>^OK/(3VD<4DTTMK!X@A1!MF?OV&MG^!IANJ+#
M)6-M=2+/CDNI5AMER""!KAF7DHC!/F)`)T._E/:@B.FWZDAS>&3*W=Q>VE]B
M'N+OQ+-8EMKM&@`52H'$.)93P<L?V9T>QJ(ZI^*6O7N<NK&7,6JM@[0P266.
M-PMQ-%-=GPF<QN!_M%VH`8A@01KOTNH^UR]G<S9:-9.'PN807+2>54;P8YM[
M/RX2J=_G]*#EF8EZL@ZGR&>LL-,F6EZ3L8B$@::**X-S(957TYF-7+<`=D`=
MCL;S9^YZMNK#JK&X6[ZBN;-L#+<VN2FLDM;J.^!)6WB'A(6#(0-A.2Z[/R/E
MZQ[S![K[UXT7NW#Q/%YCAPUOEOTUKONEI<P7EK#=6<T4]M.BR12Q.&21&&PR
MD=B""""*#F4>/S;]6V?'K#K08ZZL28YFQUN`LHE`XNIM.,9T0=NH.M]]`UEZ
M8M.I#;=+8M;S(8RU./R#WLR640?QEFA6'?*,HC$/(P''3:;L==NFTH.+775G
M5D^-Q-K*,U8Y(V&0FG]TL%DG:2*<10/(C0MQC90S^5.3;7B"`0>C^SJ_?)]#
MX:[FS$&;N)+=?'OX./AS2CM)PXJHXAPP'E!T._?=2M_B<=D)4EO\?:74L:E4
M>:%7*@]R`2.P[#^59[*TMK"SAM+&WAMK6%0D4,*!$11Z!5'8#\!09J4I0*4I
M0*4I0*ULI9C(8R[LFEFA6YA>$RPN4D3DI')6'<,-[!'H:V:QW4I@MII0I<HA
M8*/GH;U00-ETU[M?=/SK=B*+$6+V:6UK"(HY.0C!)&SI!X8T@/8ZV3H:S]$8
M$=+](8C!BX%S\/MDM_&$?A^)Q&N7'9UOZ;-5/#YS-O>^S4SWL<MGF,=/)?R(
M$,<]R88Y8PA(V!KQRH77E7OZ5.9OJ6;%C*2P0B],%]8V"0L_A*LEQ)$G=^)]
M!,K>A^G;=!+8;$?#<CG;KQ_%^*7JWG'AQ\+5O##QWOO_`+'EOM][6NVS@M\"
M\'4^8RXO7E3(VD%L;69>:1&(R:*]_NGQ3M=>HWOO4/D^K;JRFN+&^L5@OH)<
M3R]VN?$0I>7(@.F:,'RNLH(X^90I!4L0F[+U7K,G#QV,ARHO4@,+OI3;LI?W
MD,`?)Q211L`&5#'OT:@^P=(6BK<BZEENS)E!E$>:23DKB19%!(<`\>/!>P`1
M44A@IY9L-TY\-MK:+WKQ?!R=YD=^'QW[Q)._#U_L^/K?SX^@WVUNG^JKC-6>
M,NH,+=I#>7$L4@<,CVR+S"NX=5]2@!4$E2P]0"1OX_*W]SCO?'QL95I2J1P7
M/-S'S5>9Y*H!`YL5!/W0`6)T`W;K'I<Y"*XFXO$MO+;M"R<@XD,9._P\FM:[
M[J/ML(SXZ\L;V02V<I$$5N4*K%;J=!.SG;:WY]@_=V-K6Q;91[BXM(EA`:>"
M>4;9E`,;HNB&4,#Y^_8:T>QK3FZDM\9@['*YFYLX<=*J">]\0)%"[D!>6^P4
MD\>6^Q([:)("36RF$:Q->2R1"0L>79RG$Z3DNCV;1WZD#1WO=:V!PJ8?'V=I
M!X'&V,BJ1"1QC=BWAIYB5`/#YG83\B,B9;CT\^6NK2Y@1('N3;E"9@@!8`KV
M(<J!Y?D3KY5[@O9[B.&2W2SFCFM?'BDCNN2N_;L"%[H=C3C?Y>FPT\5T^EH\
MC75S/=L+Z:\MV>60&+Q"QXZ+D$#FZC0`XZ&NVSN6V/>T9S:W!17$C-$R\HS*
M[<C)W/(=RWE#:[_+UJ-]G-[<Y3H+I[)Y"7Q;V_Q]O=SN-@%Y(U8Z&]`;/H-#
MZ`5K=&]0/<^S/IW.96XCEN+G'6DMQ.Q6-3+(B<F.M*HY,=Z';OH?*@F>HL4,
MSBGM/%\&02Q7$4G`.$EBD66,E3Z@.B[&QL;T0>XWHA*$C\5T9@NG*H5#-V[@
M;.AZ]N_Y_6%R'4(Q]YD8KR&&."T6UE\8S@#PII&0N^P.'$HY/J"`#L=P,'4W
M4R8J#*>'&)9+*WMKDJDH#%9I70>H.A^S/?1WW^E!OW>`L+N_-Y-!"TY()9K>
M)CL``>8H6^7UK)FL:^1DQKQSK%[G=K<LCQ\UE`5E*D;'?S<@>^F53HZU7R_R
MCVUS':I;GWF=WCMO%Y+'*1$7[NJL$&P1YM'L2`>P,3F.J#!T%D\_#;2@VN,N
M+R2(.%>*6-&)BV58<PRNI['17N#Z4%C,3FXBD)A/$.I/A^;1(T`=]O0;]=Z'
MI47B\!%83XV4.CO96TULFH@NEE>-RJ:^X@\,`(.P`4?V:P75_<I\3XRD>%E+
M6!.P[(_N_)?X\V_G7JVZ@EOKR2''VB2K;WS6=R7D=6C50-L-(5)V0>)9?*0V
M]GC08^F^F!A(,1$ERDHQ]O/;@^#QY+(Z/V[^77!1KOO\*SSX)_@\]I9W8MKF
M2\-Z)Q%L<_'\4!E#`L.P0]QM?I7W!WT\V;S]E<.\BVMQ&828P`L;PHW#>_,0
MW,^@T&4?*IN@@KCIV&;*WN05HH[BZ:TY,D6BRP2>(`YWYB26`/R!&AZ[]]5X
M^>_L;1K0,\]I>P70C#!?$5)`77OVWQY:V0.079U4U2@K3=)P.O57BR12-G+A
M;CDT`)@*V\,2?/S%6AY@]M%NWIL[-Y@!?6_4%I?3K<6&677@R1\O!W$(V`V2
M"IXJP&AHECL[[3E*#0S-C-?8M[:TN?=IN4;)*RLX!1U;N`RD@\='S`]_6HS+
M](X[)6=Q;DW,!N;E+J6>*=Q.LBH$#QR<MQMQ55Y+_9V/GNK%2@IUSTI/'=8Z
M6$8_(6UM#+;O97L96-@7Y)*I\VI?D[%3SV3Y/0UV'V:WD'3%M8!L2V2@6Z:U
MO(XFCBQ\EQ*9&6*W8.CPKJ,!&UV3U'+R]3I0<SS'LZN;Z]ZM666PO;7/E?#N
M;M";G'`IP<1'1#`:Y1_<XL>^_6L60]ES7V2]H-U<W%K<-U!9PP8]KB+F]E*E
MMX1DV?0EA&VUT?(/H*ZC2@HV5Z"BF3JB'$/;XJWR^+@LHTM8A&(Y8VG)=E70
M(82QJ1V)5"-^E:<'L^MQ89&WGP>(,602W2[@%]<E+CPR[!MD>0ABA4@$]B"?
M0CHM*#GPZ6RD473=AQMWM[;+G(2RJB<;:!$?A&".#.Y8H.97TY[[ZY7FS%T/
M']\:!OVK>%X2D:C_`+(;9.V]=D=JV*4',;;V?91N@!T9=W5@N+ENII+RY3F\
MLT$EP\S1(OE$;'F%Y\FUHGCLC6;*]!9#(=02W\UQ8N1E;6]MYPIB>*"*6.1H
M>"`!F/%QXC,=@@:'K72*4'/FZ*O[:TZEM\7\'@DR5T;B"[-N"ZQLT;/`ZE2"
M#QD','MM3QV*E_9_TS)TU%FUD6VB2_R!O(X;=W=84\&*(*6?NQ_9$D]O7T%6
MJE!S^RZ%GMY\O`'L4AO[V\NAE(4*9"!+A'VL;Z\DB/(>,FSY`%X[\U:V"]G4
MD,6$BR9L(CC<=-827./3PY;WQ$6/E)M?*.*EBNVV_$[`71Z32@H?372>7QLO
M2,%U<6!L.GK#W)?##M)<-X2Q^(=Z"#2@\?-Z_>[=]*3V86:]`]-X6*VQWO\`
MB),?.\HA5$NGMV0N'/$G3@/W[G;;.^X/2:4'-\Y[.XLI?YBYN\;C[XY)(R%G
MO)XA:LL*Q^&OA@<HP4##7$[9O38UMWG1EY+UA#E;)<590RW3RY)Q'XSWT1C\
M-4X.I$9XA0S*W?1^NJOM*"A>S?I?)8B_R=QG&61;9WQV&V`7BQX<N@)!/<[5
M3Z$K#&3W]-3J?V?W65R75LL4F/D&?M8K>.YNXR\V-XQM&QB&O,-'FHY)IRQV
M=UTBE!5<!T?!B>I),FTGODGPRRL$N;H"2Z9X#.&E>37=G65`3\^)_"M?*=/Y
MB/KF]ZCPLF/:6?#IC8TNV<".1)9)!(0H\R_M!Y=J>Q[BKE2@HUA[/X((.G8+
MZ2WR4>.DNKBY-Q;KQGGG8R.ZIW5!XC,0O?B-#9UNK+)9WF0Z<GLLG);I>7,$
MD,CVZL8U+`C8#'9T"/GW_"I2E!SFWZ$R-WT_T=@<Q<628GI\6SS+!S>2]DMX
MPL7F(7PE#`.1YB=`;`WO*>@I!=HL0QT4:YHY=L@(MWDBF8S^#O0X^8\.7(_L
MQQX]]CH-*#G64Z'RM[-X*WMBEDG4<&>5RCF1D1T9H2OH#M6(?9[:'$;Y"I=)
M](=5P=?R9/.8&TN,?\:N[VW,DL:RV_B.X28R!F,@6)B%C*KHE?N\=UW*E!SV
M?H?('$X+'>\V-S9V2W`N;>9"HE=VW&X=1S'#S;4$<N7<C0J/N?9O?+A,%!82
MV,>8Q>)M,=%DW>1@C1>I-N08Y%^8WIAL]^]=2I00_66)?/\`2&<P\,JPRY"Q
MGM%D8;"&2-D!/X#=4GK7V?9//X7X8EQCI+;X,,='XZLC03Z*M.&4;<%2`$)`
M!&^^]5TZE!S+(=#7C]0X:UA7E@;JTBCS_F4).UL%]W"C?(%F)#]B&1`I([;E
M,OT9<W5Y?7<<ME.9<Y%EEM;J,M#*BV<=LT4GX^5G5M$!@AT=$5>:4',\?[-"
MOQ&2_;'%<AFH\G+8PVX%K'%&@18@I^\Q4`LY`#$_='SZ5#&D,210HL<2*%5%
M&@H'8`#Y"O5*!2E*!2E*!2E*!2E*!2E*!2E*",AP6,CP$>$:R@FQ*1"!;6=!
M)'X0^ZA5M@J!H`'Y`5L+C+!+&&R2RM5LX61XX!$HC1D8.A5=:!5@&&O0@$=Z
MVZ4&K/C;&XF>:XLK:65_"Y.\2LS>$Y>+9(_L.2R_W221HU[-G:M?)>FVA-XD
M9A6<H/$6,D$H&]>)*J2/38'TK/2@U%QE@E^]\ME:K>OW:X$2B1NP7NVMGL`/
MR&J^7N*QU_8&QOK"TN;(D,;>:%7C)!Y`\2-=B`?S[UN4H,:P1*\;+$@:-2B$
M*-JIUL#Z#RCM^`^E:<^%QTUA-9-9P+:S2^-)%&@17?D').O4DC9^OSJ0I0*U
MK#'V>.BDCQ]I;VL<DC3.L$:H&=CMF(`[DGN3ZFMFE!BM+:"SM8;6SAB@MH$6
M.**)`J1HHT%4#L````!47B^E>GL2]RV+P.)LFNE*3FVLXXS,I]0_$#D/P-3-
M*#1Q^'QF.QS6&/QUE:6#`@VT$"QQD$:/E`UW':L=O@,/;6KVUMB<?#;.B1M%
M';(J,B?<4@#6EV=#Y;[5)4H-6+&V,.0GOX;*VCOIU"RW*Q*))`-`!FUL@:'K
M]!1\;8R6MW:O96S6UWS]XB,2E)N8TW,:TVQV._6MJE!B:V@;GRAB/-UD;:#S
M.NN+'ZD<5T?P'TK!\+QYR?Q$V-K\0XA/>O!7Q>(WH<];T.3=M_,_6MRE!I#%
M6/\`XCG;1R^\7"7<GBCGRE3AP?1]"OAQZ^G`$=Q6[2E`I2E`I2E`I2E`I2E`
MI2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`
MI2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`
MI2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`
FI2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E`I2E!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`"O`=8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HK%U3Q;HFD
M%DN;Y&E7_EE%\[9]#CI^.*Y>]^*J`E;'3&8=GGDQ_P".C/\`.NFGA:U36,3&
M=>G#=GH5%>23_$K7Y3\GV6'_`'(L_P`R:J?\)]XG_P"@G_Y`C_\`B:ZEE==]
M5_7R,7C:?F>S45XY%\0?$J-EKY9!Z-`F/T`K1M?BCJT9'VFSM9U_V0R'\\D?
MI2EEE=;68+&4WW/4J*XS3_B=I%QA;R">S;N<>8H_$<_I7566H6>HP^;9745P
MG<QL#CZ^E<=2A5I?'&QT0JPG\++-%%%8F@4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!117`^+_`!]]E9].T9PTH^66
MY'(3V7U/O_D;4:$ZTN6",ZE2--7D=#X@\7:9X>79,YFN2,K;QGYOQ]!7FFM^
M--8UHLC3FVMC_P`L820"/<]3_+VK!DD>61I)'9W8Y9F.23ZDTVOH</@:5'5Z
ML\FKB9U--D%%%%=YSA1110`4444`%36MW<64ZSVL\D,J]'C8J:AHI-)Z,#OM
M!^)DT;+!K<?FIT^T1+AA]5Z'\,?0UZ'9WMMJ%LES9SI-"_1T.1_^NOGZM30_
M$%_X?NQ/9R?(3^\A;[D@]QZ^]>7B<NA-<U/1_@=M'%RCI/5'NE%9/A_Q%9>(
MK+S[9MLJ\2PL?F0_U'H:UJ\"4)0ERR5F>I&2DKH****D84444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!117-^-?$@T#2=L##[9<Y6'_9'=OP
M_F:NG3E4FH1W9,YJ$7)F'X\\8M"7T;3)</C%S,I^[_L`^OK^7K7F]*S,S%F)
M+'DD\Y-)7U>'H1H0Y8GAU:CJ2YF%%%%=!F%%%%`!1110`4444`%%%%`!1112
M`N:7JEUH^H1WMG)LDC/([,.ZGU!KVG0-=MO$&F)=V_RM]V6,GF-O3_`UX56S
MX7\02^'M62X!8V\F%GC'\2^OU'4?_7K@QN$5:/-'XE_5CIP]=TY6>Q[?13(9
MH[B%)H7#QR*&5AT(/0T^OF3V0HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBN6^('C%_!.A0ZG'9+>&6Y6#8TFS&59LYP?[OZT`=317GGP_P#B
MC+XVUV?3)-)2S$5LT_F+.7SAE7&-H_O?I7H=`!1110`4444`%%>5^+/C+/X:
M\3WNC)HD=PMJRJ)3<%2V5#=-I]:[_P`,:RWB'PW8ZNT`@-W'O,8;=MY(ZX&>
ME`&K1110`4444`%%%%`!1110`4444`%%%%`!1110`UV5$+NP55&23T`KP_Q-
MK3Z]KD]YD^5G9"OH@Z?GU_&O2?B%JIT[PU)"AQ)>-Y(QV7JWZ<?C7D%>[E=&
MR=5^B/,QM2[4$%%%%>R<`H!9@J@DDX`'>NVT[X8:A=6JS7=Y':.XR(MA<@>_
M(P:/AQX>%[?'5[E,PVQQ$".&D]?P_F1Z5ZC7C8W'2ISY*;VW._#893CS3/./
M^%4R_P#083_P'/\`\51_PJF7_H,)_P"`Y_\`BJ]'HK@_M#$_S?@O\CJ^JTNQ
MYQ_PJB7_`*#"?^`Y_P#BJ/\`A5$O_083_P`!S_\`%5Z/11_:&)_F_!!]5I=C
MS2?X57:Q$V^J0R/V5XR@/XY/\JXJ^L;G3;R2TNXFBFC.&4_YY%>I^/?B!9^!
M;2W:2U:\NKICY5NLFSY1C<Q;!P.1VY_/&'K5QIOQ`\()XDT=6\^T)66-@-Z@
M<LK8],[A[$^M=>%S";J*-5W3.>OA8J/-#H<!1117NGG!1110`4444`>F_#/7
M3<V<NCSME[<;X23U0GD?@3^OM7=UX1X?U0Z/KEK?`D+&X\P>J'AOT)KW8$,`
MP.0>017S68T?9U>9;,];"5.:'*^@M%%%><=@4452UC4!I.B7VI&/S!9VTD^S
M.-VQ2V,_A0!=HKY^D^+_`(\UZ<VVC6L44G54LK0S28SWW;L_D*F5_C1J:"8#
M4T'H5C@//^R=I_2@5SWNBOG:^\4?%;PN"VHSZA!&#S)/;I)'D]MY4CMZUUW@
M3XSOJ^IP:3XAMHHI;AQ'#=0`JFX]`ZDG&3W'<C@=:`/6Z**YWQ/XQLO#BB+;
M]HO&&5A5L;1ZL>U73IRJ2Y8J[%.<8*\CHJ*\H3Q;XQUZ<KIRLH'5;:`$+]6.
M<?G4\D_Q%L4,[BZ91R<)'+^@R:[7@)K24XI]KG-];B]5%V/4**\[T/XF,TRV
M^M0(JDX^T1`C;_O+_4?E6_X\U^ZT'P+?:UI<D1GB6(Q.PWJ0TBKGWX8US5L/
M4HNTT;4ZL*BO$Y7XP^,]=\*R:7#HMVMK]I61I&\I7)V[<?>!`ZFK?P9UO4]>
M\/ZC=ZK?37<WVT@-*V=HV+P!T`]A7BGBCQEK'B^6WDU>6)S;*PC\N,)C.,]/
MH*L>&?'^O^$K*6TTF:%(II/,821!OFP!U^@%8&A]3UYE\>O^1'L_^PDG_HN6
MN0\-_%[Q9J7B?2K"YGM6@NKR*&0"``[6<*<'Z&NO^/7_`"(]G_V$D_\`1<M`
MSC/@+_R/%Y_V#7_]&15]`5\\?!.^M=,\5:G?7LRP6\&E2/)(W10)(JT?$_QT
MU.ZF>#PW;I96XX%Q.@>5O<*<JOT.?PZ4`>[45\PW'Q`\>R1_:Y=8OTB;I(L8
M1#],`"KFF?&3QEI\P::^BOX@,>5<PKCZY4!L_C0(^DJ*Y?P/X[T_QOI\DMM&
MUO=6^!<6SG)3/0@]U.#SQTZ5U%`SY@^*G_)2M8_ZZ)_Z+6O=_AK_`,D[T7_K
MW_J:\(^*G_)2M8_ZZ)_Z+6O=_AK_`,D[T7_KW_J:!'4445YCXV^,MEH-S+IN
MAP)J%[&=LDSD^3&W<<<L1WP0/?J*!GIU%?-A^)'Q#UZ:2.RO;E^<^58VJ_(/
MJJEL<=S39_&_Q*T'#7M[J=IO.!]LM1@G'0;UH$?2M%>,^%?CL7N%MO%%I''&
MW`O+56^7I]Y.2>YROY5[%!/#<P1W%O*DL,JAXY$8,KJ1D$$=010,DHJKJ=P]
MII5W<Q8\R&!W7(R,A217AOASXN^+=2\3Z587-Q;&"ZO889`MN`2K.`>?H:`/
M?**\M\=_&2+0;Z72M!MXKR[A)6:>4DQ1L#RH`P6/7/(`/KSCSB3XD>/]5+/%
MJMVRH<D6T"J%]OE7^=`'TS17S#:?%7QM9L-FN22*#DK-$CY]LE<_D:]1^'_Q
M>B\2WT>D:U;Q6=_+GR98L^5,?[N#DJV.G)!YZ'`(!Z;1110!Y7\3[XS:[!9@
M_+;0Y/LS')_0+7%UL^+KC[5XLU*3.<3F/_OGY?Z5C5]=AH<E&,?(\&M+FJ-A
M4]C93:C?0V=NNZ69PBCZ]_I4%>C?#/0=J2:W.G+9CM\CM_$W]/SHQ-94:;F%
M*FZDU$[;2M-ATC3(+"W'R0IC./O'N3]3DU<HHKY)MR=V>ZDDK(****0PJ.XN
M(;6WEN;B18H84+R2.<!5`R23Z`5)7E7QO\6_V?I,?ARTE(N+X![G:>5A!X'_
M``(C\E/K0!Y-XU\3R^+O$]SJK[EA)\NVC;K'$/N@]>>I/N36S\*/%:^&O%2P
M73A=/U(""XW=%;^!C]"2#VPQ-<110![#XOT(Z#KLL2+BVF_>0'MM/;\#Q^58
M5=?X=O\`_A8GPW$+GS-:T7"$DY:08^4Y/)W*,'U92:Y"OJ,%7]M2UW6YXF(I
M>SGILPHHHKN,`HHHH`*]M\'7QU#PK8S,<ND?E-D\Y4[?Z`UXE7J7PNN#)H5U
M;DY\JXR/8%1_4&O,S.%Z/-V9UX.5JENYVU%%%?.'KA4%[9V^HV4UG=Q"6WG0
MI(A)PRGJ.*GHH`KV.GV6F6PMK"T@M(%)(B@C"*/7@58KG-=\?^%_#DC0ZCJT
M(N%.#!%F20'K@A<[?QQ7"ZI\?K%`5TC1)YB1]^ZD$8!_W5W9_,4`>KWD5M-9
MS17J1O;/&1,LH!0ICG.>,8KY`O#;IJ$YL7<VZRMY#-PVS/RD^^,5W5WXA^(?
MQ-!LK6WE:S8@/%9Q^5!D?WW)_1FQP.*X6^LY-/U"YLIBIDMI6B<J<@E20<>W
M%`CZTU#5%TS0)=3FP?*A#XZ;F(X'XD@5Y#H]C<^*_$J13RLS7#F2>3N%')_P
M'X5W?Q!G:+P5;(O2:6)&^FTM_-17!>'-0U;3;R2XTBU:>8Q[&Q"9,*2#T'3I
M7N8"FXX>4X_$SS<3*]51>R/:;*RMM.M([6TA6*&,855'^<GWJQ7F/_"7>-_^
M@8__`(!/1_PEWC?_`*!DG_@$]<;P-5N[DOO.A8J"T2?W"_$S1(;2X@U6WC""
MX8I,!P"_4'ZD9S]*U_ACJLEWI-QI\K%C:.#&3V1L\?@0?SKEM:U+Q7K]FEK?
M:7/Y:2"0;+1P<@$?U-;GPSL+RSO;YKJTG@#1J`98RN>3TS795C;!\LVFU_F<
MU.5\1S16C.6_:"_X_-#_`.N<W\TK:^`?_(J:C_U_'_T!*Q?V@O\`C\T/_KG-
M_-*VO@'_`,BIJ/\`U_'_`-`2O#/3/4J\R^/7_(CV?_823_T7+7IM>9?'K_D1
M[/\`["2?^BY:!GA>EVE[J6H1:98;C-?.L`0,0'RP(#>V0#[8SVKZ8\'_``^T
M3PA9Q""VCN+\+^]O94!=F[[?[H]AVZY/->/?!&PCO/B`)GZV5I),GU.U/Y.:
M^BJ`"O*_B]X`TV?0;CQ%IMJMM?6F'G6%`%G0GDD#C<,YW>@(.>,>J5@>//\`
MD0M<_P"O&7_T$T`>#?"/49-/^(VGJLA2.Z#P2C^\"I('_?04_A7TQ7RQ\.?^
M2A:)_P!?2_UKZGH`^8/BI_R4K6/^NB?^BUKW?X:_\D[T7_KW_J:\(^*G_)2M
M8_ZZ)_Z+6O=_AK_R3O1?^O?^IH$9/Q>\6S>&O"RVUC*T5]J3&*.13AHT`^=@
M?7D#L1NR.E>3_"_P/'XSUV0WI8:;8A7N`IP9"<[4SU`.#DCL.Q(-:_QYNGD\
M96=MO;RX;%2%/0,SODCZ@+^5=S\#;+[-X#:X(YN[R23..P"KC\U/YT`=]8Z?
M9Z9:):6%K#:V\?W8H4"J/7@5-)&DL;1R(KHXPRL,@CT(IU%`SPCXO?#JUT-%
M\0:+`(;.239=6Z`[8F/1E'92>,=`<8Z\:7P*\52R?:/"]T^Y(T-Q:$_PC/SI
MU]6#`8_O>U>B>/K2*]\`ZY%,H95LI)0#_>1=Z_JHKYY^'%^=.^(6B3@$[[H0
M\#_GH#'_`.S4`?3.N?\`(!U#_KUE_P#037R+;7$UG=175O(8YH7$D;KU5@<@
MC\:^NM<_Y`&H_P#7K+_Z":^2M+LCJ.K6=B&VFYG2$-Z;F`_K0(]I^%?PQTY=
M'M_$&NVB75S=*);:"4!DCC/W6*]&)!SSTXZ&O65544*H"J!@`#@"D1$BC6.-
M0J(`%4#@`=J=0,Y_Q7X,T?Q=I\D%]:QBYV$0W83]Y$V.#GJ1G^$\&OEV>&[T
M;5I(68PW=E.5)4\I(C8X/L17V%7R9XS_`.1XU[_L)7'_`*,:@#ZHTF^75-'L
MM0086[MXY@/0,H;^M6ZQ?!G_`"(^@_\`8-M__1:UM4`>!ZNV_6KYR,%KB0_^
M/&J=7=90QZY?QG^&YD'/^\:I5]G#X4?//<OZ+I4VM:M!80Y!E;YFQ]Q>I/Y5
M[G:VT-E:Q6L"!(H4"(H[`5R/PXT'[#IC:I.N)[P?N\_PQ]OS//T`KM*^=S#$
M>TJ<JV7YGJX2ER0YGNPHHHKSCL"BBB@"IJNIVNC:7<ZE>R".WMHS([>P[#U)
MZ`=R:^3_`!#K=SXCUZ\U>[XENI"VT=$7HJ_@H`_"O4_CKXJ??;^%[5R$P+B[
M(/WO[B=?JQ!']WTKQN@`HHHH`Z;X?^*W\(>*K>^9C]DE_<W:^L9/)Z'E3AN.
MN,=Z]&\>:&NF:Q]LM@#:7V9$*]`W\0_7(^OM7B=>U?#S5$\;^!;CPK=N/[1T
MQ0]HS$9:,<+[_*?E/'`9>]=>#K^QJIO9[G/B*7M(:;G,T4Z2-XI&CD4JZ$JR
MD8((ZBFU]4>*%%%%,`KT7X4$[=57)P/)('_?=>=5Z-\*$8)JCD?*3$!]1O\`
M\17#F'^[2^7YHZ,+_&7]=#T*BBBOESV@KQKXR?$"_LK_`/X1C2+A[;:BO>31
M,5<D\B,'L,8)QUR!TSGV6OFKXQVTT'Q*U&26,JEPD,D1/\2^6JY_[Z5A^%`#
M_`'POOO&:F_N)C8Z6C[?-VY>8@\A![=-QX!['!Q[-HGPQ\(Z$JF'28KJ8``S
M7G[YB1WP?E!_W0*I?"#5[#4/`-G:6LD8N+'='<0@_,A+,0Q'HP.<],Y&<@UW
M-`"*JHH50%4#``'`%?)'BC_D;-8_Z_I__0S7UQ7R/XH_Y&O5_P#K^G_]#-`'
MT+X_MVG\$P2+T@DBD/TP5_\`9A6!\+KE8]<NK8\>=;Y'N5(X_(G\J]#FL8]2
MT(V4WW)[<(2.V1U_"O&D-_X4\1*S+MN;.3IV<?X$?SKV<':MAYT>O]?J>=B/
MW=6-3H>Z45EZ)X@T_7K59;2=?,QEX6/SH?<?UK4KR)1E%VDK,]",E)7045%<
M75O:1&6YGCAC'5I'"C\S3;.]M]0M5NK242PN2%<=#@D']0:5G:_0+J]CQK]H
M+_C\T/\`ZYS?S2MKX!_\BIJ/_7\?_0$K&_:"!^UZ$V#@I.`?Q2IO@+KMG%!J
M&A33)'<R2B>!6.#*-N&`]2-H./?V-(#V6O,OCU_R(]G_`-A)/_1<M>CW%U;6
MB![FXBA5B%!D<*"3T'-><?'K_D1[/_L))_Z+EH&<9\!?^1XO/^P:_P#Z,BKZ
M`KY_^`O_`"/%Y_V#7_\`1D5?0%`!6!X\_P"1"US_`*\9?_036_6!X\_Y$+7/
M^O&7_P!!-`,^=_AS_P`E"T3_`*^E_K7U/7RQ\.?^2A:)_P!?2_UKZGH$?,'Q
M4_Y*5K'_`%T3_P!%K7N_PU_Y)WHO_7O_`%->$?%3_DI6L?\`71/_`$6M>[_#
M7_DG>B_]>_\`4T`>5?'JSDB\7V-WL(BGL@H;U97;(_)E_.NU^!E^+KP/+:%A
MOL[MUVYY"L`P..W);\C5[XM>$9/$_A7SK.(R7^G$S0HHRTBD?.@'J0`1ZE0.
M]>._#7QM_P`(9K[27`9M.O%$=TJC)7'W7`[D9/'H3WQ0!].454TS5=/UFR2]
MTV\BNK=QP\39'T/H?8\BIKBX@M+>2XN9HX88U+/)(P55'J2>`*!F%\0;V*P\
M`:Y-,<*UG)"/]Z0;%_5A7SY\-K#^T?B'HL/9+@3?]^P7_P#9:ZCXN?$6W\1.
MN@Z/)YEA;R;YKA3Q.XX`7U49Z]SR.`"=WX&^$IK6*X\3WD93[0GDVBMW3.6?
M'N0`/HWJ*!'J6N?\@#4?^O67_P!!-?+7@S_D>-!_["5O_P"C%KZEUS_D`ZA_
MUZR_^@FOEKP9_P`CQH/_`&$K?_T8M`'UG1110,*^3/&?_(\:]_V$KC_T8U?6
M=?)GC/\`Y'C7O^PE<?\`HQJ`/IGP9_R(^@_]@VW_`/1:UM5B^#/^1'T'_L&V
M_P#Z+6MJ@#Q+QG;?9?%VH)MP&E\P>^X!OZTSPMHC:]KD-H0?)7]Y.1V0=?SZ
M?C70_%&P,6JVE^H^6>(QL<?Q*?\`!A^5=1X#T'^QM#6:9,75YB23/55_A7\C
MGZDU]#+%<F$C);M6/)C0YJ[B]D=*B+&BHBA548``X`IU%%?/'K!1110`52U?
M4X='TN>_G^["N0N?O'L/Q-7:\N^).O?;-032('S#:G=+@\-)Z?@/U)]*Z<+0
M=:JH].IC7J>S@WU/-O%\<VL&;5)3ON0Q=SZJ>OY=O;-<;7HA&00>0:XC5[`V
M%^\8'[MOFC/MZ?ATKT,RPRC:K%:;/]#EP=6_N,I4445XQZ`5L>%/$,_A;Q)9
MZO!N(A?$L8/^LC/#+^73T.#VK'HH`]T\>:;;R/;>(].8266I(K[EZ;B,@_B/
MU!KCZV_A)K4&O:!>^!]1<`A6ELF..`3E@/<-\WOENPK*O+2:PO)K2X7;+"Y1
MA[C^E?1Y=B/:4^1[K\CR,52Y)\RV9#1117IG(%>J?#"V,7AZ>=ACSK@X]P`!
M_/->5U[EX6L#IGAJQM6&'$0=P>S-\Q'YFO+S.=J*CW9V8.-ZE^QK4445\Z>L
M%<CX^^']CXXLH]TOV2_M\^1<A=PP>JL.X_4'GU!ZZB@#YS;X5_$'0+XS:9$6
M=%P+FPO`AY[#)5OTK0_L?XSSQ>1YNJ!<`9^W1H>/]K>#^M>^44`<%\+?"^NZ
M%:ZC>^)))6U&^D0$2SB9@B`XRP)Y)9N_85PFM?!;Q3J&N7][#+IXBN+F25-T
MS`X9B1GY?>O>**!6(X$,=O'&V,J@!Q["LKQ#X7T_Q'`!<@QSH,1SI]Y?8^H]
MJV:*J$Y0ES1=F*45)69Y->?#C7[*7?9-%=!3E6CDV-^1QC\S3/\`A'O'3*$V
MWNWT-X,?^A5ZY17H+,JMO>2?R.7ZG#HV>2Q?#SQ+>OONC#$QZM//N/\`X[FO
M3='L/[+T>TL<AC!$%8J.">Y_/-7:*YZ^*J5TE+9&M*A"D[HY/XA^"(_&^AK;
MI*D%];,9+69QQDC!5N^T\9QW`/.,'Q&Y^$GC>WF9!HWG*"0'BN(RK>X^;/Y@
M5]-45RFY\]^%/A/XNB\2Z9>7^F1VUK;W44TK2W"'*JP)`"DG.!Z5ZE\3_">H
M^,?#=OI^F/`LT5XLQ\]RHVA'7L#SEA7944`>6?"_X;:YX/\`$EQJ.IR6;0R6
M;0J(9&9MQ=&[J.,*:]3HHH`*RO$^FSZQX8U/3;8H)KJV>*,N<+DC`R:U:*`/
M$O"/P@\2Z'XKT[5+N6P,%K,)'$<S%L>PVU[;110!XOXW^$OB/Q#XPU#5K*6Q
M%O<NI022L&X11R-I[BO3O!^D7.@^$].TN\,9GMHMCF,Y7.2>#Q6U10*P5YMX
MW^#NG^(KB;4](F73]0E.Z1&&89FYY('*DG&2,_3))KTFB@9\W2_"?Q[I-V7L
M[+S"GW;BTNT7/TR0WZ4V7X:_$75YE-[87,Q!QYEU>HVW/?E\]NU?2=%`'D'A
M3X%Q6MPEWXFNX[K8<BSMB=A]-SG!/T`'U/2O7(HHX(DABC6..-0J(@P%`X``
M["GT4`5M2MWN]+N[:,@/-"\:YZ9*D"O$_#WP:\4:7XDTO4;B73S#:7D4T@29
MB=JN&./EZX%>ZT4`%%%%`!7A7B'X,^*-4\2:IJ%O-IXAN[R6:/?,P.UG+#/R
M]<&O=:*`,[P]83:7X;TS3K@J9K2SBAD*'*EE0*<>V16C110!0U71[368X([Q
M-RP3+,H]2.Q]CFK]%%-R;20DDG<****0PHHHH`R?$NM)H.B37A(\W&R%3_$Y
MZ?X_05X?)(\TCRR.7=V+,S'))/4FNH\?Z]_:VM&UA;-M9$HN/XG_`(C_`$_#
MWKE:^FP&']E2N]V>-BJO/.RV05G:Y8?;K!BBYEB^9,=3ZC\?YXK1HKLJ0C4B
MXRV9A"3A)21YW16GK]A]COBZ#]U-EE]CW'^?6LROD:M-TIN$NA[L)J<5)!11
M1699<TC5;O0]6M=4L7V7%K()$/.#CJ#CJ",@CN":]L\80VNOZ)8>,=+&8;J-
M1..I4]!G'<$%3[@5X/7J7P:\1Q/-=>#M3.ZSU%6:WW'[LF/F4<<9`SUX*^K5
MOAZSHU%-&5:FJD'$HT5=U?3)M'U2>PG'S1-@-_>7L?Q%4J^MC)22:/"::=F:
M_A;23K7B&UM2NZ(-YDWIL7D_GT_&O<:XWX<Z"=.TEM1G0B>]`*@_PQ]OSZ_E
M795\WF%;VM6RV6AZ^$I\D+O=A1117GG6%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!6'XK\1-X:T^*Z6U%QYDOE[2^W'!.>A]*W*XGXI?\@"T_Z^A_Z"
MU=&&A&=:,9;,RK2<:;:-KPKXD7Q+I\MQY`MY(I-C1A]W&`0<X'O^59OBCQT/
M#VJ+8Q62W+>6'=C+MVDYXZ'M@_C67X?8>'/B#J.ER$1V]T&=,\`8^=?R!85S
MM\IUJTUOQ'*IP9TCASVR?YA0H_&N^GA:3K-M>Y96^>WZG)*O-4TD_>UO\CT:
MY\2M;^#5\0?90S&-'\G?@?,P7KCW]*PK;Q_K%Y")K7PK<3QDX#Q%V4_B$I=1
M_P"20)_UPA_]&+6?X2UCQ!9Z#'#I^A?;(`[$2^9C)SR*F%"G[.4N5-J36KMI
M]XY59<T5>VG8Z_0-:O\`5;>YEOM(FTYH<;5E##?P>F0*YNT^(VIW^_[%X:EN
M=F-_DNS[<],X7CH:Z[3+J^O-),VH6?V.<[@8MV<#L:XSX3_\Q7_MC_[/6<(T
M^2I.4=K:7?H7*4^:$5+>Y>@^(WD7BV^M:-<:<&Z.V21[E2`<?3-;OB3Q`-"T
M9=2BA6Z5G55&_`(()SG!K-^(]O!+X5>611YD,J&(]P2<$?D3^5<]J<LDWPDT
MYI"2PE"C/H&<#]`*J%&E54)J-DW9H4JE2'-%N^E[G=:3K":AH$.K3JMLCQF1
MP6R$`)SS^%<U)\0IKV\:WT+19[X)U<Y''K@`X'UQ5'4)I(OA':"/($FU'(]-
MY/\`05T'P_M8(/"5K)$`7G+/(P'5MQ'Z``5+I4J<)5)*_O-)#4YS<8)VTNQ^
M@^(-6U#46M-2T*6Q7RRZRG=M)!`QR/<]^U7_`!!K46@:1+?R)YA4A4CSC>QZ
M#^OX5IUY=\0=:AO?$$&FN[FSLV'G>7R2Q^]CMD#CZYK.A3CB*R2C9=2ZLW2I
MZN[.F\+^-QXAU"2RFLQ:R"/S$_>;MX[]AV(-:'BKQ`WAO3([Q;87!>81;2^W
M&58YS@_W:\YU+Q'I_P#PE=IK6D030K"$$D<B*,X^4XP3U7BNK^)<L=QX4LYH
MF#QR72,K#H04<@UT3PL57I^[:,NAC&M)TY:W:ZG4Z1?G5-)MKXQ^69XP^P'.
MW/O5VL?PE_R*FF_]<%K8KS:B49M+N=D&W!-A4-Y/]ELI[@+N\J-GVYQG`SBI
MJIZM_P`@>]_Z]Y/_`$$THJ\DBI.R9E>$O%#>)H+F1K06WD,JX$F[.<^P]*Q;
M3XF1RZLEG=V"V\)D,;3>=G;V!(QTS3/A5_QYZC_UT3^1KG=$\.CQ#%KD<8Q=
M0,KP'U.6ROX_X5ZWU>@JE136BM\KGGNK5<(.+U=_P/5=4O3IVE75\$$GV>)I
M`N<;L#.,U4\.:W_;NC+J+PBWW,P*[]P&#US@5R&C>(6O_!6JZ3>$B\L[20#?
MP60`C\QT/X4:;-);_"*[>+.XETX]&<*?T)KG>%Y8N+WYDK^3-?;WDFMK-FC>
M?$(2WYLM#TR74G!^^,@'W``)(]SBKFC^)-:N]5AL]1\/36D<V[$_S;5(!//&
M.<>M5?AE:6\7AZ2Z0`S33,)&QR`,87^OXUV537=&G)TXPVTO=W*I*I-*;E\@
MHHHKA.H*Y[QKKW]AZ$YB?%U<9CA]1ZM^`_7%=`2`"2<`=37BOC#73KVNR2QM
MFVA_=P#_`&1U/XGGZ8KNP.']M5UV6YS8FK[.&F[,+.31117U!XP4444`5-4L
M1J%B\/1Q\R$]F'^<5PS*58JP((."#VKT2N<UK0YYKWS[.(.)!EQN`PWX^O\`
MC7DYCAG42J05VCNPE91;C)Z'/45H_P!@:I_SZ_\`D1?\:/[`U3_GU_\`(B_X
MUXWU>M_(_N9Z'M:?\R^\SJDMKF:SNHKJVD:*:!UDC=>JL#D$?0BKO]@:I_SZ
M_P#D1?\`&C^P-4_Y]?\`R(O^-'U>M_(_N8>UI_S+[SVC6)X/''@JS\66*J+F
MW7R[V)>J$?>'X$Y'^RV:S?!GAEM?U,/,I%E;D-*W9CV0?7O[?A53X+IK=EK%
MYI=Q8/+I-Y$3.2P*1.`<$C/\0RI`Y/'85[+INF6FD6*6=E%Y<2=NI)[DGN:Z
MXXRI1HNDU9]/)',\/&I4YT]"T`%4*H``&`!VI:**\T[0HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"N2^(FG7FI:-;165M)<.MP&*QKD@;6Y_6N
MMHK2E4=*:FNA%2'/%Q9PGQ#T"^O;JTU#3+>664(T4HB'..H_FP_*DN_#MW;_
M``UBT^"U>2[D=99(U7+;B<G(]A@?A7>45O'%S4(P_E=S)X>+E*7<X^^TV]D^
M&"Z>EK(UV(8AY(7YLAU)X^@K)T#4/$^@:4EA'X:FF569M[`@\G/I7HU%$<5[
MKC**:;OU!T-4T[65C$T/4M4U2UN3J6EM8.G$:G/SY!]:X?PN/$OAG[5Y7AZ>
M?[3LSN4C&W/_`,57J=%*&)45)<JM*VFO0)47*SYM4><W^G^+?&5Q##?6BZ=8
MHV[#<`=LD9RQQG'0?2MGQAHLO_"'0:9I=M)-Y$D85$&3@`\UUM%-XN7-%I)*
M.R#V"L[N[?4YK2]"^V^`X-(OXWA=HB&###(VXD''UQ7/:8OBSP89+1=,.I61
M;<GE9;!]1C)'N"*]&HI1Q+7,I)--WL-T%HT[-'(VGB;Q#=BXD?PW-;QQ0LR!
ME8L\G`4#('<\\=`:J>`?#MW;3WFJ:M;NES*VQ!,OS<\LWXG'Y&NYHH>(M&48
M12N"H^\I2=['/>,M#&K^'9HH(0UQ$1+$%')(ZC\03^.*Y.[T_7+WP#:Z;+IM
MS]IM+P!5*')CVM@_@3C\J]-HITL5*G%1M>SN*=!3;=[75C@-+UOQ3I>F6]BO
MA>618$"!CN!./PK3O_&-WI6@V][?:48[N>8QBU9RI`'\6<?3\ZZRJ-[H^GZA
M=VUU=VXEFM&W0DLP"'(.<`X/0=?2CVU*<KSA]U_\Q>RJ1C:,B>SDGFLX9;F$
M03.@9X@V=A/;-,U.-Y=+NXXU+.\#JJCJ25/%6J*Y;V=SHMI8XOX<:7?:9:WR
MWUI+;EW0J)%QG@TSP!I5_IVH:L]Y:2P+*R^677&[ENGYBNWHKIGBI3Y[KXK?
M@8QH*/+KM?\`$\\\<>$[QM0&JZ-!([7`*7$<0YR1@MCT(R#_`/7K:\):/)_P
MA9TS4[=XO-,BNC##`$]:ZFBB6*G*DJ;Z=>H*A%3<UU/.+&P\4^"+J9+.S_M.
MPD.XB,$Y/K@<J<>Q'UK>TCQ'K^IZI#!/X=EL;8D^;+,&X`!(QD#O@5U-%.>)
M52[G!7[ZBC1<-(R=NQSUQJ6OIXMBLH;$-I;;=\_EDD?+SSG'7VKH:**YYR4K
M65K&T8M7UN<C\0]>_LS1_L$#XN;T%>.JQ_Q'\>GY^E>2U[QJ^AZ=KEOY-_;B
M3'W''#I]#7G&M_#C4[`M+IQ^W0#G:.)%'T[_`(?E7LY?B*,(<CT9YV*I5)2Y
MMT<=13Y8I8)6BFC>.13AD=2"/J*97LG`%%%%,`HHHH`***T-+T+4]9DV6%G)
M*,X+XP@^K'BIE)15Y.P)-NR,^N@\->$+_P`0RB0*8+,'YYV'7V4=S^E=?H/P
MUM;0K/J\@NI1SY*9$8/OW;]!]:[=$2-%1%"(HP%48`%>1B<R2]VE]YWT<&WK
M,J:5I-GHMBEG91".->2>I8]R3W-7:**\-MR=V>DDDK(****0PHHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`*E_I6GZFF
MR^LX;@#H70$CZ'J*YF]^&>BW!+6TEQ:GLJOO4?GS^M=C16U.O5I_!)HSG2A/
MXD>:S?"JY4_N-5B<?[<17^1-5/\`A5VN?\_5A_W\?_XBO5:*ZEF.(77\#%X2
MEV/+8OA;JY;][>V2KZJSL?\`T$5HVOPJC!!N]59AW6*(+^I)_E7H-%3+,,0^
MMOD"PE)=#G=/\">']/(86?VEQ_%<-O\`TZ?I70(B1H$10JC@*HP!3J*Y)U)U
<'>3N=$81C\*L%%%%04%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
